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ABSTRACT 
As the principal vector for the transmission of the Plasmodium 
falciparum parasite, and hence the spread of malaria in Sub-Saharan 
Africa, Anopheles gambiae is a globally significant species of 
mosquito. Over recent years, the efficacy of established insecticides 
has waned and there is a constant need for novel effective compounds. 
Cytochrome P450 reductase (CPR) is a diflavoprotein known to have a 
central role in phase I metabolism of xenobiotic compounds and, in 
mosquitoes, this involves the detoxification of insecticides. Due to an 
inherent lack of understanding regarding the mechanisms of action of 
A. gambiae CPR, the selective inhibition of this enzyme is a previously 
untried approach. This project aims to biochemically characterise A. 
gambiae CPR in direct comparison to the human enzyme. 
It was found that A. gambiae CPR was deficient in bound FMN, and to 
a lesser extent FAD, relative to human CPR with 20 % less FMN 
bound to the purified mosquito protein. Following the dissection of A. 
gambiae CPR into its constituent FMN- and FAD-binding domains, 
and using Isothermal Titration Calorimetry (ITC), a 4-fold decreased 
was observed for the binding affinity for FMN in the A. gambiae 
FMN-binding domain as compared to the equivalent human protein. 
The redox potential of the oxidised/semiquinone transition of the A. 
gambiae FMN-binding domain was -92 mV, much more negative than 
the published value for human FMN-binding domain. These data 
suggest a clear difference between these enzymes in the binding 
strength of FMN and its propensity to accept electrons.  
The binding characteristics of NADPH nucleotides were probed in 
some detail. Comparison of the binding of NAD
+
 and NADP
+ 
revealed 
a strong bias for the phosphate containing NADP
+
. In addition, the 
position of the phosphate was important as 3‟-AMP bound very poorly 
whilst 2‟-AMP bound more strongly. 2‟, 5‟-ADP binding highlighted 
the importance of additional stabilising interactions involving the 5‟-
phosphate. Comparison of 2‟, 5‟-ADP and NADP+ binding confirmed 
that the 2‟-phosphate interaction was the principal site for NADPH 
recognition and provided the majority of the binding energy for this 
interaction.  A. gambiae CPR was shown to bind NADPH nucleotide 
analogues 2‟-AMP, 2‟, 5‟-ADP and NADP+ much less strongly than 
the human enzyme highlighting a potentially significant difference in 
coenzyme binding. Binding affinities for the nucleotide ligand to intact 
CPR and the isolated FAD domain showed that the FAD-binding site   
is fully contained within the FAD-binding domain However, 
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differences in the thermodynamic parameters between the intact 
enzyme and the isolated FAD-binding domain suggest that, although 
not directly involved in NADPH binding, the presence of the FMN 
binding domain had an effect on the overall binding energetics. 
Despite an apparent difference between A. gambiae and human CPR in 
flavin incorporation and NADPH binding affinity, it was interesting 
that the activity of cytochrome c reduction of both enzymes was 
similar. The measured Km with respect to NADPH corroborated the 
ITC data by suggesting a stronger interaction of the coenzyme with 
human CPR compared to A. gambiae CPR. There was an approximate 
2-fold increase in potassium ferricyanide reduction with the isolated A. 
gambiae FAD-binding domain compared to the intact enzyme with the 
presence of the FMN-binding domain again seemingly imparting an 
effect of events involving the FAD-binding domain.  
In order to fully understand and rationalise all of the data, a 
comprehensive structural determination of A. gambiae CPR is 
required. With this in mind, isotopic labelling and subsequent 
biophysical analysis was carried out on the intact CPR and its FMN- 
and FAD-binding domains. Successful labelling was achieved for all 
samples, including the deuteration of the intact CPR and FAD-binding 
domain However, the greatest success involved the FMN-binding 
domain with sufficient triple resonance spectra collected for backbone 
assignments. Although this success could not be matched for the intact 
CPR and FAD-binding domain, the work has provided a solid base for 
more a comprehensive study in the future. 
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ABBREVIATIONS 
ACT – artemisinin combination 
therapy 
AChE – acetyl cholinesterase 
2‟, 5‟-ADP – adenosine 2‟, 5‟-
diphosphate 
AEX – anion exchange 
chromatography 
2‟-AMP – adenosine 2‟- 
monophosphate 
3‟-AMP – adenosine 3‟-
monophosphate 
BES - N,N-Bis(2-
hydroxyethyl)-2-
aminoethanesulfonic acid 
BM3 – Bacillus megaterium 
P450 reductase 
BSA – bovine serum albumin 
CPR – NADPH-cytochrome 
P450 reductase 
CYP – cytochrome P450 
DDT – di-chloro di-phenyl 
trichloroethane 
DNase1 – deoxyribonuclease 
dNTPs - deoxyridonucleotides  
DTT - dithiothreitol 
E
0 
- redox potential 
EDTA – 
ethylenediaminetetraacetic acid 
FAD – flavin adenine 
dinucleotide 
FADH·- FAD semiquinone 
FADH2 – FAD hydroquinone 
FMN – flavin mononucleotide 
FMNH· - FMN semiquinone 
FMNH2 – FMN hydroquinone 
FNR – ferredoxin NADP+-
reductase 
GST – glutathione S-
transferase 
H4NADP – 1,4,5,6-tetrahydro- 
NADP 
His-tag – 6x histidine tag 
HSQC – heteronuclear single 
quantum coherence 
HPLC – high performance 
liquid chromatography 
IPTG – isopropyl β-D-1 
thiogalactopyranoside 
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ITC – isothermal titration 
calorimetry 
kDa – kilodaltons 
Kd – dissociation constant 
LB – Luria Bertani medium 
MHz - megahertz  
MOPS – 3-(N-morpholino) 
propanesulfonic acid 
MSR – methionine synthase 
reductase 
NAD
+
 - reduced nicotinamide 
adenine dinucleotide 
NADH – nicotinamide adenine 
dinucleotide 
NADP
+ 
-
 
reduced nicotinamide 
adenine dinucleotide phosphate 
NADPH – nicotinamide 
adenine dinucleotide phosphate 
NMN – nicotinamide moiety 
NMR – nuclear magnetic 
resonance 
NOS – nitric oxide synthase 
NR1 – novel reductase 1 
OD600 – optical density at 600 
nm 
PABA – p-aminobenzoic acid 
PCR – polymerase chain 
reaction 
PDB – protein data bank 
PMSF - 
phenylmethanesulfonylfluoride 
p.p.m – parts per million 
RO H2O – reverse osmosis H2O 
ROS – reactive oxygen species 
r.p.m – revolutions per minute 
SDS – sodium dodecyl sulphate 
SERCA – sarco/endoplasmic 
reticulum-Ca
2+
ATPase 
SR – sulfite reductase 
TEMED – N,N,N,N‟-
tetramethylethylenediamine 
TEV – tobacco etch virus 
TROSY – transverse relaxation 
optimised spectroscopy 
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Chapter 1 
 
 
1. INTRODUCTION 
1.1 Mosquitoes 
Mosquitoes are common insects found in many different environments 
throughout the world. Although they are more prevalent in tropical 
climates some, more robust species can also be found in much cooler, 
temperate regions. They are a globally significant member of the class 
Insectera and the number of known species is in the region of 3,500. 
Mosquitoes are probably most renowned as vectors for some of the 
most major infectious diseases with more than 60 species being 
responsible for the transmission of such infections. Yellow Fever and 
Dengue Fever are transmitted by Aedes species such as Aedes aegypti 
whilst Anopheline mosquitoes such as Anopheles gambiae are 
responsible for malarial transmission in humans. It is perhaps worth 
noting that Anopheline mosquitoes are the sole vectors for human 
malarial transmission. Whilst both male and female mosquitoes feed 
on nectar, the female mosquitoes are capable of hematophagy by
9 
  
 
 
 
 
 
 
 
Fig. 1.1. The life cycle of the Anopheline mosquito. The four stages of development are shown along with the average 
time it takes to progress to the next stage. The length of time spent at each stage will differ depending on species as well 
as environmental factors such as temperature. 
2-3 days 
2-4 days 7-14 days 
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administering bites to mammals; this is the reason for the spread of 
mosquito-borne infectious diseases.  
Mosquitoes undergo a four-stage life cycle from egg to adult via two 
intermediate stages; larva and pupa (Figure 1.1). Eggs are laid on water 
and providing the temperature is adequate, hatch within 2-3 days. The 
larvae rest just below the surface of the water and 1-2 weeks later then 
develop into pupae. After 2-4 days, pupae metamorphose into fully 
developed adult mosquitoes. Adult Anopheline mosquitoes have a 
typical life-span of anywhere between one week and one month. 
 
1.2 Malaria 
Malaria is a vector-borne disease of major global significance 
responsible for up to and beyond 3 million deaths per year worldwide. 
The highest prevalence for the disease is in the Sub-Saharan African 
region where up to 90 % of incidences of clinical illness are thought to 
occur (Breman et al., 2004) as well as the vast majority of deaths in 
children under five (Snow et al 2005). Malaria is caused by Plasmodia 
parasites which are transmitted to humans through the bite of 
Anopheline species of mosquitoes. There are four species of Plasmodia 
which promote human infection: Plasmodium malariae, Plasmodium 
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vivax, Plasmodium ovale and Plasmodium falciparum (Deen et al., 
2008) 
Clinical symptoms of malaria, chills and fever, along with more severe 
complications such as hypoglycaemia, anaemia and coma are 
attributed to invasion and development within human erythrocytes 
during the Plasmodium life cycle (Weatherall et al., 2002). The full life 
cycle takes place within both mosquito and human hosts and begins 
when Plasmodium sporozoites are transferred to the human 
bloodstream following a blood-meal from an infected A. gambiae 
female (Figure 1.2). Sporozoites circulate in the bloodstream for a 
short time before the invasion of hepatocytes. For P. falciparum the 
time between transfer of sporozoites and their subsequent invasion of 
hepatocytes is a matter of minutes. Within 10-12 days, infected 
hepatocytes rupture releasing thousands of daughter merozoites which 
invade circulating erythrocytes and over the next 48 hr they embark 
upon the clinically important intra-erythrocytic cycle of asexual 
replication. The action of P falciparum differs from other malarial 
parasites in that parasitized erythrocytes do not remain in circulating 
blood for the entirety of their lives. Within 24-32 hr of invasion by 
merozoites, young parasites mature into trophozoites and the 
parasitized erythrocytes adhere to endothelial cells or to various bodily 
organs. At this stage of development, the trophozoites mature further 
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one of two ways. They either mature into schizonts which rupture and 
release daughter merozoites to go on and invade fresh erythrocytes. 
This pattern of invasion, release and re-invasion into erythrocytes 
highlights the cyclical pattern of clinical pathologies associated with 
malarial infection (Weatherall et al. 2002). Some trophozoites however 
will mature into male and female gametocytes. These are taken back 
into the mosquito when a second A. gambiae female takes a meal. 
Once inside the mosquito, the gametocytes fuse and undergo full 
development into sporozoites before being transferred to the salivary 
glands ready for re-admission into a fresh human host (Haldar et al 
2007). 
 
1.3 Treatment of malaria 
Targeting infective Plasmodia parasites is imperative in the treatment 
of malarial symptoms and there are currently a large number of 
compounds available.  
 
1.3.1 Chloroquine 
Chloroquine (Figure 1.4) is one of the more traditional malarial 
treatments and its mode of action is to interfere with the parasitic heme 
13 
Fig  1.2. The life cycle of the Plasmodium falciparun parasite. The parasites require both mosquito and human hosts in order to fully develop 
into fully infective entities. The major symptoms of malaria occur during the invasion of the erythrocytes by P. falciparum merozoites (Adapted 
from Haldar et al. 2007) 
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detoxification processes (Krugliak and Ginsburg, 1991; Bray et al., 
1998). In red-blood cells, parasites need to degrade haemoglobin to 
acquire essential amino acids. Heme, however, is toxic to parasites and 
thus is bio-crystallised to form to non-toxic molecule hemozoin. 
Chloroquine inhabits parasitic cells by diffusion and caps hemozoin 
preventing further crystallisation, thus, causing an accumulation of 
heme in the parasitic food vacuole. Chloroquine then binds to heme 
resulting in an extremely toxic chloroquine-heme complex which 
causes parasitic cell lysis and subsequent autodigestion (Hempelmann, 
2007). Chloroquine, therefore, has no effect against sporozoites or exo-
erythrocytic stages of parasites which do not consume haemoglobin. 
One major problem however is the growing levels of resistance to 
chloroquine in P. falciparum rendering it almost useless as a treatment. 
Resistance is due to mutations in transporters resulting in decreased 
chloroquine concentration at the parasitic food vacuole, its site of 
action. Chloroquine is, however, still effective against infections with 
P. vivax, P. ovale or P. malariae (Deen et al., 2008). Due to 
chloroquine resistance, alternative aminoquinolines amodiaquine and 
primaquine (Figure 1.4) are more readily used. Amodiaquine works in 
a similar manner to chloroquine and has some efficacy against low-
level chloroquine resistant P. falciparum strains (Olliaro et al., 1996). 
However, due to cross-resistance, it is completely ineffective in places 
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with higher levels of chloroquine resistance (Lemnge et al., 2006; 
Nsimba et al., 2008). The mechanism of action of primaquine is 
unknown but is effective against all intra-hepatic forms of malarial 
parasite (Deen et al., 2008). 
 
1.3.2 Sulfadoxine 
Sulfadoxine (Figure 1.4) is a slowly eliminated sulfonamide and acts 
as a competitive inhibitor of the enzyme dihydropteroate synthase. 
Folic acid is essential for DNA and RNA synthesis in many species 
and p-aminobenzoic acid (PABA) is an intermediate of folic acid 
synthesis. PABA is non-essential in humans as they lack the necessary 
enzymes to convert it into folic acid. Sulfadoxine is structurally similar 
to PABA and, thus, interferes with the activity of dihydropteroate 
synthase which is responsible for the conversion of PABA to folic acid 
meaning the parasitic growth is limited through folic acid deficiency 
whilst having no effect on humans (Deen et al., 2008). 
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1.3.3 Pyrimethamine 
Pyrimethamine (Figure 1.4) is a diaminopyrimidine which acts by 
inhibiting plasmodial dihydrofolate reductase and consequently 
blocking the synthesis of nucleic acids within the parasites. As in the 
case of dihydropteroate synthase, dihydrofolate reductase is similarly 
involved in the conversion of PABA to folic acid.  
Dihydrofolate reductase is an enzyme that catalyses the reduction of 
dihydrofolate to tetrahydrofolate using NADPH as an electron donor 
(Figure 1.3 A). Dihydrofolate reductase has been recently studied on a 
biophysical level and a number of solution structures have been solved 
in complex with NADPH and various inhibitors (Kovalevskaya et al., 
2005; Beierlein et al., 2009) 
Whilst sulfadoxine has no effect on humans, pyrimethamine can lead 
to folic acid deficiency in humans due to effects on host dihydrofolate 
reductase. It is effective against all forms of human malarial causing 
Plasmodia; however, resistance is developing. Currently, 
pyrimethamine is no longer used in isolation; it is only used in 
combination with a sulfonamide, traditionally sulfadoxine. As a 
combination, sulfadoxine and pyrimethamine maximise efficacy by 
acting on two separate enzymes in the conversion of PABA to folic 
acid (Figure 1.3 B) (Deen et al., 2008). 
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Figure 1.3. The role of dihydrofolate reductase and dihydropteroate 
synthase in tetrahydrofolate metabolism. A = The mechanism of 
tetrahydrofolate metabolism by dihydrofolate reductase. NADPH bound 
to dihydrofolate reductase is the electron donor in the reduction of 
dihydrofolate to tetrahydrofolate. B = The positions of dihydropteroate 
synthase and dihydrofolate reductase in the conversion of PABA to 
tetrahydrofolate. 
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The sulfadoxine-pyrimethamine combination has rapidly become the 
successor to chloroquine in places of high-level resistance. 
Unfortunately, resistance to the sulfadoxine-pyrimethamine 
combination is growing in P. vivax but in areas where P. vivax is still 
susceptible, this combination is still a widely used treatment (Hawkins 
et al., 2007). Sulfadoxine-pyrimethamine is appropriate as the unified 
malarial treatment in places where P. falciparum and P. vivax coexist 
and are both susceptible to this combination. The numbers of areas 
which meet these criteria are rapidly declining and there is a growing 
need for alternative treatments in these and other malaria hot-spots 
(Leslie et al., 2007). 
 
1.3.4 Quinine  
Quinine is another traditional compound for the treatment of malaria. It 
is an alkaloid (Figure 1.4) derived from the bark of the Cinchona tree. 
Its proposed mode of action involves, similar to chloroquine, the 
inhibition of the heme detoxification in the food vacuole; however, its 
mechanism is poorly understood. It is effective against all stages of P. 
vivax, P. malariae and P. ovale but is ineffective against mature 
gametocytes of P. falciparum. Acyl aminoalcohols mefloquine, 
halofantrine and lumefantrine are all relatives of quinine but are rarely 
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given alone. They are commonly given as drug combination therapies 
involving artemisinin derivatives (Deen et al., 2008). 
 
1.3.5 Artemisinin derivatives and artemisinin-based combination 
therapies (ACTs) 
Artemisinin (Figure 1.4) is extracted from the leaves of the sweet 
wormwood (Artemisia annua) It acts rapidly as a blood schizontocide 
against all malarial Plasmodia parasites. Its broad activity means it is 
active against all stages along the parasitic life cycle including against 
P. falciparum gametocytes which are otherwise only sensitive to 
primaquine (Pukrittayakamee et al., 2004). There is no consensus 
regarding the precise mode of activity of artemisinin. On a chemical 
level, artemisinin is thought to bind to liberated heme, produced 
following haemoglobin degradation, leading to the generation of 
reactive oxygen species (ROS) and subsequent cell death (Cumming et 
al., 1997). There is evidence that artemisinin inhibits cysteine protease 
activity within the digestive vacuole leading to haemoglobin 
accumulation and inhibition of hemozoin (Pandey et al., 1999) 
Alternatively, it has been suggested that artemisinin, acts via inhibition 
of the essential calcium adenosine triphosphatase (SERCA) activity 
(Eckstein-Ludwig et al., 2003).  
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Artemether, artemotil and artesunate are the three major derivatives of 
artemisinin and in vivo become converted to dihydroartemisinin, the 
very potent active metabolite. Today, artemether, artemotil and 
artesunate are very effectively combined in artemisinin-based 
combination therapies (ACTs) with other compounds and the current 
recommended combinations for treatment of malaria, particularly P. 
falciparum derived, are: i) Artemether-lumefantrine, ii) Artesunate and 
amodiaquine, iii) Artesunate and mefloquine, iv) Artesunate and 
sulfadoxine-pyrimethamine (Deen et al., 2008). 
The advantages of ACT lie primarily in overcoming the effects of drug 
resistance. The use of a second compound will render the therapy 
effective even if there is growing resistance to one of the partners. 
Another key advantage is that artemisinin and its derivatives are 
remarkably safe and extremely well-tolerated by humans making them 
ideal as treatments (Ribeiro and Olliaro, 1998; Price et al., 1999). The 
major considerations when contemplating use of ACTs are cost and 
availability as well as levels of resistance to the partner compound in 
the area of interest. Deciding on the correct therapy can be difficult and 
is complicated further in areas of vast multidrug resistance. 
Worryingly, however, P. falciparum resistance to artemisinin has been 
shown to be emerging is isolated areas of South-East Asia which, if it 
spreads further afield, could have major consequences for current 
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malarial treatment strategies (Dondorp et al., 2009) particularly as 
currently, there are no compounds currently in-line to replace 
artemisinin should resistance become more widespread (Dondorp et 
al., 2010). 
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Figure 1.4. The chemical structures of some of the major compounds used in 
malarial treatments. The vast diversity of compounds is displayed and a wide variety 
of compounds is shown from the more traditional chloroquine and quinine to the more 
modern used artemisinin. 
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1.4 Insecticide use 
The use of pesticides, principally to protect crops, has been common 
place for many hundreds of years. Sulphur-based compounds, as well 
as toxic chemicals such as lead, mercury and most commonly arsenic 
were the main weapon against invading pests. This was the case until 
the discovery of the insecticidal properties of 
dichlorodiphenyltrichloroethane (DDT) in 1939 by chemist Paul 
Müller (Turusov et al., 2002) 
Insecticides, pesticides used to target insects, are used in a multitude of 
ways. They are used to protect to crops and plants, both agriculturally 
and in house-hold gardens; however, in many regions of the world, 
such as Sub-Saharan Africa, their major use is in the prevention of 
spread of vector-borne disease such as Malaria. However, the high 
intensity and prolonged usage of such insecticides is having a dramatic 
impact on a whole host of ecosystems (Relyea et al., 2005). 
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1.4.1 Organochlorines 
Dichlorodiphenyltrichloroethane (DDT) (Figure 1.5) is probably the 
most notable of the organochlorine class of insecticides. Its mode of 
activity involves maintaining Na
+ 
channels in an open state. With the 
Na
+ 
channels unable to close, the dramatic alteration of polarity leads 
to severe convulsions followed by death of the insect (Narahashi, 
1992). DDT is very efficiently stored in all tissues of living organisms 
and is highly fat soluble. The compound itself is not acutely toxic but 
due to its poor biodegradability and heavy, prolonged usage, DDT has 
become concentrated and accumulated within food-chains. The higher 
up the food-chain, the more severe the problems have become with 
pronounced effects on avian populations. There are cases of marked 
thinning of eggshells within populations of birds such as the falcon 
(Turusov et al., 2002) as well as reproductive failing in other birds 
such as grebes, ospreys and eagles (Fry, 1995). These ecological issues 
have led to the subsequent banning of DDT and other related 
compounds in a number of countries. 
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Figure 1.5. Structural examples of the four major groups of chemical insecticides. The structures shown are of the organochlorine, 
DDT; the organophosphate, malathion; the carbamates, carbofuran and aldicarb and the pyrethroid, permethrin. 
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1.4.2 Organophosphates 
Organophosphate insecticides, such as malathion (Figure 1.5) and 
parathion, have similar effects on mammals as they do on insect which 
is down to their mode of activity. They target, and phosphorylate, 
serine hydroxyl groups on the enzyme acetylcholinesterase (AChE). 
With the AChE activity impaired, there is an accumulation of the key 
neurotransmitter acetylcholine at cholinergic synapses. This build-up 
of acetylcholine is the cause of a number a symptoms and death is 
generally due to respiratory failure. The modification of AChE by 
phosphorylation is potentially irreversible depending on the chemical 
structure of the organophosphate and rate of dephosphorylation. If left 
phosphorylated for long enough, the AChE can be considered 
irreversibly inhibited and the only means of restoring function is by 
synthesis of fresh enzyme (Costa, 2006).  
The analogous nature of insect AChE compared to its mammalian 
counterparts makes these compounds as toxic to humans as they are to 
the insects they are meant to target. However, they hold some 
advantages over other insecticides such as DDT. The major advantages 
are that they are highly biodegradable and thus do not accumulate 
within ecosystems, unlike the organochlorines. This coupled with their 
high efficacy as well as low cost, has made the likes of malathion and 
parathion ideal insecticides (Fukato, 1990). 
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1.4.3 Carbamates 
The carbamate insecticides have a mechanism of action that is virtually 
identical to the organophosphates. They also target the AChE enzyme. 
The only difference is that whilst organophosphates impair AChE 
activity by phosphorylation of serine hydroxyl groups, the carbamates 
target the same serine hydroxyl groups by addition of a carbamyl 
group. This carbamylation is more readily reversible than the 
phosphorylation by organophosphates and a simple hydrolysis reaction 
can easily restore nerve function. Despite this, the carbamates are still 
regarded as potent inhibitors of AChE. Two common carbamate 
insecticides are carbofuran and aldicarb (Figure 1.5) (Fukato, 1990). 
 
1.4.4 Pyrethroids 
The environmental and human health issues associated with the 
organophosphates, organochlorines and carbamates has accelerated the 
need for a „safer‟ class of insecticides. Pyrethrin is a natural organic 
product contained within the seed cases of the pyrethrum plant 
(Chrysanthemum cinerariaefolium) and analysis of its structural 
properties led to the production of the first synthetic pyrethroid – 
allethrin. 
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Other pyrethroids, such as permethrin (Figure 1.5) and deltamethrin, 
have subsequently been synthesized and are becoming the first choice 
insecticide across most parts of the world. Pyrethroids are similar in 
their mode of action to the organochlorines in the sense that they target 
the insect Na
+
 channels leading to a series of convulsions, closely 
followed by death (Vijverberg and van den Bercken, 1990). There are 
two major advantages of the pyrethroids over other insecticides. 
Firstly, they are effective against a much broader spectrum of pests that 
other insecticides. Secondly, they lack efficacy towards humans. 
Mammalian Na
+
 channels are in the region of 1,000 times less 
sensitive to pyrethroids than the insect Na
+ 
channels and this, coupled 
with a higher body temperature and faster metabolism of the 
compounds in mammals, makes pyrethroids ideal pest-control agents 
(Vais et al., 2001). 
 
1.5 Insecticide resistance 
Initially, the use of DDT and other such insecticides and their effect on 
mosquito populations was remarkably successful. This early success in 
the control of malarial-vectors gave hope that the disease could be 
eradicated. However, the increase in disease prevalence over recent 
years has clearly indicated that this hope was false. The principal 
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reason for this is the pronounced increase in insecticide resistance 
(Ranson et al., 2000a). Although the basis of some of this resistance is 
still poorly understood, it is clear that insecticide resistance generally 
occurs either through enzymic metabolism of the compounds 
(Hemingway and Ranson, 2000) or through insensitivity of the target 
site, rendering it resistant to insecticide action. A specific example of 
the latter is the observed mutation in a Na
+
 channel gene in pyrethroid 
resistant Anopheles gambiae strains (Ranson et al., 2000b).  
Three classes of enzymes have been shown to confer resistance to 
insecticides; the carboxylesterases, the glutathione-S-transferases 
(GSTs) and the monooxygenases. Insecticide resistance is conferred by 
either amplification of the genes coding for these enzymes, altered 
gene expression leading to an over-expression of the enzymes or 
enhanced metabolic activity of the enzymes (Hemingway et al., 2004). 
 
1.5.1 Esterase-mediated insecticide resistance 
Esterase enzymes have been extensively studied as mediators of 
insecticide resistance. The majority of the work regarding the role of 
esterases in resistance has been performed on Culex mosquitoes and 
the Myzus aphid (Hemingway and Ranson, 2000) although other 
species such as Anopheles mosquitoes are also known to show 
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esterase-mediated resistance (Vulule et al., 1999). The increased levels 
of these carboxylesterases observed in resistant strains are generally 
the result of amplification of the genes coding for the enzymes 
resulting in increased enzyme synthesis (Mouches et al., 1986; Field et 
al., 1988). The mechanism of activity of these implicated 
carboxylesterases is perhaps a consequence of their overproduction in 
that their principal mode of action is by rapid binding and slow 
turnover of the insecticide. This leads to more of a sequestration of 
insecticide activity rather than an extensive metabolism of them 
(Kadous et al., 1983). 
 
1.5.2 GST-mediated insecticide resistance 
Glutathione-S-transferase (GST) is another enzyme implicated in 
conferring insecticide resistance. GST acts on insecticides by 
catalysing the nucleophilic attack of reduced glutathione (GSH) on 
electrophilic centres of lipophilic compounds (Hemingway and 
Ranson, 2000). Early studies suggested that the primary role of GST in 
insecticide resistance was by way of detoxification of DDT 
(Hemingway et al., 1985). As is the case of the carboxylesterases, 
many resistant insects have been shown to have elevated levels of GST 
(Grant et al., 1991), further enhancing the case for its role in 
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insecticide resistance. It would appear however that there are 
differences at the molecular level between how carboxylesterase and 
GST concentrations are increased. Whereas the increase in 
carboxylesterases is primarily down to gene amplification, GST levels 
are enhanced by alterations in regulatory genes leading to increased 
production and hence overall activity of these enzymes (Grant and 
Hammock, 1992). 
 
1.5.3 Monooxygenase-mediated insecticide resistance 
Due to the large number of implicated enzymes, monooxygenases 
confer the most common form of insecticide resistance to current 
compounds. Similarly to GST-mediated resistance mechanisms, the 
monooxygenases are generally up regulated as a result of alterations in 
regulatory genes (Cohen et al., 1994). Monooxygenases, such as 
cytochromes P450, are slightly different from other detoxification 
enzymes in that they are also required to activate certain 
organophosphate compounds to their more toxic form (Hemingway et 
al., 2004) and resistance can be conferred due to either a decrease in 
this activation as well as the conventional increase in detoxification 
(Scott et al., 1999). 
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Likewise with carboxylesterase and GST-mediated mechanisms, 
monooxygenases are also shown to be up-regulated in resistant strains 
(Vulule et al., 1994) but this system is complicated further by the 
requirement for binding partners to the monooxygenases. NADPH-
cytochrome P450 reductase (CPR) is required by all cytochromes P450 
to achieve its function and the up-regulation of CPR has also been 
implicated in pyrethroid resistance (Lycett et al., 2006). It is this 
binding partner, the CPR, which I shall focus on in more detail. 
 
1.6 NADPH-cytochrome P450 reductase 
NADPH-cytochrome P450 reductase (CPR) is a 78 kDa diflavin-
containing enzyme found primarily bound to the membrane of liver 
microsomes within eukaryotic systems.  CPR is also found in bacterial 
systems; however, the machinery is quite different in these prokaryotes 
with the Bacillus megaterium P450 reductase (P450BM3) being a 
prominent example (Narhi and Fulco, 1986). Eukaryotic CPRs have 
four distinct domains; the N-terminal FMN-binding domain, the linker 
region, the C-terminal FAD/NADPH-binding domain and connecting 
domain. The FMN and FAD/NADPH-binding domains interact, 
respectively, with the prosthetic groups flavin mononucleotide (FMN) 
and flavin adenine dinucleotide (FAD). These cofactors are essential 
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for a fully functioning enzyme (Smith et al., 1994). The FMN and 
FAD cofactors bind with the protein in a 1:1:1 protein:FMN:FAD ratio 
(Vermilion and Coon, 1978).  
 
1.6.1 The diflavin-reductase „family‟ 
The domain organisation of CPR and other members of the diflavin 
reductase family are represented (Figure 1.6) and there is a marked 
similarity between them. Although the amino acid sequences differ 
slightly between the members of the family the overall domain 
structure is remarkably similar. Whilst novel reductase I (Paine et al., 
2000) and methionine synthase reductase (Leclerc et al., 1998) are 
almost identical to CPR, they lack only the membrane anchoring 
region, other diflavin-reductases are more noticeably different in 
organisation.  
The previously mentioned P450BM3 (Narhi and Fulco, 1986) is 
unique amongst diflavin-reductases in that its cytochrome P450 
element is linked to the reductase element in a single polypeptide chain 
(Figure 1.6) effectively providing B. megaterium with a fully 
functioning monooxygenase system with only the need for a single 
protein. Nitric oxide synthase (NOS) is another member of the family 
with its own additional features (Bredt et al., 1991).
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Fig. 1.6. A schematic overview of the domain organisation of the diflavin reductase family. In the above, CPR = cytochrome P450 
reductase; NR1 = novel reductase; BM3 = B. megaterium P450 containing reductase, SR = sulfite reductase; NOS = nitric oxide 
synthase and MSR = methionine synthase reductase. FAD and NADPH bind at separate regions within the same FAD/NADPH-
binding domain (orange). FAD binds towards the N-terminus of the domain whilat NADPH bidns at the C-terminus. *The α-subunit in 
SR is one of a octomer containing 3 other α-subunits along with four heme containing β-subunits. 
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Unlike P450BM3, which is linked to a cytochrome P450, NOS has an 
N-terminal oxygenase domain. This catalytic domain is linked to the 
reductase domain by a calmodulin binding region. Sulfite reductase 
(SR) is the member of the family most different to the rest (Ostrowski 
et al., 1989). In the case of SR, the FMN- and FAD/NADPH-binding 
domains first come together to form the α-subunit. Four of these α-
subunits then combine to form what is effectively an octomer 
containing 4 FMN and 4 FAD molecules. In the fully formed 
molecule, the α-subunit octomer combines with 4 heme containing β-
subunits resulting in a α8β4 oligomer. 
 
1.6.2 Ancestry of diflavin-reductases 
Despite structural and functional differences between the members of 
the diflavin-reductase family, the presence of the „reductase domain‟ 
remains constant throughout. It is now commonly regarded that this 
linking of an FMN-binding region to an FAD/NADPH-binding region 
to create a single diflavin-reductase has come about through a genetic 
fusion event (Porter and Kasper, 1986). Indeed, studies have uncovered 
significant homology between the major domains of diflavin 
reductases, such as CPR, and the two bacterial, monoflavin electron 
transport enzymes. The FMN-binding domain of CPR shows a distinct 
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homology to the bacterial flavodoxin whilst the FAD/NADPH-binding 
domain is homologous to the ferredoxin-NADP
+ 
reductase (Porter and 
Kasper, 1985). Evidence for CPR, and other diflavin-reductases, 
essentially being a fusion of these two bacterial enzymes comes from 
the fact that they themselves can serve as an electron transport system 
for cytochrome P450, albeit at a much lower rate (Jenkins and 
Waterman, 1998). The same is observed when the FMN- and 
FAD/NADPH-binding domains from CPR are expressed individually. 
The two domains can be recombined to regain reductase activity, again 
however at only a fraction of the rate of the intact enzyme (Smith et 
al., 1994). In both cases, this lower rate of activity is likely to come 
from the fact that in CPR, the inter domain linker region (Figure 1.6) 
acts to bring the flavin cofactors closer together so as to increase 
electron transfer efficiency (Sevrioukova et al., 1996).  
 
1.6.3 Electron transfer in CPR 
The transfer of electrons through CPR enzymes is a complex process 
and one that has been studied extensively. The coenzyme NADPH 
binds and delivers a pair of electrons in the form of a hydride ion to the 
FAD cofactor. In the majority of cases, the two-electron reduced FAD 
hydroquinone then supplies FMN one electron at a time before final 
37 
reduction of the terminal acceptor. There are two types of electron 
acceptor; firstly, those which accept electron from the FMN-binding 
domain such as cytochromes P450. Cytochrome c is a non-
physiological one-electron acceptor which also interacts at the FMN-
binding domain (Vermilion et al., 1981; Kurzban and Strobel, 1986).  
The second type, those which accept electrons from the FAD-binding 
domain such as ferricyanide. Oxidised nucleotide, NADP
+
, can also be 
an electron acceptor in a transhydrogenase reaction which is essentially 
a reversal of the hydride ion reduction of FAD (Murataliev et al., 
2004). 
For multi-substrate enzyme reactions, there are two schemes of kinetic 
mechanism: Ping-Pong and either ordered or random Bi-Bi (Cleland, 
1977). The Ping-Pong kinetic scheme requires the substrates to bind 
one at a time; essentially, the first substrate binds and is released 
before the second substrate binds and has its effect. The Bi-Bi scheme 
differs in that both substrates bind at the same time to make a 
substrate-enzyme ternary complex (Figure 1.7). This complex acts as 
the reactive intermediate before the substrates disassociate (Cleland, 
1977). In the case of insect CPR, early work suggested a Ping-Pong 
mechanism of kinetics for house fly (Musca domestica) (Wilson and 
Hodgson, 1971; Mayer and Prough, 1977) and the southern armyworm 
(Spodoptera eridania) (Crankshaw et al., 1979). However, more 
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recently, studies on primarily house fly CPR have provided compelling 
evidence that CPR actually operates with a random Bi-Bi kinetic 
mechanism (Murataliev et al., 1999).  
In addition to uncovering the kinetic mechanism, work on house fly 
CPR has also identified the rate limiting step of enzyme activity, in this 
case using cytochrome c reduction. The results show that the rate of 
hydride transfer from NADPH to FAD is about half the rate of overall 
catalysis. These data strongly imply that the rate of hydride transfer, 
and subsequent FAD reduction, is the rate limiting step in enzyme 
catalysis (Murataliev et al., 1999). This is in agreement with an earlier 
finding that for rat liver CPR, interflavin electron transfer occurs at a 
much faster rate than FAD reduction by NADPH (Oprian and Coon, 
1982). 
Another important question when considering electron transfer in CPR 
is which species acts as the terminal electron donor: the FMN 
semiquinone species (FMNH·) or the FMN hydroquinone species 
(FMNH2). There are two distinct forms of the FMN semiquinone CPR. 
The first form is generated following two electron reduction, after 
hydride donation, from NADPH. The second form is the so-called „air-
stable‟ semiquinone, so named presumably because of its remarkable
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Figure 1.7. A representation of the types of kinetic mechanism for multi-substrate systems. A – Ping-Pong 
mechanism where only one substrate is ever bound at one time. B – Random Bi-Bi mechanism where both substrates 
bind concurrently before activity and subsequent product release. In this scheme the reaction can take place along either 
pathway with the same end result achieved. In the above, E=enzyme, A and B = substrates, P and Q = products. Figure 
re-created from Murataliev et al., 2004. 
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stability in atmospheric oxygen; it is formed over time following 
incubation with stoichiometric amounts of NADPH. Interestingly, of 
the two forms of FMN semiquinone, only the first form is catalytically 
active whereas the „air-stable‟ form fails to effectively reduce 
cytochrome c. It is postulated that following prolonged incubation with 
nucleotide, the „air-stable‟ FMN semiquinone drifts into a kinetically 
stabilised conformation rendering it catalytically inactive (Murataliev 
and Feyereisen, 1999). 
The ability of CPR to readily form the „air-stable‟ semiquinone has 
compromised study of the kinetic mechanism of the enzyme. Early 
studies highlighted the formation of the „air-stable‟ semiquinone which 
was shown to be catalytically inactive. Because of this, the general 
assumption was that the FMN hydroquinone was the active species in 
enzyme catalysis (Masters et al., 1965). Two models were proposed 
where the enzyme cycled through 1-3-2-1 or 2-4-3-2 reduction states 
where the numbers signify the number of electrons present on the 
flavin cofactors. In both models, the FMN hydroquinone was the 
electron donor and a priming reaction was required for the enzyme to 
achieve a 3 or 4 electron state. During more recent studies, a number of 
observations have highlighted inconsistencies and contradictions in 
both the 1-3-2-1 and 2-4-3-2 cycles (Murataliev et al., 2004). 
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The observations, mentioned above can be summarised as follows. 
Firstly, although house fly reductase is able to oxidise two molecules 
of NADPH, but because NADPH will only readily bind to fully 
oxidised CPR, only oxidation of the first molecule is rapid enough to 
be considered part of the catalytic cycle. This strongly implies that no 
priming reaction is required for rapid catalysis (Murataliev and 
Feyereisen, 1999). Secondly, the 2-4-3-2 reduction state cycle should 
be excluded as a possible mechanism based on the unfavourability of 
its formation. Four-electron reduced CPR can only be achieved 
following approximately 8 hr under anaerobic conditions in the 
presence of both NADPH and a coenzyme regeneration system 
(Vermilion and Coon, 1978). 
With the 2-4-3-2 cycle all but eliminated as a possibility, the focus is 
turned to whether the 1-3-2-1 cycle is a probable kinetic mechanism or 
not. If this cycle is realistic as a potential mechanism, for one molecule 
of NADPH to reduce two cytochrome c, at least one of the electron 
pair must be delivered from the FMN semiquinone form meaning the 
semiquinone is a catalytically active species (Murataliev and 
Feyereisen, 1999). During steady state catalysis, only a minor 
proportion of CPR is in the FMN hydroquinone form (Murataliev and 
Feyereisen, 2000). This coupled with the fact that the rate of FMN 
hydroquinone formation from the semiquinone is around 5-10 times 
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slower than the maximal rate of cytochrome c reduction (Oprian and 
Coon, 1982; Shen et al., 1989; Bhattacharyya et al., 1991) strongly 
points towards the FMN semiquinone as the terminal electron donor. 
Although the above comparisons are between experiments performed 
on house fly, rabbit and rat CPR‟s, the same can be seen in human 
CPR where the rate of hydroquinone formation is considerably slower 
than cytochrome c reduction (Gutierrez et al., 2001). Although 
cytochrome c, the terminal acceptor used for catalysis experiments, is a 
non-physiological terminal acceptor, comparable results can be seen 
cytochrome P450 is incorporated (Guengerich and Johnson, 1997). 
Other members of the diflavin reductase family provide compelling 
evidence for the electron transfer mechanism is these enzymes; 
P450BM3 has been extensively studied and in this enzyme, the two-
electron reduced form is the catalytically active species. The three-
electron reduced form is catalytically inactive and, as in CPR, the four-
electron reduced enzyme is unobtainable in aerobic conditions (Li et 
al., 1991; Murataliev et al., 1997). The FMN semiquinone in sulfite 
reductase is also catalytically active (Zeghouf et al., 1998). 
All these data combined had led to the proposed catalytic mechanism 
in house fly CPR. NADPH binds to the enzyme and transfers two 
electrons, in the form of a hydride ion, to FAD. Two-electron reduced 
FAD transfers one electron to FMN to form an FAD/FMN double 
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Figure 1.8. The proposed catalytic mechanism of cytochrome c reduction in Musca domestica CPR. A = The oxidation of NADPH which occurs 
during stage 2 of the cycle generates two electrons (2 e
-
) and a proton (H
+
). B = The reduction of cytochrome c which occurs during stages 4 and 6 of 
the cycle. Two different cytochrome c molecules bind to and accept and electron from CPR. Electrons are passed to the cytochrome c molecules one at 
a time which gives rise to the proposed catalytic cycle of 0-2-1-0. Flavin cofactors become fully reduced (FADH2) by accepting two electrons or 
partially reduced (FAD· or FMN·) by accepting one electron.Figure adapted from Murataliev et al., 2004. 
B. Cytochrome c (Fe
3+
) + e
-   Cytochrome c (Fe2+) 
A. NADPH    NADP+ + H+ + 2e- 
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semiquinone species. This form is the catalytically active electron 
donor and once the FMN delivers an electron, the FMN semiquinone is 
replenished with the second electron from FAD. In essence the 
catalytic mechanism acts with a 0-2-1-0 reduction state cycle with 
electrons donated from the FMN semiquinone form (Murataliev and 
Feyereisen, 1999). An overview of the proposed mechanism of 
electron transfer is detailed in Figure 1.8. 
 
1.6.4. Interacting partners of CPR 
CPR is a key component of many pathways and thus has the ability to 
bind to and affect a number of interacting partners. These binding 
partners include squalene monooxygenase, heme oxygenase, fatty acid 
desaturase, cytochrome b5 and cytochromes P450. Interactions with the 
latter are possibly what CPR is best known for. However judging by 
the known interactions, it is clear that CPR is involved in a wide 
variety of different biological processes, enhancing its importance to 
cellular activity. 
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1.6.4.1 Cholesterol synthesis 
Squalene monooxygenase, formally squalene epoxidase, is an essential 
enzyme in the process of cholesterol synthesis. It is involved during the 
later stages of the process and is responsible for the epoxidation of 
squalene to 2, 3-oxidosqualene prior to its conversion to lanosterol. It 
is a 64 kDa FAD-containing enzyme bound to the endoplasmic 
reticulum and requires interaction with CPR to act as a reductant 
following binding to NADPH (Laden et al., 2000). 
 
1.6.4.2 Cytochrome b5 reduction 
Cytochromes b5 are ubiquitous electron transport hemoproteins found 
in a variety of organisms. Microsomal and mitochondrial cytochromes 
b5 are membrane bound whilst those found in erythrocytes are water 
soluble. Cytochrome b5 becomes reduced by NADH via cytochrome b5 
reductase, an FAD-containing flavoenzyme, however by binding at the 
FAD-binding domain of CPR; cytochrome b5 is also reduced by 
electrons acquired from NADPH (Enoch and Strittmatter, 1979). By 
acting through cytochrome b5, CPR has since been implicated in fatty 
acid elongation by incorporation of malonyl-CoA into fatty acid chains 
(Ilan et al., 1981). 
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1.6.4.3 Lipid peroxidation 
Lipid peroxidation is the oxidative degradation of unsaturated lipids by 
a free-radical chain reaction. It very readily affects cell membrane 
polyunsaturated lipids and can lead to damage of the membrane. CPR 
can act as the electron source for two stages of the lipid peroxidation 
reaction: the reduction of ADP-Fe
3+ 
to the radical ADP-Fe
3+
-O2
- 
and 
also the formation of the lipid hydroperoxide species which itself 
creates new lipid radicals capable of sustaining the peroxidation 
process (Sevanian et al., 1990). 
 
1.6.4.4 Heme oxygenase 
Heme oxygenase is a microsomal enzyme required to catalyse the 
oxidation of heme, at the α-methene bridge, to form biliverdin and 
carbon monoxide. Biliverdin is subsequently converted, by biliverdin 
reductase, to bilirubin. NAPDH and O2 are required for oxidation of 
heme by heme oxygenase and it has become apparent that active heme 
oxygenase utilizes electrons gained from CPR to fulfil its function. 
Heme oxygenase is probably most active in the spleen in the 
conversion of heme from old erythrocytes (Schacter et al., 1972).   
 
47 
1.6.4.5 Cytochrome P450 
The major physiological electron acceptors for CPR are the 
cytochromes P450. Cytochromes P450 (CYPs) are an extremely large 
super-family of heme-containing enzymes consisting of many 
hundreds of members and are found in nearly all forms of life. 
Eukaryotic CYPs are located within the membrane of the endoplasmic 
reticulum or mitochondria. They are heavily involved in the 
metabolism of fatty acids, steroids and, possibly most significantly, 
xenobiotic compounds using molecular oxygen as well as reducing 
equivalents, gained from CPR upon binding of NADPH (Feyereisen, 
1999). 
Insects come into contact with a multitude of exogenous compounds 
on a daily basis. CYPs, therefore play an essential role in the 
metabolism of such compounds. Insects contain hundreds of different 
CYP isoforms each with its own duty in the effective clearance of 
potentially toxic substances, indeed some compounds are actually 
activated by CYPs which could be either helpful or harmful to the 
insect. Figure 1.9 provides a simplified overview of the 
monooxygenase system involving CPR and CYP with CPR in a central 
position. The role of insect CPR in reducing CYP is vital in xenobiotic 
metabolism and subsequent conferring of monooxygenase-mediated 
insecticide resistance mechanisms. With this in mind, the potential for 
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Fig. 1.9. A schematic overview of the monooxygenase system involving cytochrome P450 and 
cytochrome P450 reductase. CPR, after interaction with coenzyme NADPH, reduces CYP as part of 
phase I metabolism in xenobiotic processing. CPR may also interact with a number of other acceptors 
such as heme oxygenase and squalene monooxygenase as well as a number of non-physiological 
acceptors including cytochrome c and potassium ferricyanide. 
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inhibition of CPR in insecticide resistant strains in particular, the 
Anopheline malarial vectors, cannot be ignored.  
 
1.6.5 Sequence alignments of CPRs  
For many years, CPR‟s from a multitude of organisms have been 
studied. Figure 1.10 is the alignment of the amino acid sequences of 
the most commonly studied CPR‟s with a few additions. The 
Anopheline mosquito‟s A. gambiae and A. minimus, the well 
characterised Musca domestica and the model organism D. 
melanogaster are samples from the insect family. As well as these 
insect enzymes, the mammalian Homo sapiens and Rattus norvegicus 
have been compared. The remaining enzymes in the alignment are 
from the Saccharomyces cerevisiae whose structure was recently 
solved, the FMN-binding domain-like flavodoxin, and the FAD-
binding domain-like ferredoxin and for additional comparison 
methionine synthase reductase (MSR), another member of the diflavin 
reductase family (Figure 1.6). 
The alignment confirms the high levels of similarity between all the 
sample CPRs with particularly high homology between the insect 
derived enzymes and, likewise, between the rat and human samples. 
The yeast enzyme is the least similar to any of the rest of the sample; 
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however, at around 30 % similarity to the other CPRs there is still a 
clear sequence similarity. The flavodoxin aligns well to the FMN-
binding domain of all the CPR‟s as does the ferredoxin align with the 
FAD-binding domains corroborating the theory that diflavin reductases 
such as CPR derived from some sort of fusion between these 
monoflavin proteins (Porter and Kasper, 1986). 
The highlighted regions on the alignment show a high level of 
homology between all the CPR‟s for the particular residues known to 
be involved in FMN, FAD and NADPH binding. Subtle differences, 
however, are present such as residue Y456 in rat CPR. This residue is 
implicated in FAD binding and differences in the equivalent residues 
in the Anopheline samples (H459 in A. gambiae and S459 in A. 
minimus) could potentially have an impact on FAD binding in these 
enzymes. Such high levels of similarity between the CPRs, particularly 
in the key residues for flavin and coenzyme binding, do not account for 
the differences in observed characteristics. It is more likely that local 
conformational differences could be responsible. There is, therefore, a 
need for more in-depth structural analysis in order to explain these 
differences.
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A.gambiae       MDAQTETEVPAGSVS---DEPFLGPLDIVLLVSLLAGTAWYLLKGKKKESQASQFKSYSI 57 
Minimus         MDAQAETEMPTGSVS---DEPFLGPLDIILLVCLLAGTAWYLLKGKKKENQASQFKSYSI 57 
Fly             MSAEHVEEVVS-------EEPFLGTLDIALLVVLLVGATWYFMRSRKKEEAP--IRSYSI 51 
Drosophila      MASEQTIDGAAAIPSGGGDEPFLGLLDVALLAVLIGGAAFYFLRSRKKEEEP--TRSYSI 58 
Human           MGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVP------EF 54 
Rat             MGDSHEDTSATMPEAVAEEVSLFSTTDMVLFSLIVGVLTYWFIFRKKKEEIP------EF 54 
Yeast           ------------------MPFGIDNTDFTVLAGLVLAVLLYVKRNSIKELLMS------- 35 
MSR             ------------------------MRRFLLLYATQQGQAKAIAEEMCEQAVVH------- 29 
Flavodoxin      ------------------------------------------------------------ 
Ferredoxin      ------------------------------------------------------------ 
                                                                             
 
A.gambiae       QPTTVNTMTMVENSFIKKLQSSGRRLVVFYGSQTGTAEEFAGRLAKEGIR-YQMKGMVAD 116 
Minimus         QPTTVNTMTMVENSFIKKLQSSGRRLVVLYGSQTGTAEEFAGRLAKEGIR-YQMKGMVAD 116 
Fly             QPTTVSTVSTTENSFIKKLKASGRSLVVFYGSQTGTAEEFAGRLAKEGLR-YRMKGMVAD 110 
Drosophila      QPTTVCTTSASDNSFIKKLKASGRSLVVFYGSQTGTGEEFAGRLAKEGIR-YRLKGMVAD 117 
Human           TKIQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHR-YGMRGMSAD 113 
Rat             SKIQTTAPPVKESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHR-YGMRGMSAD 113 
Yeast           DDGDITAVSSGNRDIAQVVTENNKNYLVLYASQTGTAEDYAKKFSKELVAKFNLNVMCAD 95 
MSR             -GFSADLHCISESDKYDLKTETAPLVVVVSTTGTGDPPDTARKFVKEIQN----QTLPVD 84 
Flavodoxin      -----------------------AKALIVYGSTTGNTEYTAETIARELAD-AGYEVDCRD 36 
Ferredoxin      ------------------------------------------------------------ 
                                                                             
 
A.gambiae       PEECNMEELLMLKDIDKSLAVFCLATYGEG--DPTDNCMEFYDWIQNNDL-----DMTGL 169 
Minimus         PEECNMEELLMLKDIDKSLAVFCLATYGEG--DPTDNCMEFYDWIQNNDL-----DMTGL 169 
Fly             PEECDMEELLQMKDIPNSLAVFCLATYGEG--DPTDNAMEFYEWITNGEV-----DLTGL 163 
Drosophila      PEECDMEELLQLKDIDNSLAVFCLATYGEG--DPTDNAMEFYEWITSGDV-----DLSGL 170 
Human           PEEYDLADLSSLPEIDNALVVFCMATYGEG--DPTDNAQDFYDWLQETDV-----DLSGV 166 
Rat             PEEYDLADLSSLPEIDKSLVVFCMATYGEG--DPTDNAQDFYDWLQETDV-----DLTGV 166 
Yeast           VENYDFESLNDVPVIVS----IFISTYGEG--DFPDGAVNFEDFICNAEAG----ALSNL 145 
MSR             FFAHLRYGLLGLGDSEYTYFCNGGKIIDKR--LQELGARHFYDTGHADDCVGLELVVEPW 142 
Flavodoxin      AASVEAGGLFEG----FDLVLLGCSTWGDDSIELQDDFIPLFDSLEETGAQ-------GR 85 
Ferredoxin      ------------------------------------------------------------ 
                                                                             
 
A.gambiae       NYAVFGLGNKTYEHYNKVGIYVDKRLEELGANRVFELGLGDDDA-NIEDYFITWKEKFWP 228 
Minimus         NYAVFGLGNKTYEHYNKVGIYVDKRLEELGANRVFELGLGDDDA-NIEDYLITWKEKFWP 228 
Fly             NYAVFGLGNKTYEHYNKVAIYVDKRLEELGATRVFELGLGDDDA-NIEDDFITWKDRFWP 222 
Drosophila      NYAVFGLGNKTYEHYNKVAIYVDKRLEELGANRVFELGLGDDDA-NIEDDFITWKDRFWP 229 
Human           KFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDG-NLEEDFITWREQFWP 225 
Rat             KFAVFGLGNKTYEHFNAMGKYVDQRLEQLGAQRIFELGLGDDDG-NLEEDFITWREQFWP 225 
Yeast           RYNMFGLGNSTYEFFNGAAKKAEKHLSAAGAIRLGKLGEADDGAGTTDEDYMAWKDSILE 205 
MSR             IAGLWPALRKHFRSSRGQEEISGALPVASPASLRTDLVKSELLHIESQVELLRFDDSGRK 202 
Flavodoxin      KVACFGCGDSSYEYFCGAVDAIEEKLKNLGAEIVQDGLRIDGDPRAARDDIVGWAHDVRG 145 
Ferredoxin      ------------------------------------------------------------ 
                                                                             
 
A.gambiae       --TVCDYFGIESTGEDVLMRQYRLLEQPDVSADRIYTGEVARLHSLQTQR---------- 276 
Minimus         --TVCDFFGIESTGEDVLMRQYRLLEQPEVGADRIYTGEVARLHSLQTQR---------- 276 
Fly             --SVCDFFGIEGSGEEVLMRQFRLLEQPDVQPDRIYTGEIARLHSMQNQR---------- 270 
Drosophila      --AVCDHFGIEGGGEEVLIRQYRLLEQPDVQPDRIYTGEIARLHSIQNQR---------- 277 
Human           --AVCEHFGVEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQK---------- 273 
Rat             --AVCEFFGVEATGEESSIRQYELVVHEDMDVAKVYTGEMGRLKSYENQK---------- 273 
Yeast           --VLKDELHLDEQEAKFTSQFQYTVLNEITDSMSLGEPSAHYLPSHQLNRNADGIQ---- 259 
MSR             DSEVLKQNAVNSNQSNVVIEDFESSLTRSVPPLSQASLNIPGLPPEYLQVHLQESLGQEE 262 
Flavodoxin      --AI-------------------------------------------------------- 147 
Ferredoxin      -------------------------AKTDIPVN--------------------------- 8 
                                                                             
 
A.gambiae       ---PPFDAKNPFLAPIKVNRELHK-AGGRSCMHVEFDIEGSKMRYEAGDHLAMYPVN-DR 331 
Minimus         ---PPFDAKNPFLAPIKVNRELHK-AGGRSCMHVEFDIEGSKMRYEAGDHLAMYPVN-DR 331 
Fly             ---PPFDAKNPFLASVIVNRELHK-GGGRSCMHIELDIDGSKMRYDAGDHIAMYPIN-DK 325 
Drosophila      ---PPFDAKNPFLAPIKVNRELHK-GGGRSCMHIELSIEGSKMRYDAGDHVAMFPVN-DK 332 
Human           ---PPFDAKNPFLAAVTTNRKLNQ-GTERHLMHLELDISDSKIRYESGDHVAVYPAN-DS 328 
Rat             ---PPFDAKNPFLAAVTANRKLNQ-GTERHLMHLELDISDSKIRYESGDHVAVYPAN-DS 328 
Yeast           --LGPFDLSQPYIAPIVKSRELFS-SNDRNCIHSEFDLSGSNIKYSTGDHLAVWPSN-PL 315 
MSR             SQVSVTSADPVFQVPISKAVQLTTNDAIKTTLLVELDISNTDFSYQPGDAFSVICPNSDS 322 
Flavodoxin      ------------------------------------------------------------ 
Ferredoxin      ----IYKPKNPYIGKCLSNEELVREGGTGTVRHLIFDISGGDLRYLEGQSIGIIPPG--- 61 
                                                                             
 
A.gambiae       DLVERLGRLCNAELDTVFSLINTDTDSSKKHP-----FPCPTTYRTALTHYLEITALPRT 386 
Minimus         DLVERLGKLCNADLETVFSLINTDTDSSKKHP-----FPCPTTYRTALTHYLEITALPRT 386 
Fly             ILVEKLGKLCDANLDTVFSLINTDTDSSKKHP-----FPCPTTYRTALTHYLEITAIPRT 380 
Drosophila      SLVEKLGQLCNADLDTVFSLINTDTDSSKKHP-----FPCPTTYRTALTHYLEITAIPRT 387 
Human           ALVNQLGKILGADLDVVMSLNNLDEESNKKHP-----FPCPTSYRTALTYYLDITNPPRT 383 
Rat             ALVNQIGEILGADLDVIMSLNNLDEESNKKHP-----FPCPTTYRTALTYYLDITNPPRT 383 
MEMBRANE ANCHOR REGION 
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Yeast           EKVEQFLSIFNLDPETIFDLKPLDP--TVKVP-----FPTPTTIGAAIKHYLEITGPVSR 368 
MSR             EVQSLLQRLQLEDKREHCVLLKIKADTKKKGATLPQHIPAGCSLQFIFTWCLEIRAIPKK 382 
Flavodoxin      ------------------------------------------------------------ 
Ferredoxin      ------------------------------------------------------------ 
                                                                             
 
A.gambiae       HILKELAEYCGEEKDKEFLRFISSTAPDGKAKYQEWVQDSCRNIVHVLEDIPSCHPPIDH 446 
Minimus         HILKELAEYCSEEKDKEFLRFISSTAPEGKAKYQEWVQDSCRNVVHVLEDIPSCHPPIDH 446 
Fly             HILKELAEYCSDEKDKEFLRNMASITPEGKEKYQNWIQNSSRNIVHILEDIKSCRPPIDH 440 
Drosophila      HILKELAEYCTDEKEKELLRSMASISPEGKEKYQSWIQDACRNIVHILEDIKSCRPPIDH 447 
Human           NVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDH 443 
Rat             NVLYELAQYASEPSEQEHLHKMASSSGEGKELYLSWVVEARRHILAILQDYPSLRPPIDH 443 
Yeast           QLFSSLIQFAPNADVKEKLTLLSKDKDQFAVEITSKYFNIADALKYLSDGAKWDTVPMQF 428 
MSR             AFLRALVDYTSDSAEKRRLQELCSK--QGAADYSRFVRDACACLLDLLLAFPSCQPPLSL 440 
Flavodoxin      ------------------------------------------------------------ 
Ferredoxin      ---------TDNNGKPHKLRKYSIASTRHG------------------------------ 82 
                                                                             
 
A.gambiae       VCELLPRLQPRYHSISSSSKLHPTTVHVTAVLVKYETK---TGRLNKGVATTFLAEKHPN 503 
Minimus         VCELLPRLQPRYSSISSSSKIHPTTVHVTAVLVKYETK---TGRLNKGVATTFLAEKHPN 503 
Fly             ICELLPRLQPRYYSISSSSKLYPTNVHITAVLVQYETP---TGRVNKGVATSYMKEKNPS 497 
Drosophila      VCELLPRLQPRYYSISSSAKLHPTDVHVTAVLVEYKTP---TGRINKGVATTYLKNKQPQ 504 
Human           LCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETK---AGRINKGVATNWLRAKEPA 500 
Rat             LCELLPRLQARYYSIASSSKVHPNSVHICAVAVEYEAK---SGRVNKGVATSWLRAKEPA 500 
Yeast           LVESVPQMTPRYYSISSSSLSEKQTVHVTSIVENFPNPELPDAPPVVGVTTNLLRNIQLA 488 
MSR             LLEHLPKLQPRPYSCASSSLFHPGKLHFVFNIVEFLST-ATTEVLRKGVCTGWLALLVAS 499 
Flavodoxin      ------------------------------------------------------------ 
Ferredoxin      ------------------DHVDDKTVSLCVRQLEYKHP--ETGETVYGVCSTYLCNLEAG 122 
                                                                             
 
A.gambiae       DGEP---------------------APRVPIFIRKS-QFRLPPKPETPVIMVGPGTGLAP 541 
Minimus         DGEP---------------------LPRVPIFIRKS-QFRLPPKPETPVIMVGPGTGLAP 541 
Fly             VG-----------------------EVKVPVFIRKS-QFRLPTKSEIPIIMVGPGTGLAP 533 
Drosophila      GSE----------------------EVKVPVFIRKS-QFRLPTKPETPIIMVGPGTGLAP 541 
Human           GENG--------------------GRALVPMFVRKS-QFRLPFKATTPVIMVGPGTGVAP 539 
Rat             GENG--------------------GRALVPMFVRKS-QFRLPFKSTTPVIMVGPGTGIAP 539 
Yeast           QNNVNIAETNLPVHYDLNGPRKLFANYKLPVHVRRS-NFRLPSNPSTPVIMIGPGTGVAP 547 
MSR             VLQPN--------IHASHEDSGKALAPKISISPRTTNSFHLPDDPSIPIIMVGPGTGIAP 551 
Flavodoxin      ------------------------------------------------------------ 
Ferredoxin      AD--------------------------VAITGPVGKEMLLPEDEDATIIMMATGTGIAP 156 
                                                                             
 
A.gambiae       FRGFIQERDHCKQEGKE------IGQTTLYFGCRKRSEDYIYEDELEDYSK--RGIIN-L 592 
Minimus         FRGFIQERDFSKQEGKD------IGQTTLYFGCRKRSEDYIYEDELEDYSK--RGIIN-L 592 
Fly             FRGFIQERQFLRDGGKV------VGDTILYFGCRKKDEDFIYREELEQYVQ--NGTLT-L 584 
Drosophila      FRGFIQERQFLRDEGKT------VGESILYFGCRKRSEDYIYESELEEWVK--KGTLN-L 592 
Human           FIGFIQERAWLRQQGKE------VGETLLYYGCRRSDEDYLYREELAQFHR--DGALTQL 591 
Rat             FMGFIQERAWLREQGKE------VGETLLYYGCRRSDEDYLYREELARFHK--DGALTQL 591 
Yeast           FRGFIRERVAFLESQKKGGNNVSLGKHILFYGSR-NTDDFLYQDEWPEYAKKLDGSFEMV 606 
MSR             FIGFLQHREKLQEQHPDG----NFGAMWLFFGCRHKDRDYLFRKELRHFLK--HGILTHL 605 
Flavodoxin      ------------------------------------------------------------ 
Ferredoxin      FRAFLWRIFKEQHEDYK------FKGLWALFFGIPYSPNILYQQELEELQEEFPENFR-L 209 
                                                                             
 
A.gambiae       RVAFSRDQ------EKKVYVTHLLEQDSDLIWSVIGENKGHFYICGDAKNMATDVRNILL 646 
Minimus         RVAFSRDQ------DKKVYVTHLLEQDSDLIWNVIGENKGHFYVCGDAKNMATDVRNILL 646 
Fly             KTAFSRDQ------QEKIYVTHLIEQDADLIWKVIGEQKGHFYICGDAKNMAVDVRNILV 638 
Drosophila      KAAFSRDQ------GKKVYVQHLLEQDADLIWNVIGENKGHFYICGDAKNMAVDVRNILV 646 
Human           NVAFSREQ------SHKVYVQHLLKQDREHLWKLI-EGGAHIYVCGDARNMARDVQNTFY 644 
Rat             NVAFSREQ------AHKVYVQHLLKRDREHLWKLIHEGGAHIYVCGDARNMAKDVQNTFY 645 
Yeast           VAHSRLPN------TKKVYVQDKLKDYEDQVFEMINNG-AFIYVCGDAKGMAKGVSTALV 659 
MSR             KVSFSRDAPVGEEEAPAKYVQDNIQLHGQQVARILLQENGHIYVCGDAKNMAKDVHDALV 665 
Flavodoxin      ------------------------------------------------------------ 
Ferredoxin      TLAISREQQ--NPEGGKMYIQDRIKENADQLWELIQKPNTHTYICG-----LKGMEGGID 262 
                                                                             
 
A.gambiae       KVIRSKGGLSETEAQQYIKKMEAQKRYSADVWS 679 
Minimus         KVIRSKGGLSETEAQQYIKKMEAQKRYSADVWS 679 
Fly             KILSTKGNMNESDAVQYIKKMEAQKRYSADVWS 671 
Drosophila      KILSTKGNMSEADAVQYIKKMEAQKRYSADVWS 679 
Human           DIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWS 677 
Rat             DIVAEFGPMEHTQAVDYVKKLMTKGRYSLDVWS 678 
Yeast           GILSRGKSITTDEATELIKMLKTSGRYQEDVW- 691 
MSR             QIISKEVGVEKLEAMKTLATLKEEKRYLQDIWS 698 
Flavodoxin      --------------------------------- 
Ferredoxin      EGMSAAAGKFDVDWSDYQKELKKKHRWHVETY- 29
Figure 1.10. Sequence alignments of a variety of CPR’s and related proteins. The 
key residues in FMN, FAD and NADPH binding are highlighted in yellow. Residue 
Y456 (rat numbering) and its equivalents are highlighted in blue. The membrane anchor 
region, FMN-binding domain, inter-domain linker region and FAD/NADPH-binding 
domain boundaries are shown. The alignment was generated using ClustalW. 
FAD/NADPH-BINDING DOMAIN 
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1.6.6 Structure of CPR 
The domain organisation of CPR involving the N-terminal FMN-
binding domain, the linker region, the C-terminal FAD/NADPH-
binding domain and connecting domain is shown in Figure 1.6. 
Although the FMN- and FAD/NADPH-binding domains have the 
ability to fold and behave independent of each other (Porter and 
Kasper, 1985), the other major domains of CPR such as the linker 
region and connecting domain are absolutely essential for a fully 
functioning reductase (Smith et al., 1994). The first crystal structure of 
a CPR enzyme was that of the Rattus norvegicus CPR (rCPR) in 1997 
by Wang et al. The solved crystal structure (PDB: 1AMO) is a soluble, 
NADP
+
 bound form of the enzyme crystallised without the 6 kDa 
hydrophobic membrane anchor domain. Whilst this soluble CPR lacks 
the ability to interact with membrane bound CYPs, (Anderson et al., 
1994) it retains enzymatic activity as shown by its ability to transfer 
electrons to non-physiological acceptors such as cytochrome c.  
The FMN-binding domain consists of five α-helices flanking a five-
stranded parallel β-sheet with the FMN cofactor binding to the tip of 
the β-sheet at the C-terminal side. The FAD/NADPH-binding domain 
comprises two separate entities, the FAD-binding portion and the 
NADPH binding portion. The FAD binding portion is an anti-parallel 
β-barrel whilst the NADPH-binding portion is of similar structure to 
54 
the FMN-binding domain with a parallel β-sheet sandwiched by α-
helices. The primarily α-helical connecting domain appears to almost 
split the FAD-binding portion and this domain, along with the 
disordered inter-domain loop region appear to act as a hinge to bring 
the FMN- and FAD/NADPH-binding domains together. This positions 
the FMN and FAD flavins within close proximity of each other to 
enhance electron transfer efficiency (Wang et al., 1997). More 
recently, a second structure has been solved, that of N-terminal 
truncated Saccharomyces cerevisiae CPR in 2006 by Lamb et al.  
Although the two structures appear well conserved with the same 
general structure consisting of the FMN-binding, FAD/NADPH-
binding and connecting domains along with the inter-domain linker 
region, there appear to be two major observable differences between 
the two proteins.  
The crystallised yeast CPR (yCPR) appears to have a second FMN 
molecule incorporated into the structure. The second FMN binding site 
(the „FMN2 site‟) is positioned at the interface between the FMN-
binding domain and the connecting domain. The second FMN cofactor 
appears to be less tightly bound to the CPR as it is more exposed and 
highly accessible to the bulk solvent. However, analysis of the flavin 
content of the yCPR gives an equimolar FMN:FAD:CPR ratio
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NADP
+
 
FAD 
FMN 
Figure 1.11. The solved structure of rat CPR. The 
crystal structure was reported by Wang et al., 1997. 
The FMN-binding domain (blue), FAD-binding 
domain (green) and connecting regions (red) are 
clearly shown. The flavin cofactors are shown as 
purple ball and stick models whilst the partially 
resolved NADP
+ 
is shown as orange. This truncated 
soluble form is without the membrane anchor region. 
PDB – 1AMO. 
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suggesting that only one of the two FMN-binding sites is normally 
occupied. The apparent unnatural occupancy of both FMN-binding 
sites in the solved structure could be due to the large excess of FMN 
added to the sample prior to crystal growth. It is thought that a single 
FMN cofactor shuttles between the two FMN-binding sites during 
electron transfer in yCPR. It has recently been shown that this second 
FMN binding site, despite being exposed at the protein surface, is 
highly specific for FMN over other similar compounds including FAD 
(Ivanov et al., 2010). 
A second observed difference between the solved yCPR and rCPR 
structures is the conformation of the FAD adenosine moiety. In yCPR, 
the FAD adenosine sits in a hydrophobic pocket formed between the 
connecting and FAD/NADPH-binding domains whilst in rCPR its 
position is slightly shifted (Figure 1.12). It is possible that the position 
of the FAD adenosine moiety creates hindrance and prevents FMN 
binding to the „FMN2‟ site which is conserved in rCPR. This is a 
possible reason as to why only one FMN cofactor is observed in the 
rCPR solved structure compared to the two FMN cofactors in the 
yCPR equivalent (Lamb et al., 2006).. 
Although the rat and yeast CPR structures have been the only ones 
currently solved for wild type enzymes, a number of other structures 
have also been reported. The range of W677 mutant rat CPR‟s
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A B 
Figure 1.12. The relative orientation of the flavin cofactors in yeast and rat CPR’s. A = Yeast CPR, B = Rat CPR. In both 
cases the FMN (blue), FAD (red) and NADP
+ 
(purple) are shown. The protein molecule has been removed in each case for ease of 
viewing Note the presence of the second FMN molecule in yeast CPR. The FAD isoalloxazine ring and NADP
+ 
in the rat CPR 
structure are poorly resolved. The different orientation of the FAD adenosine ring is highlighted. Figures generated using PyMol 
and PDB numbers 1AMO for rat CPR and 2BF4 for yeast CPR. 
FAD adenosine ring 
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(Hubbard et al., 2001) are, like the rat and yeast structures, in a closed 
conformation with FMN and FAD in close proximity. However, 
recently, a mutated rat CPR with four amino acids deleted from the 
inter-domain linker region has been solved in three extended open 
conformations (Hamdane et al., 2009). In these structures, the 
distances between the FMN and FAD cofactors are between 29 and 60 
Å rather than the 3.5 Å seen in the wild type rat CPR structure (Wang 
et al., 1997). It is suggested that CPR is likely to adopt such an open 
conformation when interacting with cytochrome P450. The structure of 
a yeast FMN-human FAD-domain chimera in an open conformation 
has also been solved showing a similarly large distance between the 
flavin cofactors with a separation of 86 Å (Aigrain et al., 2009). 
 
1.6.7 FMN-binding domain 
The N-terminal FMN-binding domain is primarily involved in 
interactions with its physiological partners, CYP molecules, and with 
non-physiological proteins such as cytochrome c.  The position of the 
FMN cofactor means it is regularly exposed to the surrounding solvent, 
particularly when the domain moves via the hinge region during 
electron transfer. This exposure to solvent explains the findings that 
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FMN easily and readily dissociates from the CPR (Vermillion and 
Coon 1978).  
In the solved rCPR structure, the FMN cofactor was shown to be 
bound to fragments 
139
TYGEGPD and 
175
NKTYEHFN where tyrosine 
residues Y140 and Y178 cover the isoalloxazine ring of FMN on the re 
and si-sides respectively (Wang et al., 1997) (Figure 1.13). Prior to full 
structural determination, previous biochemical data highlighted the 
necessity of these residues. Sequence comparison of rat liver 
oxidoreductase with Desulfovibrio vulgaris flavodoxin indicated Y140 
and Y178 were indeed involved in FMN-binding. Site-directed 
mutagenesis confirmed that substitution of Y178 with a non-aromatic 
aspartate virtually abolished both FMN-binding and subsequent 
catalytic activity. Although the same substitution of Y140 did not have 
a dramatic effect on FMN-binding, catalytic activity was 
compromised, suggesting that the cofactor binds in an unfavourable 
conformation for electron transfer (Shen et al., 1989). 
Several flavodoxin structures from a wide range of species have been 
elucidated using both X-ray crystallography and Nuclear Magnetic 
Resonance (NMR) techniques. Flavodoxin structures from Clostridia 
(Burnett et al., 1974), Desulfovibrio vulgaris (Watt et al., 1991; 
Stockman et al., 1993; Knauf et al., 1996), the red alga Chondrus 
crispus (Fukuyama et al., 1992), Anabaena (Rao et al., 1992), 
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Azotobacter chroococcum (Peelen et al., 1996) and Desulfovibrio 
desulfuricans (Romero et al., 1996) have all been solved. In addition, 
the FMN-binding domain crystal structure of human CPR has also 
been solved by NMR (Zhao et al., 1999).   
 
1.6.8 FAD/NADPH-binding domain 
The larger C-terminal FAD/NADPH-binding domain is principally 
involved in binding NADPH thus beginning electron transfer through 
FAD and FMN to respective acceptor molecules. Unlike the FMN 
molecule, FAD is less readily available to the surrounding solvent due 
to its position within the CPR molecule. The isoalloxazine ring is 
positioned at the boundary between the FAD and NADPH binding 
sites; this is ideal positioning for accepting electrons from NADPH. 
The remainder of the FAD molecule is positioned at the hydrophobic 
interface between the FAD-binding and connecting domains. 
In the solved rCPR structure, the FAD molecule is shown to be bound 
within the fragments 
455
YYSIAS and 
471 
ICAVAV. The penultimate 
residue in the amino acid sequence, W677, is also essential in FAD 
binding as the tryptophan indole ring is stacked against the re-side of 
FAD whilst the residue Y456 stacks against the si-side of the 
flavin.isoalloxazine ring. 
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A B 
FMN 
FAD 
Y178 
Y140 
Y478 
W677 
Y456 C472 
T491 
R454 
Figure 1.13. The residues involved in FMN and FAD-binding in rat CPR. A = the FMN binding site. The flavin is shown bound to the edge of 
the FMN-binding domain (blue) and is stacked by the two tyrosine residues. B = the FAD binding site. The key residues involved in FAD binding 
are highlighted including the W677 residue stacked against the isoalloxazine ring of FAD. In both cases for simplicity, some of the surrounding 
residues have been removed from the image. PDB-1AMO.  
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The pyrophosphate region is stabilised by the side chains of T491 and 
R454 and the ribityl-pyrophosphate chain lies almost parallel to 
residue C472 and Y478 (Figure 1.13). Y478 is further involved by 
stacking of its phenolic ring against the adenine ring of the adenosine 
moiety (Wang et al., 1997). 
 
1.7 Nucleotide binding 
NADPH binding is the key event in CPR catalytic activity, having a 
marked effect on a number of events including electron transfer and 
the rate of reduction on both physiological and non-physiological 
electron acceptors. Studies on the ferredoxin-NADP+ reductase (FNR) 
protein family have an established bipartite nature of coenzyme 
binding suggesting that the flexibility of the NADPH molecule is 
crucial in how it interacts with FNR as well as members of the diflavin 
reductase family such as CPR (Deng et al., 1999; Piubelli et al., 2000). 
A 2:1 nucleotide:protein ratio model indicating two NADPH binding 
sites had been proposed (Gutierrez et al., 2001); however, a more 
recent 1:1 stoichiometric model has been suggested (Daff et al., 2004). 
This 1:1 stoichiometry has since been confirmed and the 2:1 model 
withdrawn citing possible sample contamination with 2‟-AMP, 
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following 2‟5‟-ADP sepharose purification, as the culprit for erroneous 
data (Grunau et al., 2006). 
 
1.7.1 Recognition of 2‟-phosphate 
The bipartite nature of NADPH binding is further revealed by the 
presence of distinct binding sites for the 2‟-phosphate and 
nicotinamide (NMN) moieties. The 2‟-phosphate binding site in human 
CPR is shown to involve residues S596, R597, K602 and Y604 (Figure 
1.14). Initial recognition of NADPH takes place at this 2‟-phosphate 
binding site and interestingly, the NMN moiety seems to provide little 
by way of contribution to the overall binding energy. Probably the key 
residue in the 2‟-phosphate binding site is R597 which is positioned to 
form a salt bridge with the 2‟-phosphate of NADPH with the R597A 
mutant showing severely impaired nucleotide binding affinity. 2‟-
phosphate is the primary source of binding energy; however, the 5‟-
phosphate group has also been shown to be of significance. CPR has a 
much lower binding affinity for 2‟-AMP than for 2‟5‟-ADP 
highlighting a synergistic effect involving 5‟-phosphate. The residue 
likely to be involved in interacting with 5‟-phosphate is R298 – a basic 
residue positioned close to the 2‟-phosphate binding site. Recognition 
of the 2‟-phosphate group is highly precise as shown by the very weak 
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Y604 
K602 
R597 
S596 
2’ phosphate 
Figure 1.14 The residues surrounding the 2’ phosphate binding site. Residues that make up the 2‟ phosphate binding site are shown 
from the rat CPR structure. S596 (red), R597 (blue), K602 (cyan) and Y604 (purple) are shown surrounding the 2‟ phosphate group of 
NADP
+
. PDB- 1AMO. 
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binding affinity of CPR for 3‟5‟-ADP in relation to 2‟5‟-ADP (Grunau 
et al., 2006). 
CPR interacts with and receives electrons from NADPH much more 
effectively than NADH. The similarity in redox potentials observed 
when either nucleotide is used implies that electron transfer from 
NADH is just as energetically favourable as with the catalytic 
NADPH. Despite this, the maximal rate of catalysis is orders of 
magnitude faster when using NADPH (Shen et al., 1991; Murataliev et 
al., 1999). The principal reason for this efficient nucleotide 
discrimination is the much higher affinity which CPR shows for 
NADPH over NADH because of the presence of the 2‟-phosphate 
moiety. Added to this is the fact that flavins reduced by an NADPH 
source are a lot more stable than those reduced by NADH (Dohr et al., 
2001). 
 
1.7.2 Reduction state effect on interaction 
The highly flexible nature of NADPH not only affects the mechanism 
by which the nucleotide binds but also contributes to the shape of the 
molecule. In its reduced form, the NADPH adopts a flat conformation 
whereas the oxidised form adopts a so-called „boat‟ conformation. The 
similarities in binding affinity of CPR to 2‟,5‟-ADP and NADP+ 
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indicate a distinct lack of interaction between the oxidised NMN 
(NMN
+
) moiety and oxidised flavoprotein. This is a different case for 
reduced NADPH meaning oxidised CPR binds oxidised and reduced 
nucleotides with different affinities. Addition of a positive charge, as 
well as the altered shape of the nicotinamide ring is the reason for this 
apparent specificity. 
As well as the reduction state of the nucleotide, protein-nucleotide 
interaction is also dependent on the reduction state of the flavoprotein. 
Electron transfer and rapid enzyme catalysis occur when reduced 
NMN interacts with oxidised flavoprotein and as discussed above, the 
same oxidised enzyme cannot interact with NMN
+ 
moiety. In the same 
vein, reduced flavoprotein cannot accept further reducing equivalents 
from reduced NMN under normal aerobic conditions however it can 
interact with NMN
+
. This is one of the more intriguing aspects of the 
activity of CPR activity as the enzyme can effectively undergo a 
reversal of traditional electron transfer. The transhydrogenase reaction 
occurs by transferring electrons, in hydride ion form, from FADH2 to 
NADP
+
 (Murataliev and Feyereisen, 2000). The difference in binding 
properties of protein of different reduction states is important to 
remember when ascertaining binding affinity and properties of 
NADPH. When establishing, for example, binding affinity an 
alternative form of NADPH must be employed. 1,4,5,6-tetrahydro 
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NADP (H4NADP) is an example of a nonreactive analogue which has 
near identical binding properties of NADPH yet cannot serve as an 
electron donor and hence does not have the ability to alter the 
reduction state of the flavoprotein during the course of experiments 
(Grunau et al., 2006). 
 
1.7.3 Structural aspects of nucleotide interaction 
Structural study of this enzyme has brought to light some interesting 
features which could serve to explain mechanisms involved in 
nucleotide binding and the effect this may have on electron transfer 
and enzyme catalysis. Interaction of 2‟-phosphate is integral in 
correctly positioning the NMN moiety for binding. Although the NMN 
portion of NADPH is not fully resolved in solved structures of CPR 
(Wang et al., 1997), FNR (Karplus et al., 1991) or sulfite reductase 
(Sibille et al., 2005) yet the position where it is expected to bind is 
occupied by a bulky aromatic residue. This added to the fact that the 
regions where the 2‟-phosphate and nicotinamide moieties bind can be 
between 10-12 Å apart. These data suggest that, in order to overcome 
both the spatial overcrowding imparted by the aromatic residue and 
distance constraints, interaction with 2‟-phosphate could be coupled 
with a conformational shift to allow fast hydride transfer from NADPH 
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to FAD. This conformational shift is likely to be the reason for hydride 
transfer to FAD being the rate limiting step in catalysis (Murataliev 
and Feyereisen 1999).  
The residue C566 in rat CPR, equivalent residue C560 in house fly 
CPR (C568 in A. gambiae CPR), is close to where the NMN moiety is 
thought to interact. These suggestions are corroborated by evidence 
that the C560Y mutation shows decreased affinity for NADP
+
 but has 
little effect on 2‟-AMP affinity. Other substitutions with less bulky 
residues serine and methionine failed to yield such an effect suggesting 
spatial hindrance involving the aromatic tyrosine and the nicotinamide 
ring (Murataliev et al., 1999). The rat CPR crystal structure places the 
C566 residue close to the adenine ribose of NADP
+
 so it is possible 
that the residue is bought to the nicotinamide binding sire following 
initial NADPH interaction and subsequent conformational change 
(Wang et al., 1997). 
 
1.7.4 Global effect of NADPH binding 
NADPH binding, although occurring within the FAD-binding domain, 
is responsible for a number of effects throughout the enzyme. Not only 
is there a conformational change which allows NMN interaction, the 
structural shift has a more global effect. Inter-domain electron transfer 
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is strongly gated (Gutierrez et al., 2002) and binding of NADPH 
analogues leads to an increase of inter-domain electron transfer 
suggesting that FAD and FMN cofactors are brought into a favourable 
orientation for electron transfer (Gutierrez et al., 2003). Studies 
pertaining to the degree of separation of the two flavins show the 
degree of conformational shift that CPR undergoes following NADPH 
binding. In the ligand free protein there can be up to 20 Å separation of 
the flavins (Bastiaens et al., 1989) whilst the crystal structure, with 
NADP
+
 bound, positions the flavins as little as 4 Å apart (Wang et al., 
1997). 
Studies involving human CPR and the isolated FMN-binding domain 
with regards to different forms of cytochrome c reduction have 
highlighted the global effect that NADPH binding has on the rest of the 
enzyme. Fully oxidised CPR (or isolated FMN-binding domain) fails 
to interact with oxidised cytochrome c and the fact that reduced 
cytochrome c cannot interact with any form of CPR; this means that 
oxidised cytochrome c needs a form of reduced reductase to accept 
electrons.  
Dithionite reduced FMN-binding domain gives rise to the FMN-
semiquinone and subsequently, electron transfer and cytochrome c 
reduction take place. Despite the FMN-semiquinone being required for 
formation of the kinetically competent complex, the use of dithionite to 
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partially reduce CPR by one electron, thus leading to the formation of 
the „air-stable‟ semiquinone, fails to show any binding or reduction 
with respect to cytochrome c. This resembles the inhibition seen when 
house fly CPR is subjected to prolonged incubation with NADPH to 
form the equivalent „air-stable‟ semiquinone. The inactive „air-stable‟ 
semiquinone becomes kinetically stabilised by drifting into a „locked‟ 
conformation preventing interaction of the FMN-binding domain with 
cytochrome c (Murataliev and Feyereisen, 1999). Interestingly, only 
when CPR is reduced by NADPH does it form an interaction with 
cytochrome c which proves that the presence of a reduced species 
alone is not enough to lead to efficient electron transfer. The 
conformational change observed upon binding of NADPH to CPR 
effectively unlocks the FMN-binding domain into a position capable of 
cytochrome c interaction. The binding affinities of both full length 
CPR and the isolated FAD-binding domain to 2‟,5‟-ADP are 
remarkably similar, thus placing the NADPH binding site totally 
within the FAD-binding domain. NADPH binding at the FAD-binding 
site causes not only a local conformation change but also has a more 
dramatic effect by impinging on events involving the FMN-binding 
domain, located at the opposite end of the enzyme to the NADPH-
binding site (Grunau et al., 2006). 
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1.7.5 The W677 residue 
The penultimate residue in all CPR sequences is a large, aromatic 
tryptophan (W677 in rat, W676 in human and W678 in A. gambiae 
CPR) (Figure 1.10). Analysis of a number of CPR, and related, 
structures locates this residue where the NMN of NADPH is expected 
to bind (Karplus et al., 1991; Wang et al., 1997; Ingelman et al., 1997; 
Gruez et al., 2000; Zhang et al., 2001). Due to its location, the residue 
must be displaced by the nicotinamide ring for electron transfer and 
catalysis to occur, as indicated by stopped flow fluorescence on human 
CPR (Gutierrez et al., 2001; Gutierrez et al., 2002). In addition to this, 
the solved structures of FNR (Deng et al., 1999) and CPR (Hubbard et 
al., 2001) mutants show NMN in a position which should allow for 
fast hydride ion donation. However, it is somewhat paradoxical that 
these mutants in fact have impaired electron transfer properties (Dohr 
et al., 2001; Elmore and Porter, 2002). 
This diminished electron transfer ability could be explained when 
considering what is proposed to be the major role of this highly 
conserved residue. It is suggested that the residue is heavily involved 
in shielding of the FAD isoalloxazine ring from the surrounding 
solvent (Figure 1.15). When the residue is removed, the exposure to 
solvent is likely to have the effect of increasing the reduction potential 
of the FAD flavin (Calcaterra et al., 1995) making physiological 
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electron transfer to FMN thermodynamically unstable. If NADPH 
were then to be bound to CPR, the reduction potential of the FAD 
would be decreased, thus the favourability of electron transfer to FMN 
increased due to contact and shielding by the nicotinamide ring. This 
decrease in reduction potential is likely to impart some sort of 
energetic cost, such as increasing binding affinity for NADPH making 
release of the nucleotide more difficult. The proposed major role of 
this penultimate residue is therefore to shield the FAD cofactor, when 
the nicotinamide ring is not present, to limit the high energetic costs 
which are involved in decreasing the reduction potential to a level 
required for physiological activity (Murataliev et al., 2004). 
Though this is the major proposed role for the penultimate tryptophan 
residue, other roles have been suggested such as being involved in 
discrimination between NADPH and NADH (Dohr et al., 2001), the 
removal of NADP
+
 once hydride ion transfer has taken place 
(Gutierrez et al., 2000) and protection of the reduced FAD from re-
oxidation by solvent once NADP
+
 has been removed (Murataliev et al., 
2004). The exact contribution that W677 provides is yet to be defined 
but the available evidence suggests it is likely that this important 
conserved residue has a number of duties within CPR and related 
enzymes. 
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W677 
NADP
+
 
FAD 
Figure 1.15. The position of W677 residue in rat CPR. The position of the W677 residue in the rat crystal structure is clearly stacked against the 
isoalloxazine ring of FAD. The nicotinamide ring of NADP
+
 is not resolved however it is thought to interact in the region where W677 occupies in 
the above structure. PDB – 1AMO. 
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1.8 Aims 
The overall objective of this work is the biochemical characterisation 
of A. gambiae cytochrome P450 reductase and to make comparisons 
with the human enzyme. In addition, a biophysical study will be 
performed for the first time on A. gambiae CPR using NMR 
spectroscopy. 
Specifically, the aims include: 
a) The establishment of an E. coli expression system for efficient 
production and purification of recombinant A. gambiae and human 
CPRs. The design of expression vectors for the production and 
purification of the individual A. gambiae FMN-binding and FAD-
binding domains for use throughout the project. 
b) Characterisation of the spectral properties of the A. gambiae CPR 
and its domains including the establishment of the redox potentials of 
the intact reductase along with the isolated FMN-binding and FAD-
binding domains. HPLC analysis will be used to determine the flavin 
contents of A. gambiae CPR and human CPR with a view to making a 
direct comparison between the two enzymes. 
c) Stable isotopic labelling techniques using 
15
N, 
13
C and 
2
H isotopes 
will be investigated in order for NMR spectroscopy on A. gambiae 
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CPR, FMN- and FAD-binding domains to be performed. This will be 
the first instance of such biophysical analysis being carried out on A. 
gambiae CPR. The success of the NMR experiments will be 
determined by the efficiency of isotope labelling along with the 
stability of the protein samples. 
d) Isothermal Titration Calorimetry (ITC) will be used as a tool for the 
probing of the NADPH binding site. NADPH nucleotide analogues 
will be utilised in the determination of binding and thermodynamic 
properties in the hope of establishing any potential differences that 
have arisen in coenzyme binding between A. gambiae and human CPR. 
ITC will also be used to compare the binding affinity of the flavin 
cofactor, FMN, to the isolated FMN-binding domains of A. gambiae 
and human CPR. 
e) The activity of both A. gambiae and human CPR will be compared 
using the non-physiological electron acceptors cytochrome c and 
potassium ferricyanide. Kinetic parameters of cytochrome c reduction 
will be elucidated for each enzyme as a way of potentially increasing 
the level of understanding of A. gambiae CPR relative to the human 
equivalent. 
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Chapter 2 
 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Water 
Water was purified using a Direct-Q System (Millipore Corp., Mass. 
USA). This system removes ions, bacteria and organic material present 
in tap water through a reverse osmosis cartridge, followed by an ion-
exchange resin cartridge. As a final purification step, the water is 
passed through a 0.22 µm filter as it is drawn from the system. The 
water produced has a resistivity of 18.2 M cm or greater. This water 
was used for all procedures, excluding bacterial culture experiments. 
For molecular biology experiments nuclease free water (Sigma) was 
used. 
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2.1.2 General solvents 
Ethanol: redistilled; Department of Chemistry, University of 
Liverpool. 
All other solvents were of AnalaR grade from BDH Ltd., Poole, 
Dorset, UK unless otherwise stated. 
All HPLC solvents were of HPLC grade and filtered and degassed 
prior to use. 
 
2.1.3 General reagents 
Unless otherwise stated, chemical reagents were supplied by AnalaR 
and were of laboratory grade. In general, reagents for molecular 
biological techniques were of high purity. BES buffer, 2‟-AMP, 3‟-
AMP,  2‟,5;-ADP, NADP+ and NAD
+
 nucleotides for ITC experiments 
were supplied by Sigma. NADPH, horse heart cytochrome c, 
potassium ferricyanide, FMN and FAD were also all supplied by 
Sigma.
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2.1.4 Expression vectors 
 pET-15b 
 
 
 
 
 
 
 
 
pETM-11 
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2.1.5 Bacterial strains 
 
BL21-CodonPlus(DE3)-RP strain: 
Genotype - E. coli B F– ompT hsdS(rB
-
 mB–) dcm
+
 Tet
r
 gal λ(DE3) 
endA Hte [argU proLCam
r
] 
 
2.2 General Methods 
2.2.1 Molecular Biology Methods 
2.2.1.1 Polymerase Chain Reaction 
Forward and reverse PCR primers were designed for molecular 
dissection of the full length A. gambiae CPR into its individual FMN- 
and FAD-binding domains. Primers were designed for cloning into the 
pETM-11 expression vector using the Kpn1 and Nco1 restriction 
enzyme sites. The PCR mixture was prepared in PCR tubes with 
special care taken to ensure that all components were kept on ice at all 
times. The PCR mixture contained the following, at final 
concentrations; 1x PCR buffer, 0.2 mM dNTPs, 1.5 mM MgSO4, 1.2 
µM forward primer, 1.2 µM reverse primer, 0.5 µL A. gambiae CPR 
template DNA. The mixture was made up to 49 µL using MilliQ H2O 
before addition of 1 µL hot start Kod high fidelity polymerase 
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(Novagen). Control tubes were set up which contained no template 
DNA, all other components remained the same. All tubes were 
transferred to a thermo cycler for PCR.  
 
2.2.1.2 Agarose gel electrophoresis 
1 % (w/v) agarose gels were prepared as follows: 1 g agarose was 
dissolved in 100 mL 1 x TE buffer (1 L 10 x TE buffer consists 880 
mL, 100 mL 1 M Tris; pH 8.0, 20 mL 0.5 M EDTA; pH 8.0). The 
mixture was heated until the agarose was fully dissolved and left to 
cool slightly. Once the mixture had cooled, but not sufficiently to 
allow the agarose to set, it was poured into a gel casting tray. Ethidium 
bromide to a final concentration 0.1 µg/mL was added and loading 
wells were formed using gel combs. The gel was left to stand for 
approximately 20 min to set before the combs were removed. 6 x 
sample buffer (sterile distilled water, glycerol, 0.25 % (w/v) 
bromophenol blue, 0.5 M EDTA) was added to each sample before 
being loaded into the wells. 1 kb standard markers were also loaded 
(New England Biolabs) before the gel was run at 120 V in 1 x TE 
buffer until the size of the bands could be determined relative to the 
markers; typically this took 20-30 min. DNA bands were visualised 
under U.V conditions using an ultraviolet transilluminator.  
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2.2.1.3 Restriction digestion of PCR products 
Following PCR amplification, the DNA coding for FMN- and FAD-
binding domains underwent restriction digestion. Care was taken to 
ensure all components remained on ice at all times. The restriction 
digestion mixture contained the following, at final concentrations; 1x 
restriction digestion buffer, 1x BSA, 15 µL DNA. The mixture was 
made up to a volume of 24 µL using MilliQ H2O before addition of 3 
µL Kpn1 (New England Biolabs) and 3 µL Nco1 (New England 
Biolabs). Another reaction was set up to digest the pETM-11 vector 
and was treated in exactly the same way as the PCR product. Reactions 
were allowed to proceed at 37 °C for 2 hr before being returned to ice. 
The reactions were stopped by addition of 6 x sample buffer and run 
on an agarose gel as described earlier (method 2.2.1.2). The visualised 
bands, both insert and vector, were carefully cut out of the gel and the 
DNA extracted using a gel extraction kit (Qiagen).  
 
2.2.1.4 Ligation into expression plasmid 
The digested inserts were ligated into digested pETM-11 vectors (Arie 
Geerlof, EMBL) using a quick DNA-ligase reaction. Care was taken to 
ensure that all components remained on ice throughout. A number of 
reactions were performed, each differing in the ratio of insert to vector; 
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a 1:1 insert to vector, a 2:1 insert to vector and a control reaction 
containing just the vector. The ligation reaction mixture for the 1:1 
insert to vector contained the following: 1 x ligation buffer, 0.5 µL 
digested vector, 0.5 µL digested insert. The mixture was made up to 19 
µL using MilliQ H2O before 1 µL quick ligase (New England Biolabs) 
was added. For the 2:1 insert to vector reaction, 0.5 µL digested vector 
was incubated with 1 µL digested insert whilst the control simply 
contained 0.5 µL digested vector. The rest of the mixture remained the 
same. The ligation reaction was allowed to proceed at room 
temperature for 15 min before being returned to the ice. The mixture 
was then used to transform OmniMax cells (Source Bioscience 
LifeSciences, Nottingham) and allowed to grow on agar plates 
selective for the antibiotic kanamycin (see method 2.2.2.2) 
 
2.2.1.5 Plasmid preparation from ligation product 
Bacterial colonies were screened for the correct ligated plasmid by 
PCR. The PCR reaction was performed as above (method 2.2.1.1) 
using portion of the bacterial colony as the template DNA. The 
remaining portions of the colonies containing the correct insert were 
used to inoculate 10 mL LB media (Melford) containing 32 µg/mL 
kanamycin (Sigma). This was incubated overnight at 37 °C with 
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shaking at 170 r.p.m and the resulting culture used for plasmid 
preparation using a microcentrifuge mini prep kit (Qiagen). All new 
plasmids were sent for sequencing (Source Bioscience LifeSciences, 
Nottingham) to ensure correct incorporation of the insert.  
 
2.2.1.6 Preparation of competent cells using the rubidium chloride 
method 
1 µL of a commercial stock of BL21-CodonPlus(DE3)-RP E. coli was 
added to 50 µL selective LB media containing chloramphenicol (34 
µg/mL) (Duchefa Biochemie) and left to grow overnight at 37 °C. 500 
µL of this culture was used to inoculate a further 250 mL 
chloramphenicol-selective LB media containing 20 mM MgSO4. This 
was returned to 37 °C shaking incubator and allowed to grow until an 
OD600 = 0.4-0.6 was achieved. The cells were harvested by 
centrifugation at 10,000 x g for 5 min at 4 °C and resuspended in 100 
mL ice-cold, filter-sterilized TFB1 (30 mM KAc, 10 mM CaCl2, 
50mM MnCl2, 100 mM RbCl (Sigma), 15 % glycerol; adjusted to pH 
5.8 using 1M acetic acid). The suspensions were incubated on ice for 5 
min before once again being harvested by centrifugation at 10,000 x g 
for 5 min at 4 °C. The pellets were re-suspended in 10 mL ice cold, 
filter sterilised TFB2 (10 mM MOPS; pH 6.5, 75 mM CaCl2, 10 mM 
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RbCl (Sigma), 15 % glycerol; adjusted to pH 6.5 using 1 M KOH). 
The suspensions were incubated on ice for 1 hr before being divided 
into 200 µL aliquots and flash frozen using liquid nitrogen. The 
transformation efficiency was determined prior to use (see method 
2.2.1.7). 
 
2.2.1.7 Transformation of competent E. coli 
50 µL competent E. coli cells were thawed on ice and incubated with 2 
µL plasmid DNA for a further 30 min on ice. The cells were heat-
shocked at 42 °C for 45 s before being returned to ice for a further 2 
min. 950 µL of non-selective LB media was added before incubation at 
37 °C with shaking at 200 r.p.m for 1 hr. 100 µL of this culture was 
spread thinly on an agar plate; selective for either ampicillin (Melford) 
or kanamycin (Sigma), depending on the plasmid used, as well as 
chloramphenicol resistance and the plates incubated at 37 °C for 
approximately 16 hr. Control plates were also set up; one without 
antibiotic selectivity and another where no plasmid DNA was used in 
the transformation reaction. 
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2.2.2 Protein Expression Methods 
2.2.2.1 A. gambiae CPR, human CPR and human FMN-binding domain 
expression in LB media 
50 mL selective LB media containing ampicillin (250 µg/mL) and 
chloramphenicol (34 µg/mL) was inoculated with a single transformed 
bacterial colony containing the desired expression vector. This was 
incubated at 37 °C, with shaking at 170 r.p.m, for approximately 16 hr. 
This starter culture was centrifuged at 8,000 x g for 10 min at 4 °C and 
the pellet re-suspended in 5 mL fresh selective LB. Using this re-
suspension, a further 1 L selective LB broth containing 1 mM 
riboflavin (Sigma) was inoculated to an OD600 = 0.05-0.1 and divided 
equally into 4 x 2 L flasks. These were transferred to a 37 °C incubator 
and allowed to grow, with shaking at 170 r.p.m., until an OD600 = 0.7–
0.9 was reached. Typically, this took approximately 2-2.5 hr. All 
OD600 measurements were taken using a Cary 300 Bio U.V visible 
spectrophotometer and the machine zeroed using fresh LB broth. Once 
the desired growth was achieved, protein expression was induced by 
addition of 1 mM IPTG (Sigma). The cultures were transferred to a 25 
°C incubator, shaking at 170 r.p.m, for 16 hr. The bacterial cells were 
harvested by centrifugation at 8,000 x g for 10 min at 4 °C. The pellets 
were either re-suspended in Ni
2+
-affinity buffer A (500 mM NaCl, 50 
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mM Tris-HCl (Melford), 10 % glycerol; pH 8.0) or placed at -20 °C 
for short-term storage. 
 
2.2.2.2 A. gambiae FMN and A. gambiae FAD expression in LB media 
The expression protocol for A. gambiae FMN and FAD binding 
domains is identical as above (method 2.3.3.1) with the following 
alteration: The selective media contains the antibiotic kanamycin (32 
µg/mL) instead of ampicillin. 
  
2.2.2.3 A. gambiae CPR expression in minimal media 
Minimal media solutions A and B were made up separately and 10 mL 
solution B was added to every 1 L solution A. To make 1 L minimal 
media solution A required: 12.5 g Na2HPO4 (anhydrous), 7.5 g 
KH2PO4 (anhydrous); pH 7.2. This was prepared using Reverse 
Osmosis (RO) H2O and autoclaved. To make 10 mL minimal media 
solution B required: 4 g glucose, 1 g NH4Cl, 0.24 g MgSO4.7H2O, 0.02 
g CaCl2.2H2O, 0.1 g ampicillin and 0.01 g thiamine-HCl (Duchefa 
Biochemie). Chloramphenicol (34 µg/mL) was also added. This was 
also prepared using RO H2O and passed through a 0.22 µm sterile filter 
prior to use. Once prepared, and suitably sterilised, solutions A and B 
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were mixed together and 2 mL inoculated with a single transformed 
bacterial colony containing the desired expression vector. Over the 
course of the day, this culture was gradually increased in volume and a 
50 mL culture left to grow overnight. This culture was harvested by 
centrifugation at 8,000 x g for 10 min at 4 °C and the pellet re-
suspended in 5 mL fresh minimal media (solutions A and B). Using 
this re-suspension, 1 L fresh minimal media (solutions A and B), 
containing 1 mM riboflavin, was inoculated to an OD600 = 0.05-0.1 and 
divided equally between 4 x 2 L flasks. These were transferred to a 37 
°C incubator and allowed to grow, with shaking at 170 r.p.m, until an 
OD600 = 0.7 was achieved. Typically this took approximately 4 hr. 
Protein expression was induced by addition of 1 mM IPTG and the 
cultures transferred to a 25 °C incubator, shaking at 170 r.p.m, for 16 
hr. The bacterial cells were harvested by centrifugation at 8,000 x g for 
10 min at 4 °C. The pellets were either re-suspended in Ni
2+
-affinity 
buffer A (500 mM NaCl, 50 mM Tris-HCl (Melford), 10 % glycerol; 
pH 8.0) or placed at -20 °C for short-term storage.  
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2.2.2.4 A. gambiae FMN and A. gambiae FAD expression in minimal 
media 
The expression protocol for A. gambiae FMN and FAD-binding 
domains is identical as above (method 2.3.3.3) with the following 
alteration: Minimal media solution B contained the antibiotic 
kanamycin (32 mg in 10 mL) instead of ampicillin. 
 
2.2.3 Protein Purification Methods 
2.2.3.1 Cell Lysis 
The Ni
2+
-affinity buffer A re-suspension (section 2.3.3) was added to 
with an EDTA-free protease inhibitor tablet and also DNase1 from 
bovine pancreas (12.5 µg/mL) (Sigma) prior to cell lysis. Cells were 
lysed by French Press using the Sim Aminco French Pressure Cell at 
1000 PSI. The lysate was centrifuged at 20, 000 x g for 30 min at 4 °C 
and the supernatant passed through a 0.22 µm syringe filter prior to 
purification. 
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2.2.3.2 Ni
2+
-affinity chromatography 
Ni
2+
-affinity chromatography was performed using a 5 mL HisTRAP 
HP column (GE Healthcare) using the AKTA purifier system. Prior to 
column equilibration, 50 mL MilliQ H2O was washed through the 
column at a flow rate of 2.5 mL/min. Following this, the column was 
equilibrated using, firstly, 50 mL buffer A (500 mM NaCl, 50 mM 
Tris-HCl (Melford), 10 % glycerol; pH 8.0) before 25 mL buffer B 
(500 mM NaCl, 50 mM Tris-HCl (Melford), 1 M imidazole, 10 % 
glycerol, pH 8.0) was washed through. A further 25 mL buffer A was 
passed through the column to complete the equilibration. All 
equilibration washes were at a flow rate of 2.5 mL/min. The filtered 
supernatant (method 2.4.1) was loaded onto the column at a flow rate 
of 1 mL/min, the unbound material collected and the column was 
washed with 25 mL of buffer A. Increasing concentrations of 
imidazole; 10 mM, 20 mM and 40 mM respectively, were then washed 
through the column at 2 mL/min (30 mL each) before the bound 
protein was eluted, again at 2 mL/min, using 250 mM imidazole and 
the peak fractions analysed.    
 
90 
2.2.3.3 Desalting of samples using a PD-10 column 
Desalting and buffer exchange of protein samples were performed using 
a Sephadex G-25 Medium PD-10 desalting column (GE Healthcare). 
The column was equilibrated with 25 mL of the desired buffer before 
sample application. Prior to loading, samples were prepared with an 
excess of additional flavin (either FMN, FAD or both depending on the 
sample). This was done before each desalting step during the 
purification procedure. Between 1 mL and 2.5 mL of sample was loaded 
to the column and the flow through discarded. To elute the sample, 3.5 
mL of the equilibration buffer was applied to the column and the sample 
collected. 
 
2.2.3.4 Anion exchange chromatography 
Final clean-up of samples was performed using a 1 mL MonoQ 5/5 
anion exchange column (GE Healthcare) using the AKTA purifier 
system. Prior to column equilibration, 10 mL MilliQ H2O was washed 
through the column at a flow rate of 1 mL/min. Following this, the 
column was equilibrated using firstly 10 mL anion exchange wash 
buffer (20 mM Tris-HCl (Melford), 0.2 mM DTT, 1 mM EDTA, 1 mM 
benzamidine HCl (Sigma); pH 7.5) before 5 mL anion exchange elution 
buffer (20 mM Tris-HCl (Melford), 0.2 mM DTT, 1 mM EDTA, 1 mM 
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benzamidine HCl (Sigma), 1M KCl; pH 7.5) was washed through. To 
finish the equilibration, 5 mL wash buffer was washed through the 
column, all equilibration steps were performed at 1 mL/min. The sample 
was injected onto the column and the unbound material was collected. 
The bound protein was eluted at 1 mL/min with a 0-500 mM KCl 
gradient over 20 mL and the peak fractions analysed. Cruder protein 
samples were processed using a 5 mL HiTrap Q FF anion exchange 
column (GE healthcare). The method used was identical to that for the 
MonoQ 5/5 column, however, the volumes of buffer required were 
scaled up 5-fold to compensate for the increased volume of the column. 
Samples eluted off the HiTrap Q FF column were further processed on 
the MonoQ 5/5 column if required. 
 
2.2.3.5 Size exclusion chromatography 
Size exclusion chromatography was performed using a 320 mL 
HiLoad 26/60 Superdex 75 column. Prior to use the column was 
calibrated using molecular weight standards (). The column was 
initially washed at 1 mL/min with 350 mL MilliQ H2O followed by 
equilibration using 350 mL gel filtration buffer (50 mM Tris-HCl 
(Melford), 50 mM NaCl; pH 7.0). The sample was injected onto the 
column and run at 1 mL/min. Elution samples were collected after the 
void volume (110 mL) and peak fractions analysed. 
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2.2.3.6 His-tag removal using thrombin 
Prior to his-tag removal, the protein sample was exchanged into 
thrombin cleavage buffer (150 mM NaCl, 20 mM Tris-HCl (Melford), 
2.5 mM CaCl2; pH 8.4) using a PD-10 desalting column (method 
2.2.3.3). Thrombin (Sigma) was added to the protein sample in a ratio 
of 2000:1 (w/w) protein:thrombin. The thrombin used contained 0.324 
µg/NIH unit. This was incubated at room temperature, with slow 
shaking, for 2 hr. The reaction was stopped by addition of 60 µg/mL 
PMSF and the sample applied to a Ni
2+
-affinity column to removed 
free his-tags and uncut protein. The untagged protein did not bind to 
the Ni
2+
-affinity column and was collected in the flow through. 
 
2.2.3.7 His-tag removal using TEV protease 
Prior to his-tag removal, the protein sample was exchanged into 
cleavage buffer (500 mM NaCl, 50 mM Tris-HCl (Melford), 10 % 
glycerol; pH 8.0) using a PD-10 desalting column (method 2.2.3.3). 
TEV protease was added to the protein sample in a ratio of 20:1 (w/w) 
protein:TEV. This was incubated at room temperature, with slow 
shaking, overnight to allow cleavage to occur. To remove free his-tags 
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and uncut protein, the sample was loaded back onto a Ni
2+
-affinity 
column and the flow through was collected.  
 
2.2.3.8 Concentration of protein samples 
Protein samples were concentrated using Amicon Ultra Centrifugal 
Filter Units (Millipore). For larger volumes, units with a capacity of 15 
mL were used whilst for smaller volumes, 4 mL units were employed. 
The different sized units worked and were used in an identical fashion. 
The protein samples were applied to the units and centrifuged at 4,500 
x g. Centrifugation was allowed to occur for 10 min before the 
remaining sample mixed to prevent excessive sticking of protein to the 
membrane. This process of centrifugation followed by mixing was 
used until the sample was concentrated to the desired volume. 
Throughout the process, the flow through was analysed to ensure no 
protein of interest passed through the membrane. For full length 
proteins (A. gambiae CPR, human CPR), units with a 50 kDa cutoff 
membrane were used. For FAD-binding domains, units with a 30 kDa 
cutoff membrane were used whilst for FMN-binding domains, units 
with a 10 kDa cutoff membrane were used. Units were completely 
reusable providing the membrane was kept moist during storage.   
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2.2.4 Analytical Methods 
2.2.4.1 Bradford protein assay 
Protein concentrations were determined using the Bradford Protein 
Assay (Bradford, 1976). A standard curve was generated using a series 
of known concentrations (0-2 mg/mL) of BSA. 1 mL Bradford reagent 
(Sigma) was added to 10 µL protein sample and left to incubate at 
room temperature for 10 min. The absorbance was read at 595 nm and 
the protein concentration of unknown samples determined by 
consultation of the BSA standard curve. All readings were taken using 
a Cary 300 Bio U.V visible spectrophotometer and the machine zeroed 
with 10 µL of protein sample buffer was mixed with 1 mL reagent.  
 
2.2.4.2 SDS PAGE 
10 mL of resolving gel was made to provide two 0.75 mm 15 % 
polyacrylamide minigels. The resolving gel comprised 5 mL 30 % 
acrylamide/bis solution, 2.5 mL distilled H2O, 2.4 mL 1.5 M Tris; pH 
8.8, 100 µL 10 % (w/v) SDS, 75 µL 10 % (w/v) ammonium 
persulphate, 7.5 µL TEMED (Sigma). Soon after the addition of 
TEMED, the mixture was gently but thoroughly mixed to avoid 
bubbles and promptly poured between the assembled plates. Once the 
resolving gel had been poured, the gel was overlaid with a thin layer of 
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butan-2-ol and polymerisation allowed to occur for approximately 40 
min. Once the gel was fully polymerised, the butan-2-ol was poured 
off, the gel was rinsed with distilled water and carefully blotted dry. 
Once dry, a 4 % stacking gel was poured on top of the resolving gel. 
10 mL of a 4 % resolving gel comprised 6.1 mL distilled H2O, 2.4 mL 
0.5 M Tris; pH 6.6, 1.3 mL 30 % acrylamide/bis solution, 100 µL 10% 
(w/v) SDS, 75 µL 10 % (w/v) ammonium persulphate, 7.5 µL TEMED 
(Sigma). Following gentle mixing, the mixture was poured onto the set 
resolving gel and a clean comb added to provide the wells for sample 
loading. The stacking gel was again left to polymerise for 
approximately 20 min. After polymerisation, the combs were removed 
and the wells were well rinsed with distilled H2O. Samples were 
prepared by addition of 2 x SDS-PAGE sample buffer (50 µM Tris; pH 
6.8, 10 % (v/v) glycerol, 2 % (w/v) SDS, 4 % (v/v) β-mercaptoethanol, 
0.1 % (w/v) bromophenol blue, H2O) and denatured at 95 °C for 5 min. 
Prior to loading, the samples were centrifuged at 14,000 x g for 2 min. 
The cast gels were placed in the Protean II gel running kit (BioRad) 
and placed in a tank containing gel running buffer (2.5 mM Tris-Base, 
25 mM Glycine, 0.01 % SDS.). The central cavity of the apparatus was 
filled with gel running buffer and 7.5 µL of the sample loaded into the 
wells using a syringe (Hamilton) along with 5 µL of low range protein 
standards (Sigma). Samples were allowed to run at 200 V until the 
96 
bromophenol blue dye reached the bottom of the gel; typically this 
took 45-50 min. 
 
2.2.4.3 Coomassie Brilliant Blue staining 
As soon as SDS-PAGE had been performed, the gels were placed in a 
solution of Coomassie G250 (0.1 % Coomassie G250, 45 % methanol, 
10 % acetic acid, distilled H2O). Incubation was at room temperature, 
with slow shaking, for 1 hr. The Coomassie G250 solution was 
removed and the gels washed with distilled H2O before being placed in 
distilled H2O containing methanol and returned to the shaker. The 
solution was changed regularly until complete destaining of the 
background had occurred.   
 
2.2.4.4 Gel imaging 
Gel images were acquired using a GS-710 Calibrated Imaging 
Densitometer (BioRad). 
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2.2.4.5 Electrospray mass spectrometry 
For electrospray mass spectrometry, aliquots of purified protein 
samples were taken to Manchester Interdisciplinary Biocentre for 
analysis. 
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Chapter 3 
 
 
3. CLONING, EXPRESSION, PURIFICATION AND ENZYME 
CHARACTERISATION 
 
3.1 Introduction 
Over the last 40 years, there has been considerable volume of 
biochemical and biophysical experimentation on cytochrome P450 
reductases from a number of different species. The most widely 
studied CPR‟s are those from human, house fly and rat; the latter 
providing the first crystal structure, albeit of the N-terminal truncated 
enzyme (Wang et al., 1997). Little is known about the CPR‟s from 
mosquito species and it is only recently that work has been carried out 
on Anopheline reductases such as A. minimus (Sarapusit et al., 2008). 
To date the biochemical and biophysical properties of A. gambiae CPR 
have yet to be reported. 
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With the aim of gaining biophysical information about A. gambiae 
CPR, a number of factors need to be considered. The work presented 
here is the first example of a CPR and its individual FMN-binding and 
FAD-binding domains being expressed and purified with a view to 
biophysical analysis. In order to fully understand the requirements of 
generating such biophysical information, it is important to appreciate 
the biochemical behaviour of the enzyme. With this in mind, the 
soluble, full length CPR as well as the isolated FMN and FAD-binding 
domains have been purified and expressed to ascertain primary 
biochemical behaviour and to serve as a forerunner to more detailed 
structural analysis. 
To achieve this, recombinant A. gambiae CPR, FMN and FAD-binding 
domains have been expressed in a bacterial expression system and 
purified using affinity and anion exchange chromatographies. Stable 
isotope labelling techniques to incorporate 
2
H, 
15
N and 
13
C for NMR 
experiments have also been employed for each protein. The spectral 
characteristics and levels of flavin incorporation in human CPR are 
widely known and this enzyme has been brought into the study as a 
comparative aid. 
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3.2 Methodologies and Results 
3.2.1 Expression and Purification 
To perform biochemical and biophysical analysis on A. gambiae CPR 
and its FMN and FAD-binding domains, first an efficient method for 
recombinant protein production must be developed. The expression 
system used for these expressions was bacterial utilising competent E. 
coli Codon Plus cells (Stratagene) to express the plasmid components. 
Transformed bacteria were cultured at 37 °C before protein expression, 
induced by addition of 1 mM IPTG, overnight at 30 °C. Harvested 
bacteria were lysed by French Press and samples centrifuged for at 20, 
000 x g for 30 min at 4 °C. Following cell lysis, it was imperative that 
DNase was added to remove problematic DNA, particularly when the 
sample was for biophysical analysis. 
The purification protocol was modelled on that for the human FMN 
and FAD-binding domains used by Zhao et al., 1996. It is a two step 
purification protocol employing Ni
2+
- affinity followed by anion 
exchange chromatography columns. This protocol was used as it was 
successful and reliable in producing samples for NMR spectroscopy 
which is a major requirement for sample production in this work. 
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3.2.1.1 Purification of full length CPR 
For the purposes of this study, an N-terminal truncated A. gambiae was 
utilised. The recombinant protein was derived from a pET15b 
expression vector and supplied by Dr. Mark Paine (Liverpool School 
of Tropical Medicine). This enzyme lacked the first 63 amino acid 
membrane anchor region, meaning that the enzyme was readily 
expressed and found in the soluble supernatant following bacterial cell 
lysis. The first purification step of the soluble material involved a Ni
2+
 
affinity column and the chromatogram shown in figure 3.1. The major 
peak is observed during the 250 mM imidozole elution step with small 
peaks detected at 280 nm following each of the 10, 20 and 40 mM 
imidazole wash steps. Since the flavin cofactors also absorb light at 
380 and 450 nm, these wavelengths were also analysed. At these 
wavelengths, the major elution peak was still clearly visible but the 
smaller peaks detected in the wash steps were not. This suggests that 
very little, if any A. gambiae CPR was lost during column washing 
(Figure 3.1). Minimal losses were reported during the desalting step or 
following thrombin cleavage of the N-terminal His-tag. Following 
reverse purification on the Ni
2+
 affinity column, anion exchange 
chromatography (AEX) was performed. Figure 3.2 shows the 
chromatogram following AEX with a major peak detected after 330 
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Figure 3.1. Chromatograms of A. gambiae CPR following Ni
2+
- 
affinity purification. Sample was applied to a 5 mL His-Trap Ni
2+
-
affinity column in 500 mM NaCl, 50 mM Tris-HCl, 10 % glycerol; pH 
8.0. Bound protein was eluted using the same buffer containing 250 mM 
imidazole. The traces are from the same sample detected at A = 280 nm; 
B = 380 nm and C = 450 nm. 
A 
B 
C 
0                          25                         50                         75                         100                       125      
 
Vol (mL) 
0                          25                         50                         75                         100                       125      
 
Vol (mL) 
0                          25                         50                         75                         100                       125      
 
Vol (mL) 
%B 
40 
30 
20 
10 
 
%B 
40 
30 
20 
10 
 
%B 
40 
30 
20 
10 
 
mAU 
2000 
1500 
1000 
500 
0 
mAU 
1500 
1000 
500 
0 
mAU 
5000 
4000 
3000 
2000 
1000 
0 
103 
 171007 Mono Q 5 5 SCPR001:10_UV1_280nm  171007 Mono Q 5 5 SCPR001:10_Conc
   0
 500
1000
1500
2000
2500
3000
mAU
  0
 20
 40
 60
 80
%B
5.0 10.0 15.0 20.0 25.0 cv
A 
B 
Figure 3.2. Chromatogram of A. gambiae CPR following anion exchange purification. 
and SDS-PAGE of purified sample. A = Anion exchange chromatogram. Sample was 
applied to a 1 mL MonoQ 5/5 column in 20 mM Tris-HCl 0.2 mM DTT, 1 mM EDTA, 1 mM 
benzamidine HCl; pH 7.5. Bound protein was eluted using the same buffer containing KCl 
over a 0-500 mM gradient and detected at 280 nm. B = SDS-PAGE analysis of purified peak 
sample. 
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mM KCl had passed through. This detection was confirmed by the 380 
and 450 nm curves (Figure 3.2) confirming presence of flavin. Purified 
enzyme was bright yellow in colour, indicating flavin cofactor 
incorporation, and the purity was checked by SDS-PAGE. The fully 
purified sample contained a single band of approximately 70 kDa, the 
expected molecular weight for N-terminal truncated A. gambiae CPR 
(Figure 3.2). Protein concentration was calculated by Bradford Assay 
and the standard yield was approximately 20 mg purified enzyme per 
litre of bacterial culture. The sample was verified as A. gambiae CPR 
by mass spectrometry (Appendix A) 
 
3.2.1.2 Dissection of A. gambiae CPR into FMN and FAD-binding 
domains 
The N-terminal his-tagged pET15b A. gambiae CPR expression vector 
was used as template DNA for dissection into the constituent FMN and 
FAD-binding domains. Primers were designed to the domains based on 
the rat CPR crystal structure and sequence alignments to isolate the 
positions of the domain boundaries. Initially, primers were designed 
and constructs incorporating the domain boundaries, with no additional 
residues at either terminus, were generated. One obstacle to overcome 
was that since the restriction enzymes of choice for pET15b were Nde1 
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and BamH1, a silent A to C mutation had to be incorporated into the 
residue I617 to remove a CATATG Nde1 binding sequence from 
within the FAD-binding domain. Taking into account the melting 
points of the primers, the PCR protocol was: Step 1 – 1 cycle of a 95°C 
initial step for 2 min; Step 2 – 30 cycles of a 15 s 98 °C denaturation, a 
30 s 45 °C annealing and a 15 s 72 °C elongation; Step 3 – a 72 °C 
final extension for 1 min; Step 4 – Hold step at 4 °C. 
The agarose gel of the PCR products showed bands at the correct size; 
approximately 550 bp for FMN and 1300 bp for FAD, suggesting that 
cloning had been successful. Plasmid sequencing of the FAD-binding 
domain vector failed to show the full correct insert with errors in all 
bases after the forced mutation: this rendered the plasmid unsuitable 
for use. The sequencing on the FMN-binding domain plasmid was 
successful. 
The FMN-binding domain was expressed in E. coli and purified by 
Ni
2+-
affinity and anion exchange chromatographies. Following 
purification however, the FMN-binding domain appeared as a double 
banded species which was present throughout the process. SDS-PAGE 
analysis shows the presence of two bands with the second band 
approximately 1-2 kDa below the first. The same two bands are seen 
even after His-tag removal and the molecular weight difference 
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Figure 3.3. Purified A. gambiae FMN-binding domain, pre- 
and post- his-tag cleavage. Lane 1 = Molecular weight 
markers; Lane 2 = A. gambiae FMN-binding domain pre-his-
tag removal; Lane 3 = A. gambiae FMN-binding domain post-
his-tag removal. The molecular weight protein ladder is shown 
in kDa. 
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between the two bands was maintained. Unsuccessful attempts were 
made to separate the bands by anion exchange chromatography 
techniques and since the molecular weight difference was deemed too 
small to separate by size exclusion chromatography, the expression 
vectors were redesigned. 
Due to the problems encountered with both the FMN and FAD-binding 
domains, an alternative approach was employed. The main alteration in 
this approach was to change the expression vector from a pET15b to a 
pETM-11 vector. The reason for this was to eliminate the use of NdeI 
restriction enzyme and thus eliminate the problem of incorporating a 
mutation within this domain and to move away from thrombin in the 
removal of the His-tag since pETM-11 contains a site for the much 
more specific TEV protease. Furthermore, in an attempt to solve the 
problem of the double banded FMN-domain, extended FMN and FAD-
binding domain constructs were made. These incorporated a small 
section of the linker domain in each case as a possible attempt to 
stabilise the purified domain. The design of these constructs is 
described (Figure 3.4) and the primers used to generate them are also 
described (Appendix B). Due to the similarity in melting point of all 
the manufactured primers, the same PCR protocol could be used 
throughout the process and involved; Step 1 – 1 cycle of a 95 °C initial 
step for 2 min; Step 2 – 30 cycles of a 15 s 95 °C denaturation, a 15 s 
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55 °C annealing and a 40 s 72 °C elongation; Step 3 – a 72 °C final 
extension for 10 min; Step 4 – Hold step at 4 °C. 
The agarose gel of the PCR products, as before, showed bands at the 
correct sizes meaning cloning was successful. The bands seen in 
Figure 3.5 are for the extended FMN and FAD-binding domain in each 
case; approximately 600 bp for FMN and 1300 bp for FAD-binding 
domain. Following successful ligation into the pETM-11 vector, the 
constructs were sequenced which confirmed correct cloning before 
then being taken forward for protein expression and purification 
(Figure 3.5). 
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FMN-binding domain constructs 
 
 
 
 
 
 
 
 
 
 
 
FAD-binding domain constructs 
 
A. 
B. 
C. 
D. 
E. 
Figure 3.4. A schematic representation of the generated FMN-binding and 
FAD-binding domain constructs of A. gambiae CPR. A, B and C are the FMN-
binding domain constructs where A is the entire domain incorporating a section of 
the inter-domain linker region, B is simply the entire domain and C is a slightly 
shortened domain. D and E are the FAD-binding domain constructs both of which 
are the entire domain incorporating a section of the inter-domain linker region with 
E including a slightly longer section that D. 
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Figure 3.5. Agarose gel analysis of A. gambiae FMN-
binding domain and FAD-binding domain PCR products. 
Lane 1 = DNA ladder, with sizes shown in bp; Lane 2 = FMN-
binding domain PCR product; Lane 3 = FAD-binding domain 
PCR product; Lane 4 = Negative control (without template 
DNA). 
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3.2.1.2.1 Purification of extended FMN binding domain 
The pETM-11 based FMN-binding domain expression vector was used 
to transform competent E. coli. The purification protocol was identical 
to that used for the full length soluble CPR involving a Ni
2+-
affinity 
chromatography step followed by an anion exchange chromatography 
step. The chromatogram for the FMN-binding domain following Ni
2+ 
affinity chromatography is shown, again analysed at the wavelengths 
280, 380 and 450 nm. As with the full length CPR, the major peak was 
observed during the 250 mM imidazole elution step (Figure 3.6). The 
same peak is observed when detected at 380 and 450 nm and these 
traces show little by way of lost protein during the low imidazole 
concentration wash steps (Figure 3.6). Minimal losses were observed 
following desalting, His-tag cleavage and reverse purification on the 
Ni
2+
-affinity column. 
Anion exchange chromatography yielded a major peak during the KCl 
elution gradient. The purified sample was eluted from the column at 
380 mM KCl.. The purity of the sample was analysed by SDS-PAGE. 
Unlike with the shorter FMN-binding domain, the elongated domain 
was purified as a single band at the expected molecular weight of 
approximately 21 kDa (Figure 3.7) .Protein concentration was 
determined using the Bradford Assay and a typical yield for the FMN-
binding domain was in the region of 12-15 mg purified enzyme per 
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litre of bacterial culture. The molecular weight of the FMN-binding 
domain was calculated by mass spectrometry to be 20,755 Da 
(Appendix C). This value is a lot lower than the calculated 22,631 Da 
for the domain which could be attributed to degradation of the sample 
which was sent for analysis due to its age. 
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Figure 3.6 Chromatograms of A. gambiae FMN-binding domain 
following Ni
2+
- affinity purification. Sample was applied to a 5 mL His-
Trap Ni2+-affinity column in 500 mM NaCl, 50 mM Tris-HCl, 10 % 
glycerol; pH 8.0. Bound protein was eluted using the same buffer 
containing 250 mM imidazole. The traces are from the same sample 
detected at A = 280 nm; B = 380 nm and C = 450 nm. 
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Figure 3.7. Chromatogram of A. gambiae FMN-binding domain following anion 
exchange purification and SDS-PAGE of purified sample. A = Anion exchange 
chromatogram. Sample was applied to a 1 mL MonoQ 5/5 column in 20 mM Tris-HCl 0.2 
mM DTT, 1 mM EDTA, 1 mM benzamidine HCl; pH 7.5. Bound protein was eluted using 
the same buffer containing KCl over a 0-500 mM gradient and detected at 280 nm. B = SDS-
PAGE analysis of purified peak sample. 
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3.2.1.2.2 Purification of extended FAD-binding domain 
The expression and purification of the A. gambiae FAD-binding 
domain was the same as for the full length and FMN-binding domains; 
a two-step purification including Ni
2+-
affinity and anion exchange 
chromatographies. The chromatogram following Ni
2+-
affinity 
chromatography shows a major peak after the 250 mM imidazole 
elution step (Figure 3.8). The difference between the protocol for the 
FAD-binding domain and that for the FMN-binding domain and full 
length CPR was in the wash steps. The FAD-binding domain was 
shown to bind less strongly to the Ni
2+
 affinity column under these 
conditions. Because of this, the wash steps included just 10 and 20 mM 
imidazole respectively with the 40 mM imidazole wash step removed. 
The FAD-binding domain was a lot more problematic than the other A. 
gambiae CPR derived samples. The protein showed a tendency to 
precipitate throughout the purification process, particularly during the 
desalting steps and following TEV-protease cleavage. During 
desalting, despite yellow protein being eluted from the PD-10 column, 
there were moderate levels of precipitation making the sample look 
cloudy. However, once centrifuged, the pelleted precipitate was 
distinctly clear rather than yellow in colour. The supernatant was re-
applied to the PD-10 column and eluted as a clear, yellow sample. 
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Once the sample was satisfactorily stable it was applied to the anion 
exchange column. 
The chromatogram following anion exchange chromatogram showed a 
major peak during the KCl elution gradient. The sample was shown to 
elute at around 80 mM KCl, a lot earlier than is observed in the FMN-
binding domain and full length CPR which eluted at over 300 mM 
KCl. The peak was assessed by SDS-PAGE for purity and a single 
band at the expected molecular weight of around 50 kDa was seen 
(Figure 3.9). Protein concentration was assessed by Bradford Assay 
and a typical yield was approximately 10-15 mg purified enzyme per 
litre of bacterial culture. The FAD-binding domain was calculated by 
mass spectrometry to be 48,628 Da. (Appendix C). This value is close 
to the predicted value for this domain of 48,712 Da and the observed 
difference could be attributed to potential cysteine or methionine 
modifications such as carbamidations, oxidations or carboxylations. 
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Figure 3.8. Chromatograms of A. gambiae FAD-binding domain following Ni
2+
- 
affinity purification. Sample was applied to a 5 mL His-Trap Ni
2+
-affinity column 
in 500 mM NaCl, 50 mM Tris-HCl, 10 % glycerol; pH 8.0. Bound protein was 
eluted using the same buffer containing 250 mM imidazole and detected at 280 nm. 
          30                             40                             50                            60                             70                            80                            90                              
Vol (mL)        
%B 
40 
30 
2  
10 
0 
1500 
1000 
500 
0 
 
mAU 
118 
 FAD QFF 230709:10_UV  FAD QFF 230709:10_Conc
   0
 200
 400
 600
 800
1000
1200
mAU
  0
 20
 40
 60
 80
%B
0.0 5.0 10.0 15.0 20.0 cv
45 
36 
66 
29 
24 
20 
14 
kDa 
A. gambiae FAD -binding 
domain 
Figure 3.9. Chromatogram of A. gambiae FAD-binding domain following anion 
exchange purification and SDS-PAGE of purified sample. A = Anion exchange 
chromatogram. Sample was applied to a 5 mL HiTrap QFF column in 20 mM Tris-HCl 0.2 
mM DTT, 1 mM EDTA, 1 mM benzamidine HCl; pH 7.5. Bound protein was eluted using 
the same buffer containing KCl over a 0-500 mM gradient and detected at 280 nm. B = SDS-
PAGE analysis of purified peak sample. 
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3.2.1.3 Purification of human CPR and FMN-binding domain 
The expression and purification of the human full length CPR and 
isolated FMN-binding domain was identical to that for the A. gambiae 
equivalents. Ni
2+
- affinity chromatography of both the full length CPR 
and the FMN-binding domain yielded a major peak in the 250 mM 
imidazole elution step (Figure 3.10) with minimal losses reported 
during the lower concentration imidazole wash steps in each case. 
There was a major peak following anion exchange chromatography in 
each case (Figure 3.11) with respective elutions after approximately 
325 mM KCl for human CPR and 380 mM KCl for human FMN-
binding domain. These values were very similar, almost identical to 
those observed for the A. gambiae CPR suggesting that with respect to 
this purification strategy, the mosquito and human sample behave in a 
similar fashion. 
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Figure 3.10. Chromatograms of human CPR and isolated FMN binding domain 
following Ni
2+
-affinity purification. A = human CPR; B = human isolated FMN-
binding domain. Samples were applied to a 5 mL His-Trap Ni
2+
-affinity column in 
500 mM NaCl, 50 mM Tris-HCl, 10 % glycerol; pH 8.0. Bound protein was eluted 
using the same buffer containing 250 mM imidazole and detected at 280 nm. 
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Figure 3.11 Chromatogram of human CPR and isolated-FMN-binding domain 
following anion exchange purification and associated SDS-PAGE analysis. A = 
Human CPR, inset = SDS-PAGE of purified sample; B = Human FMN-binding 
domain, inset = SDS-PAGE of purified sample. Samples were applied to a 1 mL 
MonoQ 5/5 column in 20 mM Tris-HCl 0.2 mM DTT, 1 mM EDTA, 1 mM 
benzamidine HCl; pH 7.5. Bound protein was eluted using the same buffer containing 
KCl over a 0-500 mM gradient and detected at 280 nm. For the SDS-PAGE, the 
molecular weights of the markers are shown in kDa. The peak in panel B (FMN-
binding domain) appears truncated due to column overloading leading to over an above 
maximal U.V detection being achieved. 
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3.2.2 Spectral properties  
When FMN and FAD flavins are bound to cytochrome P450 
reductases, they cause unique spectral properties to be observed in 
these enzymes under aerobic conditions. The FMN and FAD cofactors 
absorb light at around 380 and 450 nm giving rise to characteristic 
spectra. The A. gambiae FMN-binding domain was scanned between 
700-300 nm resulting in such a spectral pattern (Figure 3.12 A) .An 
almost identical spectra was achieved when the human FMN-binding 
domain was scanned under the same aerobic conditions (Figure 3.12 
B). These spectra confirm presence of the flavin bound holoenzyme.  
The propensity of CPRs to adopt an „air-stable‟ semiquinone state is 
well established and this is also the case in A. gambiae CPR. Under 
aerobic conditions, full length A. gambiae CPR shows the 
characteristic spectra with absorption peaks at around 380 and 450 nm 
(Figure 3.13). Immediately following the addition of a stoichiometric 
amount of NADPH, there is an immediate change in the spectral 
properties. The 450 nm, and to a lesser extent the 380 nm, peaks 
decrease in absorbance and there is a distinctive rise in the absorbance 
in the 500-700 nm region (Figure 3.13 B). The same sample, scanned 
after 30 min, still showed an in absorbance in the 500-700 nm region 
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A B 
Figure 3.12. The absorption spectra of the FMN-binding domain from A. gambiae and human CPR’s. A = A. 
gambiae FMN-binding domain; B = Human FMN-binding domain. Samples were scanned under aerobic conditions 
using a Cary400 UV spectrophotometer between 300 and 700 nm wavelengths. 
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Figure 3.13. The formation of the ‘air-stable’ semiquinone in A. gambiae CPR. A (blue) = oxidised A. 
gambiae CPR; B (red) = immediately following addition of NADPH; C (green) = 30 min following addition of 
NADPH. Samples were scanned under aerobic conditions using a Cary400 UV spectrophotometer between 300 
and 700 nm wavelengths. 
C 
A 
B 
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with respect to spectrum A and only partial restoration of the 380 and 
450 nm absorptions (Figure 3.13). Spectrum C remained the same even 
when the sample was left overnight confirming that A. gambiae does 
indeed adopt an „air-stable‟ semiquinone state in aerobic conditions. 
 
3.2.3 Analysis of flavin content – comparing the human and the A. 
gambiae CPR 
FMN and FAD cofactor interaction with CPR is necessary for correct 
function. Residues in and around the flavin binding regions are highly 
conserved across many species and mutations in these key residues can 
lead to impaired flavin incorporation and catalytic function. In most 
cases, the ratio of each flavin to protein is 1:1 in CPR (Vermilion and 
Coon, 1978) but there are exceptions, most notably in the A. minimus 
mosquito where the ratio is 0.63:1 for FAD and as low as 0.51:1 for 
FMN (Sarapusit et al., 2008). It is important to assess the level of 
flavin incorporation in CPR samples. Studying a sample which is fully 
saturated with flavin cofactor is of particular interest from a 
biophysical perspective as it removes any potential risks of protein 
instability or slight shifts in conformation which may arise in flavin 
deficient samples. 
126 
Flavin cofactors (FMN and FAD) were isolated from the A. gambiae 
CPR by precipitation of the protein. 100 µL A. gambiae CPR was 
prepared to a concentration of 0.1 mg/mL and the sample incubated at 
95 °C for 5 min. Precipitated samples were centrifuged at room 
temperature at 20, 000 x g for 5 min and the supernatent taken for 
HPLC analysis. Buffer samples to be analysed were treated in exactly 
the same way as the protein samples. Isolated flavin samples 
transferred to HPLC vials. A range of FMN and FAD standards were 
prepared in the same buffer conditions as the protein sample. 10 µL 
sample (or standards) were loaded into a mobile phase of 50 mM 
ammonium acetate; pH 4.5 with 20 % (v/v) acetonitrile for separation 
on a 250 mm C18 column (Acclaim®120, Dionex) at 23 °C. The flow-
through was analysed by absorption spectroscopy and fluorescence 
(excitation 450 nm, emission 525 nm) for 7 min before loading the 
next sample. Samples were diluted 10-fold prior to loading onto the 
column. Quantification was determined by integration of the 
fluorescence peaks and compared to 250 nM and 50 nM FMN and 
FAD standard sample peaks. 
The HPLC method used shows good separation of the FMN and FAD 
with FAD eluting at around 3 min compared to FMN eluting at 4 min. 
In comparing the peak areas alone, it is clear that the human CPR has a 
127 
Figure 3.14. HPLC analysis of the A. gambiae and human flavin content. A = comparison of A. gambiae CPR and human CPR flavin content. 
Blue trace: 250 nM flavin standard, Red trace: Boiled A. gambiae CPR, Green trace: Boiled human CPR B = comparison of A. gambiae CPR flavin 
contents from different preparations. Blue trace: 500 nM flavin standard, Green trace: A. gambiae CPR purified with no additional flavin, Red 
trace: A. gambiae CPR prepared with flavin added during purification. HPLC was carried out on a 250 mm C18 column (Acclaim®120, Dionex) at 
23 °C using 50 mM ammonium acetate; pH 4.5 with 20 % (v/v) acetonitrile as the mobile phase. Fluorescent emission was measured at 525 nm. 
A B 
FAD 
FAD 
FMN FMN 
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CPR sample 
Protein 
Concentration 
(nmol/mL) 
a = FAD concentration 
(nmol/mL) 
b = mol. FAD/mol. protein 
a = FMN concentration 
(nmol/mL) 
b = mol. FMN/mol. protein 
Total flavin:protein 
ratio 
A. gambiae 
a
 23.5 
a = 18.8 ± 0.2 b = 0.80 ± 0.01 a = 16.9 ± 0.2 b = 0.72 ± 0.01 1.52:1 
Human 38.4 
a  = 35.2 ± 0.7 b = 0.92 ± 0.02 a  = 33.9 ± 1.2 b = 0.88 ± 0.03 
1.80:1 
A. gambiae 
b
 16.2 
a = 11.4 ± 0.2 b = 0.70 ± 0.01 a = 9.0 ± 0.1 b = 0.56 ± 0.01 
1.26:1 
A. gambiae 
c
 15.6 
a = 6.5 ± 0.3 b = 0.42 ± 0.02 a = 3.4 ± 0.1 b = 0.22 ± 0.01 
0.86:1 
Table 3.1. Flavin concentration of A. gambiae and human CPR preparations. A. gambiae 
a
 and human samples were 
prepared with both riboflavin in the bacterial media and exogenous flavin during purification; A. gambiae 
b
 sample was 
prepared with riboflavin in the bacterial expression media but no additional exogenous flavins. A. gambiae 
c 
sample was 
prepared with neither riboflavin in the bacterial expression media nor additional exogenous flavin. 
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greater content of both FMN and FAD in comparison to A. gambiae 
CPR (Figure 3.14 Panel A). For full quantification, however, the flavin 
content in relation to the original protein samples was calculated. 
The peak areas of the sample FMN and FAD peaks were directly 
compared to the flavin standard peaks to give a concentration of flavin 
loaded onto the column. This was then used and by taking into account 
sample dilution the concentration of the original sample could be 
calculated. For ease of direct comparison, the reported units for flavin 
and protein are identical. For example, A. gambiae
a
 in table 3.1, the 
starting concentration of the protein sample was 1.65 mg/mL as 
calculated by Bradford assay. For a protein of approximately 70 kDa, 1 
mg/mL is equivalent to 14.3 µM which in turn is equivalent to 14.3 
nmol/mL. Thus 1.65 mg/mL is equal to 23.5 nmol/mL. In this 
example, the concentration of eluted FAD was 114 nM. Since the 
sample was diluted 10-fold prior to loading onto the HPLC column, the 
concentration of the 100 µL prepared sample was therefore 1140 nM. 
This was derived from 0.1 mg/mL CPR thus in the original 1.65 
mg/mL sample there was 18810 nM (18.810 µM). This equates to 18.8 
nmol/mL thus from 23.5 nmol/mL CPR there is 18.8 nmol.mL FAD 
cofactor which is a 0.8:1 ratio. The same calculation was applied to the 
other samples to generate Table 3.1. 
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These data confirm that human CPR has a higher concentration of both 
FMN and FAD than the mosquito enzyme. Having FAD and FMN 
contents of 0.92:1 and 0.88:1 respectively, the human CPR is almost 
fully saturated with flavin: the same is not true for A. gambiae CPR. 
The mosquito enzyme is both FAD and FMN deficient but whilst the 
FAD content is still reasonably high at 0.80:1, the FMN deficiency is 
more noticeable. A 0.72:1 FMN:protein ratio in A. gambiae CPR 
represents an almost 20 % decrease in FMN content when compared to 
human CPR (Table 3.1). 
Analysis of the flavin content in CPR has allowed the effect of adding 
exogenous FMN and FAD during the purification process to be 
studied. If, between each chromatography step, an excess of FMN and 
FAD was added to the sample, the flavin contents in A. gambiae CPR 
were as observed above at 0.80:1 for FAD and 0.72:1 for FMN. If 
however, the purification process carried out without the addition of 
exogenous flavin at any stage, the cofactor content is decreased further 
(Figure 3.14 Panel B). The FAD content falls to 0.70:1 and the FMN 
drops as low as 0.56:1 (Table 3.1). This suggests that FAD and to a 
greater extent FMN can be lost during purification and require 
replenishing throughout. With this in mind, to maximise cofactor 
content, all samples were prepared with exogenous flavin added during 
purification 
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The addition of riboflavin into the bacterial growth and expression 
media had a dramatic effect on the flavin levels in A. gambiae CPR. 
Riboflavin is an essential precursor for FMN and FAD production in E. 
coli thus CPR produced in a riboflavin free expression medium is 
severely depleted in flavin cofactor. Such samples had an FAD content 
of 0.41:1 whilst the FMN content was 0.22:1; around 70 % lower than 
what is observed in the sample produced with riboflavin and saturated 
with exogenous flavin during purification (Table 3.1).  
This highlights the importance of both the incorporation of riboflavin 
into the bacterial expression media and the replenishment of lost 
flavins during purification. Despite having these strategies in place, A. 
gambiae CPR still appears to be flavin depleted, a trait this protein has 
in common with CPR from the related A. minimus (Sarapusit et al., 
2008). The fact that these two related mosquito enzymes show this 
similarity could be a consequence of specialised activities of CPRs in 
these insects and in order to fulfil these roles may have sacrificed fully 
effective flavin binding. The reasons for poor flavin incorporation will 
most likely be elucidated through high-resolution structural 
determination. 
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3.2.4 NMR analysis 
3.2.4.1 Introduction 
Nuclear magnetic resonance spectroscopy (NMR) is a biophysical 
technique commonly used in the analysis and determination of protein 
structure. The technique exploits the magnetic spin of certain nuclei; in 
biological studies, the three most commonly nuclei used in NMR are 
1
H, 
13
C and 
15
N. All three nuclei have spin number if ½ which means 
that the nucleus can align either parallel or perpendicular to the 
magnetic field. The natural abundances of 
1
H, 
13
C and 
15
N are, 
respectively, 100%, 1% and 0.01%. To maximise the sensitivity for 
NMR studies, biological samples are isotopically labelled with 
15
N and 
13
C. Maximal labelling is required for most experiments. In addition to 
improving sensitivity, the use of isotopically labelled samples allowed 
more complicated NMR experiments to be performed; the most 
beneficial effects of this development is that multi-dimensional NMR 
experiments can be performed, affording improved resolution of the 
NMR data.  
Another common stable isotope employed in labelling techniques is 
2
H. Replacing protons with deuterons in a protein sample lengthened 
the transverse relaxation time, T2, of the remaining protons; in other 
words, the linewidths of the NMR resonance, which has a inverse 
relationship to T2, are much reduced, thereby giving improved 
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sensitivity. Deuteration is most pertinent and beneficial for proteins of 
molecular mass greater than 30kDa. 
In the following sections, a description on the application of NMR is 
given, focussing on issues that are directly relevant to this project 
rather than providing a comprehensive survey of the various uses of 
biological NMR. 
 
3.2.4.2 Applications of NMR for Biological Studies 
A one-dimensional (1D) proton NMR spectroscopy is a relatively 
simple experiment in part due to the fact that no isotope labelling is 
required for analysis. A 1D proton NMR spectrum is a quick and fairly 
straightforward way of assessing whether a protein is correctly folded 
or not. This is an important fact as for longer and more complicated 
experiments, it is vital that the protein sample has been properly 
prepared and behaves well in the selected sample buffer for prolonged 
periods in the magnet. Once correct folding under these conditions has 
been ascertained, more complex and informative experiments can be 
run. 
15
N labelled samples are prepared by using 
15
NH4Cl as the sole 
nitrogen source in the growth media of E.coli expressing the desired 
134 
protein. 
15
N labelled sample spectra can be used, as with proton NMR 
spectra, to further assess the folding of the sample but also to make a 
judgement on the quality of generated spectra to see whether it is worth 
expending more time and money preparing more samples for further, 
potentially more expensive experiments. For example, partial folding 
and aggregation is better assessed using 2D 
1
H-
15
N HSQC spectra.  For 
relatively small proteins, a 
15
N-labelled sample can be sufficient to 
assign a sample‟s backbone resonances. 15N-labelled samples can also 
be used in titration experiments with ligands or other proteins as a way 
of assessing binding sites or conformational shifts during complex 
formation. 
15
N, 
13
C-labelled samples are more expensive to produce as 
13
C-
labelled glucose is used in bacterial growth media. Triple resonance 
spectra are used in order to assign both backbone and side chain 
resonances, provided the spectra are of sufficient quality. In order to 
determine the structure of a protein, a very high proportion of 
backbone and side chain assignments are required. Replacing 
1
H with 
2
H in studied samples has the most dramatic effect of all isotope 
labelling by allowing much larger molecular weight samples to be 
studied. The incorporation of 
2
H removes the problems of peak 
overcrowding and overlapping which is apparent in large protein. As 
the proton magnetisation in a large protein relaxes a lot faster, that is, 
135 
there is less time available to detect the signal which in turn broadens 
the peaks until no signal is detected. Deuteration of protein samples 
overcomes this problem by lengthening the transverse relaxation, 
hence, allowing improving the sensitivity of the remaining proton 
resonances.  
 
3.2.4.3 Structural Studies of A. gambiae CPR 
The human CPR FMN-binding domain has been studied by NMR and 
its resonances assigned. (Barsukov et al., 1997) Much of the structural 
study on CPRs has been performed using the X-Ray Crystallography 
method and due to the sheer size of the protein (~70 kDa.) NMR is less 
widely used for these structural studies.. The work described in this 
thesis is the first time that the A. gambiae CPR has been characterised 
in some detail using biophysical techniques.  It is also the first instance 
that NMR has been used on a full length CPR as well as its constituent 
FMN and FAD-binding domains. To fully solve a structure of such a 
large protein, with the added difficulty of bound flavin cofactors, was 
unrealistic in the timeframe of this project; however, the work 
described will serve as important groundwork for future structural 
analysis of A. gambiae CPR and potentially other related proteins. 
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3.2.4.3.1 NMR methods 
NMR spectra were recorded at 298K on Bruker Avance 600 and 
Avance 800 MHz spectrometers equipped with 
1
H,
13
C,
15
N triple 
resonance cryoprobes. The spectra were processed using TopSpin 
(Bruker) and analysed using CCPN Analysis (Vranken et al., 2005). 
The sequence specific HN, 
15
N, Cα, Cβ and CO backbone assignments 
were based on the following experiments: 2D [
15
N,
1
H]-HSQC, 2D 
[
15
N,
1
H]-TROSY, 3D HNCA, 3D HNCO, 3D HNCACB, 3D 
CBCA(CO)NH, 3D HNCOCA and 3D HNCACO Tetramethyl silane 
(TMS) was used as a chemical shift reference for 
1
H, and 
15
N and 
13
C 
shifts were referenced indirectly using the absolute frequency ratios.  
 
3.2.4.3.2 FMN-binding domain 
The FMN-binding domain, at approximately 21 kDa, is ideally suited 
to study by NMR: this has been shown previously with the human 
equivalent (Barsukov et al., 1997). The fact that the expressed A. 
gambiae domain could be produced with high yields was also an 
advantage particularly when isotope labelling was employed.  
1D proton NMR was performed on purified samples, primarily to 
assess whether the expressed protein was correctly folded and behaved 
sufficiently in the sample buffer. The buffer used for these experiments 
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was.40 mM phosphate, 0.2 mM DTT; pH 6.8 and NMR data collected 
at 298 K. The spectrum for the FMN-binding domain confirmed that 
the sample showed correct and proper folding. This was an important 
experiment to perform as it meant that further, more expensive samples 
could be prepared safe in the knowledge that the domain could be 
produced in a folded state.  
Isotope labelling, with both 
15
N and 
13
C, was successful and 
subsequent samples showed high levels of labelling without affecting 
the yield of expressed protein. A 
15
N, 
13
C double labelled sample was 
expressed and spectra produced. The spectra were clear with separate 
clean peaks implying a good quality sample.  
However, the best quality spectra were obtained when exogenous FMN 
was added in order to saturate the protein with FMN and ensure full 
complexation with the cofactor. The improvement on the quality of the 
spectrum, with well resolved resonances reminiscent of a properly 
folded protein implies that the isolated FMN-binding domain suffered, 
as with full length CPR, from a deficiency in FMN cofactors. The very 
fact that adding FMN helped with the quality of samples indeed shows 
that poor flavin incorporation could indeed affect structural integrity of 
the FMN-binding domain in A. gambiae CPR. Figure 3.15 shows a 
1
H, 
15
N HSQC spectrum of the FMN-binding domain following the 
addition of exogenous FMN to the sample. 
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15
N 
1
H 
Figure 3.15. HSQC spectrum of 
1
H 
15
N, -labelled A. gambiae isolated FMN-binding domain. Sample was prepared in 40 mM 
phosphate, 0.2 mM DTT; pH 6.8 298 K. 
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The addition of FMN yields a good quality spectrum with good levels 
of peak detection and separation. 
Having established that exogenous FMN was required, the next step 
was to ensure that the protein sample was stable for extended period of 
up to three weeks in order for high quality NMR data to be collected 
for structure determination. It was found that over this period and at 25 
°
C (the optimal compromise temperature between resonance line-
widths and protein stability) the protein showed signs of unfolding 
despite the fact that excess FMN was present in the sample, as assessed 
by the large free FMN resonances in the spectra. Despite these stability 
limitations, a complete set of triple resonance data was acquired. 
Figures 3.16 and 3.17 are CBCA(CO)NH and HNCA projections of 
the triple resonance data. These data confirm that there is sufficient 
sensitivity in these samples to obtain complete backbone resonance 
assignments. Due to time limitations, these assignments were not 
undertaken as part of the thesis. 
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1
H 
13
C 
Figure 3.16. 3D CBCA(CO)NH HSQC spectrum of A. gambiae isolated FMN-binding domain. Sample was prepared in 40 
mM phosphate, 0.2 mM DTT; pH 6.8 298 K. 
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1
H 
13
C 
Figure 3.17. 3D HNCA HSQC spectrum of A. gambiae isolated FMN-binding domain. Sample was prepared in 40 mM 
phosphate, 0.2 mM DTT; pH 6.8 298 K.  
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3.2.4.3.3 FAD-binding domain 
The inherent lack of stability of A. gambiae FAD-binding domain was 
a clear potential obstacle in performing biophysical analysis. The 
sample buffer used for experiments was the same as for the FMN-
binding domain and despite the stability issues during purification, 
samples for NMR were produced. A 1D proton NMR spectra 
confirmed that the expressed protein was correctly folded (Figure 3.18) 
and labelled samples were hen produced. 
The FAD-binding domain is rather large at just under 50 kDa thus 
simply assessing protonated samples would likely lead to poor quality 
spectra. With this is mind, in an attempt to improve sensitivity, a 
deuterated sample was produced. Under the experimental conditions 
used for NMR, however, the 
15
N, 
2
H double labelled sample showed 
apparent problems with poor quality spectra; there was a significant 
level of aggregation. This, along with the poor yield of deuterated 
protein produced, were responsible for the poor quality of the acquired 
spectrum. Further investigation of aggregation using size exclusion 
chromatography was attempted although the low level of protein 
concentration precluded these experiments to be performed with 
confidence. 
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Figure 3.18. 1D proton NMR spectrum of A. gambiae isolated FAD-binding domain. Sample was prepared in 40 mM phosphate, 
0.2 mM DTT; pH 6.8 298 K. 
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3.2.4.3.4 Soluble full length CPR 
The A. gambiae full length CPR was produced with more success than 
the unstable FAD-binding domain. Like the FMN-binding domain, the 
diflavin reductase was expressed with high yields and showed a much 
higher level of stability than the FAD-binding domain. A 1D proton 
NMR spectrum was produced where clear, separate peaks were 
observed meaning the full length sample had been properly produced 
and was fully folded. 
A 
15
N-labelled sample was produced and 2D spectrum generated 
(Figure 3.19). The 
1
H, 
15
N spectrum for A. gambiae CPR is a very 
crowded spectrum with many poorly-resolved resonances. Even the 
resolved resonances are overlapping. There are many regions where 
very weak peaks are present although the sensitivities remain poor due 
to rapid T2 relaxation. This is characteristic of a very large protein, 
such as CPR. In order to alleviate the T2 relaxation problem the protein 
sample was deuterated to produce a 
2
H, 
15
N sample. 
Such techniques are commonly used in larger proteins like A. gambiae 
CPR which has a monomeric molecular mass of approximately 70 
kDa, deuteration was essential in order to improve the quality of data. 
An obvious problem with producing deuterated samples in E. coli is 
that D2O is not a good growth media for the bacteria
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Figure 3.19. HSQC spectrum of 
1
H 
15
N, -labelled A. gambiae CPR. Sample was prepared in 40 mM phosphate, 0.2 mM 
DTT; pH 6.8 298 K. 
15
N 
1
H 
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Growing the bacteria and expressing the protein in entirely D2O based 
minimal media successfully produced a deuterated sample but there 
were some pitfalls to using this procedure. A D2O based minimal 
media is a media consisting entirely of D2O without any H2O or 
additional rich media supplements. The growth rates of the bacterial 
cells were extremely slow compared to growth in the H2O based 
minimal media. Such growth rates not only impact on time but also 
expose the bacteria to toxic D2O for an extended period of time. This 
leads to slow growth but also an impaired yield which was another 
problem with a D2O based media approach. The levels of protein were 
so low, <1 mg CPR per litre that the amount of D2O required to 
produce a sample of adequate concentration was neither practical nor 
cost effective. 
An alternative approach was clearly required in order to produce 
enough protein to generate a spectrum of any quality. Silantes (Silantes 
GmbH, München, Germany) provides specialised media for expression 
of isotope labelled protein samples. It is a type of rich media that vastly 
improves growth and expression conditions for E. coli when compared 
to standard D2O-based media; thus protein samples can be produced 
which show high levels of labelled isotope incorporation without 
compromising on yields. As a trial of its efficacy, unlabelled Silantes 
was used in conjunction with D2O based media to try to improve 
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growth rates and protein yields. This was indeed the case and when the 
D2O media was spiked with 10 % unlabelled Silantes, the amount of 
protein produced increased to >10 mg per litre at a much more 
efficient rate. Predictably, the level of deuteration was impaired and 
the unlabelled Silantes element of the media contributed protons to the 
expressed protein. 
Nevertheless, the 
2
H, 
15
N double labelled sample which was produced, 
despite being slightly deficient in 
2
H labelling, gave significantly better 
quality spectra than the singly labelled 
15
N-labelled protein sample 
(Figure 3.20). The regions of poor peak detection due to low signal-to-
noise ratio in the protonated spectrum were much clearer in the 
deuterated spectrum. There were even several regions of peaks present 
in the deuterated spectrum that were completely missing from the 
protonated spectrum. In general, the deuterated spectrum was much 
neater with more peaks detected and those that were detected were 
much clearer and separate. Although this spectrum itself is not enough 
to generate any meaningful structural data, it confirms that 
recombinant A. gambiae CPR is folded. Nevertheless, the research 
demonstrates that it is possible and practical to prepare sufficient 
quantities of deuterated proteins for future NMR structure 
determination. This research establishes a protocol for making a 
deuterated sample, bearing in mind that potentially, there could have 
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Figure 3.20. HSQC spectrum of 
2
H, 
15
N-labelled A. gambiae CPR. Sample was prepared in 40 mM phosphate, 0.2 mM DTT; 
pH 6.8, 298 K 
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2
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been some difficulties, such as cofactor incorporation and protein 
folding.  
These data are extremely encouraging for a number of reasons. Firstly, 
this is the first NMR investigation on A. gambiae CPR and its 
constituent domains.  All samples were effectively produced for such 
biophysical analysis, albeit with varying degrees of success. 
Production of deuterated protein samples can be very difficult to 
achieve and although the samples produced were not deuterated to a 
very high level, these samples show that deuteration is a very 
achievable possibility. 
The levels of deuteration achieved in A. gambiae CPR, in this case, 
were assessed by interpretation of the 1D specta. Figure 3.18 shows a 
typical 1D spectrum and such data can be utilised to make a rough 
assessment on the levels of deuteration in an analysed sample. In 
protein structure, the protons within NH groups (detected at p.p.m = 
~9) are fully interchangeable with those in the purification buffers and 
thus will remain protonated even in a fully deuterated sample. Protons 
within CH3 groups (detected at p.p.m = ~0) are, however, not 
interchangeable and once deuterated will not be re-protonated during 
purification. Since 1D spectra analyse protons, in a fully deuterated 
sample, the CH3 peaks will disappear completely. In partially 
deuterated samples, the level is quantified by the relative peak height 
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of the CH3 groups relative to the NH groups. If, for example, the NH 
peak had an arbitrary height of 3 and the CH3 peak had an arbitrary 
height of 1, which suggests that 25 % of the total peak height over 
those two groups was as a result of protons within CH3 groups. If 25 % 
of these hydrogen‟s are protonated, this means that 75 % are deuterated 
and that sample is believed to be approximately 75 % deuterated. 
In order to further continue the NMR study on A. gambiae CPR, time 
and, more importantly, money will need to be invested and fully 
labelled Silantes media used as the base media for sample expression. 
These data have provided essential groundwork to the A. gambiae 
NMR study and have suggested that introducing labelled Silantes, 
despite being an expensive medium, would potentially be a very 
worthwhile exercise in progressing structural determination of A. 
gambiae CPR. 
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3.2.5 Redox potentiometry 
The tendency of a species to accept electrons and thus become reduced 
is measured by its reduction potential. The more positive the reduction 
potential, the more likely it is that the species will accept electrons and 
thus become reduced. Conversely, a more negative reduction potential 
increases the likelihood that a species will donate electrons and thus 
become oxidised. The transfer of electrons from one species to other is 
therefore strongly governed by the difference in reduction potentials of 
the two species.  
In the case of CPR, the redox centres are the FMN and FAD cofactors 
and these are reduced by accepting electrons, donated as a hydride ion 
by NADPH. Each flavin accepts two electrons and therefore a number 
of redox couples are possible. In each case there are the 
oxidised/semiquinone (one electron reduced) couple and the 
semiquinone/hydroquinone (two electron reduced) couple. The 
calculated values for reduction potentials of these various couples can 
provide a valuable insight into the tendencies and properties of inter-
flavin electron transfer within these enzymes. The reduction potentials 
of some CPR‟s and related enzymes are shown (Figure 3.21). 
Redox titrations were performed in a Belle Technology glove-box 
under a nitrogen atmosphere. All solutions were degassed under 
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Figure 3.21 The measured redox potentials of various diflavin reductases. The measured redox 
potentials of human CPR, rabbit CPR, P450 BM3 and the reductase domain of rat nNOS. The 
oxidised/semiquinone couples for FMN and FAD are shown in blue whilst the semiquinone/hydroquinone 
couples for FMN and FAD are shown in red. The dots are equivalent to the number of electrons: One for 
semiquinone species and two for hydroquinone species. The redox potential of the NADP
+
/NADPH couple 
is shown as the black bar.Figure taken from Munro et al., 2001. 
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vacuum with Nitrogen prior to use in the glove-boxes. Oxygen levels 
were maintained at less than 2 p.p.m. Protein samples A. gambiae 
CPR, A. gambiae FAD and FMN-binding domains were applied 
through an anaerobic G25 Sephadex column (1 x 20 cm) (10DG 
Econo-Pac column, Bio-Rad) immediately on admission to the glove 
box to remove all traces of O2, the column was pre-equilibrated and 
proteins buffer-exchanged into anaerobic buffer (100 mM potassium 
phosphate, 10 % (v/v) glycerol; pH 7.0) buffer. The protein solution (~ 
15-30 μM in 5 mL buffer), was titrated electrochemically according to 
the method of Dutton (Dutton, 1978) using sodium dithionite as the 
reductant and potassium ferricyanide as the oxidant. 0.2 µL additions 
of dithionite and ferricyanide were made from concentrated stock 
solutions (typically 10-50 mM). Prior to titration, mediators were 
added to facilitate electrical communication between enzyme and 
electrode. Typically, 2 μM phenazine methosulfate (PMS) (E0 +80 
mV), 7 μM 2-hydroxy-1,4-naphthoquinone (HNQ) (E0 -145 mV), 1 
μM benzyl viologen (BV) (E0 +311 mV), and 0.3 μM methyl viologen 
(MV) (E
0 
+430 mV) were introduced to mediate within the full 
experimental range (between +100 to –480 mV) of the titration (Munro 
et al., 2001; Ost et al., 2001). At least 10-15 min was allowed to elapse 
between each addition of reductant/oxidant to ensure full equilibration 
of the solution and stabilisation of the electrode. Spectra were recorded 
over a range of 250-800 nm using a Cary UV-50 Bio UV-Visible 
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scanning spectrophotometer coupled to a fibre optic probe. The 
electrochemical potential of the solution was measured using a Mettler 
Toledo SevenEasy S20-K meter coupled to a Calomel electrode 
(ThermoRussell Ltd.) at 25 °C. The electrode was calibrated using the 
Fe
3+
/Fe
2+ 
EDTA couple as a standard (+108 mV). The Calomel 
electrode was corrected by +244 mV ± 2 mV, relative to the standard 
(or normal) hydrogen electrode. Spectral data at wavelengths maximal 
for the optical transitions, where appropriate, between oxidised 
(quinone), 1-electron (semiquinone) and 2-electron reduced 
(hydroquinone) forms of the flavin molecules were plotted versus the 
applied potential, and the data fitted to the Nernst function using 
Origin 7.0 (OriginLab, Northampton MA). 
To ensure a good quality of redox titration experiment, spectra are 
recorded in both oxidative and reductive directions. If the data coincide 
with each other in both directions, it can be assumed the experimental 
conditions were correct and the necessary equilibria were achieved. If, 
however, the data do not coincide, hysteretical effects are seen 
meaning the correct equilibria were not achieved under the 
experimental conditions. Redox potentiometry experiments were 
carried out using the specialised equipment at Manchester 
Interdisciplinary Biocentre (MIB) with great assistance by Dr. Kirsty 
McLean and Professor. Andy Munro. 
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Experiments were performed on each of the full length soluble A. 
gambiae CPR as well as the individual FMN and FAD-binding 
domains. Data for the individual FMN and FAD binding domains were 
fitted according to equation 1 which represents a two-electron redox 
process derived by extension to the Nernst equation.and Beer-Lambert 
Law (Dutton, 1978; Daff et al., 1997,)  
Eq 1.    
A= a10
(E – E
1‟
)/59 
+ b + c10
(E
2‟
 – E)/59 
 
Equation 2 would be used to fit the data for the full length CPR and 
represents the sum of the two 2-electron redox processes (Dutton, 
1978; Noble et al., 1999) 
Eq. 2   
A= a10
(E – E
1‟
)/59 
+ b + c10
(E
2‟
 – E)/59  
   d10
(E – E
3‟
)/59 
+ e + f10
(E
4‟
 – E)/59    
 
 
Here, A is the total absorbance, a, b and c are component absorbance 
values contributed by one flavin in the oxidised, semiquinone and 
reduced states respectively, and d, e and f are the corresponding values 
from the second flavin. E is the observed potential, E1‟ and E2‟ are the 
midpoint potentials for the oxidised/semiquinone and 
1 + 10
(E – E
1‟
)/59 
+ 10
(E
2‟
 – E)/59 
 
1 + 10
(E – E
1‟
)/59 
+ 10
(E
2‟
 – E)/59 
 
1 + 10
(E – E
3‟
)/59 
+ 10
(E
4‟
 – E)/59 
 
+ 
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semiquinone/reduced couples, respectively, for the first flavin and E3‟ 
and E4‟ are tbe corresponding midpoint potentials for the second flavin 
(Munro et al., 2001)  
Full analysis on both individual domains and the full length CPR was 
not completed. The raw data was collected for all but the data not fully 
fitted to the respective two- or four-electron reduced models in each 
case. Although the diflavin reductase was stable in the reaction 
conditions and the data acquired, the complex nature of the full length 
CPR made fitting the data to the current model more difficult due to its 
four electron reduction. The individual domain data is used to 
overcome these complications and aid in fitting in the full length 
enzyme. The FAD-domain was quite unstable in the reaction 
conditions and the acquired data did not fit well into Nernst equation 1. 
The FMN domain was more stable in the reaction conditions and the 
data fitted well into Nernst equation 1. The spectrophotometric versus 
applied potential values for this domain have been plotted at the 
significant wavelengths. 
 
3.2.5.1 FMN-binding domain 
The spectral data for the A. gambiae FMN-binding domain (Figure 
3.22) highlight a number of characteristic features of the domain under 
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redox conditions. The protein was stable during the entirety of the 
experimental procedure and good quality data was produced. Isosbestic 
points at 503 and 435 nm are generated and plot the transitions from 
oxidised/semiquinone through to semiquinone/hydroquinone species 
respectively by addition of the two electrons. The maximal absorbance 
for oxidised FMN-binding domain is at 454 nm and during reduction 
with the first electron, the absorbance intensity at this wavelength 
decreases. The decrease at 454 nm is coupled with an increase in 
intensity at 587 nm indicating semiquinone formation. As the domain 
is reduced further, the 454 nm peak continues to decrease as does the 
587 nm peak. This shows that the semiquinone is being converted into 
the two-electron reduced hydroquinone form. The spectra show 
identical behaviour during both oxidative and reductive experiments 
(Figure 3.22)  
Values of reduction potential for the one and two-electron reduced A. 
gambiae CPR FMN-binding domain were generated by plotting the 
potential versus absorbance at specific wavelengths. At 479 nm 
wavelength, there is the largest separation in oxidised versus reduced 
domain absorbancies (Figure 3.22) and when plotted, produces a 
double sigmoidal curve, each representing one of the two-electron 
reduction stages of the flavin.  
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Figure 3.22.Spectral properties of A. gambiae CPR FMN-binding domain during redox titrations. 30 µM A. gambiae CPR FMN-binding domain was 
first reduced using dithionite and re-oxidised with ferricyanide with spectra recorded at multiple time-points throughout. The isosbestic point at 503 nm, 
indicated by “a”, and is observed following one-electron reduction in the oxidised/semiquinone transition. The second isosbestic point at 435 nm, indicated by 
“b”, is observed following reduction by the second electron in the semiquinones/hydroquinone transition. Experiments were carried out with the help of Dr. 
Kirsty McLean (MIB). 
a 
b
a 
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The data were fitted using the two-electron Nernst equation and the 
midpoint potentials recorded. (Figure 3.23 A). The change in the 
absorbance at 587 nm follows the formation and subsequent decay of 
the semiquinone species following one then two electron reduction 
respectively. The separation of the midpoint potentials at this 
wavelength is indicative of the level of intensity of the semiquinone 
species. (Figure 3.23 B). 
At the 435 nm wavelength, the isosbestic point for the second electron 
reduction step, any changes in absorbance will be during the first 
electron reduction step. Likewise at 503 nm, the isosbestic point for the 
first electron reduction step, any changes in absorbance will occur 
during the second electron reduction step. Thus, when absorbancies at 
the isosbestic points are plotted against the respective potentials, they 
provide a further level of comparison of calculated reduction potentials 
with respect to the data plotted at 479 and 587 nm. (Figure 3.24 A and 
B respectively). 
The calculated midpoint potentials at 479 nm were -92 mV for the 
oxidised/semiquinone transition and -271 mV for the 
semiquinone/hydroquinone transition. These were in very good 
160 
 Figure 3.23. Absorbance versus potential plots at 479 nm and 587 nm for A. 
gambiae CPR FMN-binding domain. A = The 479 nm wavelength represents the 
point at which there is the largest change in absorbance between the oxidised and 
reduced domain. B = The 587 nm wavelength plot represents the formation and decay 
of the semiquinone during one and two electron reduction respectively. Data was fitted 
using the two electron Nernst equation (eq1) by Dr. Kirsty McLean/Prof. Andy Munro 
(MIB). 
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Figure 3.24. Absorbance versus potential plots at 435 nm and 503 nm for A. gambiae 
CPR FMN-binding domain. A = The 435 nm wavelength represents the isosbestic point 
for the semiquinone/hydroquinone transition. B = The 503 nm wavelength plot represents 
the isosbestic point for the oxidised/semiquinone transition. Data was fitted using the two 
electron Nernst equation (eq1) by Dr. Kirsty McLean/Prof. Andy Munro (MIB). 
162 
agreement with the calculated midpoint potentials measured at 587 nm 
which were -92 mV and -265 mV for the oxidised/semiquinone and 
semiquinone/hydroquinone transitions respectively. The reduction 
potentials measured at the isosbestic points corroborate these data and 
are calculated at -92 mV for the oxidised/semiquinone transition and-
270 mV for the semiquinone/hydroquinone transition. The calculated 
reduction potential data for A. gambiae CPR FMN-binding domain are 
summarised in Table 3.2 with the human CPR FMN-binding domain 
data (Munro et al., 2001) added for comparative purposes.  
These data provide valuable information regarding the properties of 
flavin reduction of the FMN cofactor. These values are close to those 
seen in the human CPR FMN-binding domain (Table 3.2) with the 
major difference being a more negative E value for the 
oxidised/semiquinone transition observed in A. gambiae CPR; -92 mV 
compared to -43 mV in human (Munro et al., 2001). Known values for 
other diflavin reductases have been shown previously and the -92 mV 
observed in A. gambiae CPR is within the range of values observed for 
human and rabbit CPR‟s (Figure 3.21). Without fully convoluted data 
for the FAD-binding domain and full length soluble CPR, conclusions 
regarding the entire protein cannot be drawn. However, this work on 
the isolated FMN-binding domain is good groundwork for redox 
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potentiometry in A. gambiae CPR and suggests a well produced FMN-
binding domain. 
 
3.5.4.2 FAD-binding domain 
Although the data for the FAD-binding domain is yet to be fully 
deconvoluted, the raw data is presented (Figure 3.25). There is an 
isosbestic point at around 504 nm for the oxidised/semiquinone 
transition. The semiquinone/hydroquinone transition isosbestic point is 
less well defined but is possibly around 420 nm according to the raw 
data. The absorbance maxima for the oxidised FAD-binding domain 
are at 382 nm and 457 nm with the semiquinone absorbance maxima 
being 594 nm. These data are not too dissimilar to the FMN-binding 
domain and are also similar to values observed for the human FAD-
binding domain (Munro et al., 2001). 
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Protein (wavelength) Oxidised/semiquinone (mV) Semiquinone/hydroquinone (mV) Oxidised/reduced (mV) 
AgFMN domain (479 nm) 
-92 ± 1 -271 ± 5 -182 ± 3 
AgFMN domain (587 nm) 
-92 ± 1 -265 ± 2 -179 ± 2 
AgFMN domain (435 nm) 
-92 ± 1 - - 
AgFMN domain (503 nm) 
- -270 ± 1 - 
hFMN domain
a
 
-43 ± 7 -280 ± 8 -162 ± 8 
Table 3.2. Summary of the calculated reduction potentials in A. gambiae CPR FMN-binding domain. The E values calculated 
following absorbance versus potential plots at different wavelengths are shown as well as the published values for human CPR 
FMN-binding domain. 
a
 = human FMN domain data from Munro et al., 2001. 
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Figure 3.25. Spectral properties of A. gambiae CPR FAD-binding domain during redox titrations. 30 µM A. gambiae CPR FAD-binding domain was 
first reduced using dithionite and re-oxidised with ferricyanide with spectra recorded at multiple time-points throughout. The isosbestic point at 504 nm, 
indicated by “a”, and is observed following one-electron reduction in the oxidised/semiquinone transition. The second isosbestic point is less clear but is 
apparently at around 420 nm, indicated by “b”, is observed following reduction by the second electron in the semiquinones/hydroquinone transition. 
Experiments were carried out with the help of Dr. Kirsty McLean (MIB). 
a b 
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3.3 Discussion 
This chapter focussed on the expression, purification and initial 
characterisation of A. gambiae CPR and its isolated FMN and FAD-
binding domains. The pET15b vector containing the N-terminal 
truncated soluble CPR (Dr. Mark Paine, Liverpool School of Tropical 
Medicine) was successfully expressed in competent BL-21 Codon Plus 
RP E. coli cells for optimal recombinant protein expression. Purified 
enzyme was correctly identified as A. gambiae CPR by mass 
spectrometry and was judged to be correctly folded by 1D proton 
NMR. Verification of the full length CPR was important considering 
the plasmid was to be used as a template for molecular dissection, 
using PCR, into the isolated FMN- and FAD-binding domains. 
Initial manufacture of these domains into pET15b vectors subsequently 
proved unsuccessful for both domains. The need to remove an NdeI 
restriction site by incorporating a silent mutation into residue I617 
proved a major stumbling block, a point emphasised by the failed 
sequencing of the FAD-binding domain plasmid. The FMN-binding 
domain plasmid was successfully made and sequenced however 
problems arose during expression and purification. A prominent 
double band was present following purification even following His-tag 
removal with the molecular weight difference between the two species 
remaining the same. Considering the supposed contaminant apparently 
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decreased in molecular weight following thrombin treatment, the most 
likely explanation is a C-terminal truncation of the FMN-binding 
domain. This, however, was not investigated further or verified by 
mass spectrometry as the requirement for both isolated binding 
domains necessitated new expression constructs to be made. 
Subsequent molecular dissection, this time into the pETM-11 vector, 
of both the FMN and FAD-binding domains was much more 
successful. A method of alleviating the potential C-terminal truncation 
in the FMN-binding domain led to the manufacture of a domain which 
included an extension into the linker region. An extended FAD binding 
domain; extended at the N-terminus, was also made and following 
successful plasmid sequencing, these constructs were to be expressed, 
purified and characterisation. Both domains were successfully 
expressed in E. coli and purified without contaminating bands (Figures 
3.7 and 3.9). Correct folding of both samples was confirmed by 1D 
proton NMR. 
The redox potentials of human CPR along with its FMN and FAD-
binding domains have previously been reported (Munro et al., 2001). 
A. gambiae CPR, FMN and FAD-binding domains underwent identical 
anaerobic titrations in an attempt to establish the redox potentials of 
these enzymes. Experiments were performed successfully and raw data 
gathered. However, due to time constraints and instability issues with 
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the FAD-binding domain, full convolution of the raw data could not be 
fully undertaken. Analysis of the FMN-binding domain was, however, 
completed and a redox potential calculated. The oxidised/semiquinone 
transition in human FMN-binding domain was -43 mV, much more 
positive than the -92 mV calculated for A. gambiae FMN-binding 
domain (Table 3.2). This suggests that in the oxidised form, human 
FMN accepts electrons more readily than the Anopheline equivalent. 
One plausible explanation for this is that the FMN binds more weakly 
to the A. gambiae protein. The current data on the FMN domain only 
does not give provide much more information on potential mechanisms 
or major differences between the two CPRs, these can only be properly 
established when the FAD-binding domain and intact CPR data has 
been fully convoluted. 
CPRs are known to form „air-stable‟ semiquinones and following 
incubation with NADPH A. gambiae CPR produced a typical spectral 
pattern showing this enzyme conforms to conventional CPR behaviour. 
An interesting feature with regards to A. gambiae CPR characterisation 
was the apparent observed deficiency of incorporated FAD and to a 
greater extent FMN when compared to the human CPR (Table 3.1). 
This is particularly interesting considering that the same deficiency has 
been established in A. minimus CPR (Sarapusit et al., 2008), a very 
closely related enzyme to A. gambiae CPR. 
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In the case of A. minimus, the deficiency was more obvious for both 
FMN and FAD. Residues in the FMN binding domain, F86 and F219, 
known to be involved in FMN stabilisation are conserved between A. 
gambiae and many other CPRs including rat and human; this is not so 
in A. minimus CPR, where both phenylalanines are replaced by 
leucines, this partially explaining its weak cofactor binding. Mutating 
these leucine residues to phenylalanine in A. minimus CPR brings 
FMN incorporation in-line with established human and rat CPR. It is, 
therefore, unclear as to why the FMN incorporation in A. gambiae is 
low considering the fact that phenylalanines are found in positions 86 
and 219.  
Sequence comparison alone is not sufficient, therefore, to fully 
understand the rationale for poor flavin incorporation. This was also 
apparent when using NMR; addition of exogenous FMN to 
15
N, 
13
C 
isotopically labelled samples yielded better spectra (Figure 3..15) The 
FMN-binding domain was sufficiently stable throughout for a good set 
of triple resonance data to be was acquired (Figures 3.16 and 3.17). 
However, the protein unfolded slowly over a two week period. The 
triple resonance data were of the required quality for assigning 
backbone resonances, however, time constraints precluded this from 
being performed. The FAD-binding domain was inherently unstable 
throughout the purification process and precipitation was a continual 
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problem, culminating in aggregation of samples in the magnet during 
data gathering. Because of its molecular weight, approximately 50 
kDa, deuteration was required to improve peak sensitivity which was 
also the case for the full length CPR (Figure 3.20). 
D2O is not a good growth media for E. coli. The toxicity of D2O allied 
to incredibly poor yields of pure protein meant an alternative labelling 
strategy was required. Unlabelled Silantes media was used to boost 
bacterial growth which subsequently impacted on yield by increasing it 
by at least 10-fold compared to D2O media alone. Predictably, 
however, the preferential use of the Silantes rich media as a nutrient 
source led to isotopic dilution and a decrease in the level of 
2
H-
labelling. 
This is the first instance of NMR being used on A. gambiae CPR and 
its constituent FMN and FAD-binding domains. The biophysical data 
gathered in this thesis has provided a strong basis for future work of 
this kind. The FMN-binding domain has provided the most extensive 
data thus far; however, the successful production of isotopically 
labelled samples, including deuterated CPR and FAD-binding domain 
samples, lays the solid foundations for more comprehensive structural 
determinations of A. gambiae CPR in the future. 
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Chapter 4 
 
 
4. NUCLEOTIDE AND FLAVIN COFACTOR BINDING 
 
4.1 Introduction 
NADPH binding and subsequent hydride interaction is a significant 
event in the activity of cytochrome P450 reductase (CPR). NADPH 
has been shown to bind in a bipartite fashion with initial interaction 
being at the 2‟-phosphate moiety. Following 2‟-phosphate interaction, 
the nicotinamide moiety is correctly positioned for full binding. 
Although the methods for nucleotide binding are well established, the 
relative binding affinities and energies for the different CPRs have not 
been thoroughly investigated. This is important if the differential 
behaviours of the CPRs from different organisms are to be exploited.  
A common strategy in the purification of CPR‟s is with the use of a 2‟, 
5‟-ADP sepharose affinity chromatography resin. 2‟, 5‟-ADP is an 
analogue of NADPH and bound protein is eluted using 2‟-AMP. 
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Previous work on A. gambiae CPR highlighted a very interesting 
observation in that the standard 2‟, 5‟-ADP sepharose failed to bind 
this enzyme; which was eluted in the flow through. The same resin had 
been successful in the processing of human CPR. This serendipitous 
observation suggested a significant difference in the binding 
characteristics between A. gambiae and human CPR‟s to 2‟, 5‟-ADP. 
A comparative inhibition study using the same enzymes seemed to 
confirm this difference and suggested an approximate 10-fold weaker 
affinity of A. gambiae CPR for 2‟, 5‟-ADP when compared to the 
human equivalent. 
In this research, Isothermal Titration Calorimetry (ITC) was used to 
assess the binding affinities and energies of both A. gambiae and 
human CPR to a number of NADPH nucleotide analogues (Figure 4.1). 
A similar study was previously reported for the human CPR (Grunau et 
al., 2006). Here, the experiments for human CPR were undertaken in 
parallel with the A. gambiae protein to ensure that the studies are 
undertaken under similar laboratory conditions, giving more 
confidence to any differences found.   The crystal structure of the rat 
CPR showed that the NADPH-binding site is fully localised in the 
FAD-binding domain (Wang et al., 1997) and therefore, it is safe to 
assume that this will be the case for A. gambiae CPR. Using the 
expressed isolated A. gambiae FAD domain, binding characteristics 
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were generated for a selection of the tested analogues; these were then 
utilised as a further comparative aid for the activity of full-length A. 
gambiae CPR. 
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Figure 4.1. Structures of NADPH and related nucleotide ligands for ITC study. A = NADPH; B = NADP
+
; C = NAD
+
; D = 2‟, 5‟-ADP; E = 2‟-
AMP; F = 3‟-AMP. 
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4.2 Methodologies and Results 
Isothermal Titration Calorimetry (ITC) is a technique used to ascertain 
thermodynamic parameters of chemical interactions. It is most 
commonly used to obtain thermodynamics information of interactions 
between small molecules, i.e. ligands, cofactors, metal ions, and larger 
macromolecules, i.e. proteins, DNA. With the current hardware, it is 
now also practical to use ITC for investigating protein-protein 
interactions. The quantitative measures that can be gained by ITC 
include binding stoichiometry (n), enthalpy change (ΔH), entropy 
change (ΔS) and binding affinity (K). From these, the measurement of 
the feasibility of reaction; the Gibbs free energy change (ΔG) can be 
calculated. 
As two substances bind to each other, heat is either generated or 
absorbed in, respectively, an exothermic or endothermic reaction. . 
Traditionally, a high concentration small molecule is injected 
sequentially into the lower concentration macromolecule. The heat 
exchange, either generated or absorbed, is measured over time by ITC. 
On an ITC isotherm, each peak is representative of the heat exchange 
following a single injection. The amount of heat exchange is 
proportional to the level of binding and as the reaction reaches 
saturation, the peak sizes get smaller meaning less binding is 
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occurring. The raw isotherm data is translated into a binding curve 
allowing thermodynamic parameters to be calculated. 
The equipment used for Isothermal Titration Calorimetry 
measurements contain two cells- a reference and a sample cell. The 
reference cell, once filled with buffer or water, is not tampered with in 
order to avoid contamination. The sample cell is filled with the 
macromolecule and successively ligand is titrated into it, often in 1-2 
µL injections. There are two thermostats in the system: the first 
maintains the cells at the experimental temperature by keeping them 
the same as the thermo-jacket. The second thermostat maintains the 
temperature difference between the reference and sample cell. This 
temperature difference needs to be kept constant and forms the basis 
for the measurement of heat exchange. As heat is absorbed or 
generated by addition of ligand into the sample cell, there is a change 
in temperature. Following the change in temperature upon binding, the 
power required to return to the initial inter-cell temperature difference 
is a direct measure of the total heat resulting from the reaction. 
Appropriate buffer formulation is a major requirement in the design of 
ITC experiments. Certain substances should be not be used to avoid 
damaging the cell or having an effect on heat exchange. Phosphate 
based buffers are common; however, for ITC experiments involving 
CPR and associated enzymes, phosphate buffers are less than ideal. 
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The reason for this has been previously highlighted (Murataliev and 
Feyereisen, 2000; Grunau et al., 2006). Free phosphate binds to the 
NADPH binding site hence acting as a competitive inhibitor for 
nucleotide binding. Free phosphate has a Ki of 33 mM in house fly 
reductase (Murataliev and Feyereisen, 2000) which is enough to cause 
a decrease in the binding affinities for nucleotide ligands. This was 
reported for human CPR, where binding of 2‟, 5‟-ADP to the enzyme 
had a 13-fold weaker affinity when ITC was performed in phosphate 
buffer as opposed to BES, a non-phosphate buffer (Grunau et al., 
2006). For this reason, all of the ITC experiments performed in this 
study were carried out in a BES based buffer rather than one 
containing phosphate. 
Purified protein samples were buffer-exchanged into ITC buffer (100 
mM BES; pH 7.0) prior to experiments. This buffer was used for each 
experiment throughout the study. Unless freshly purified, samples were 
generally buffer-exchanged from 50 % glycerol stocks stored at -20 
°C. Samples were centrifuged at 13,000 x g for 10 min and degassed at 
23 °C (2 °C below the temperature at which the experiments were 
performed). All experiments were performed at 25 °C using the ITC200 
calorimeter (Microcal) and data analysed using Origin 7.0 (Microcal). 
Typically, the protein concentration in the cell was in the region of 10-
20 µM whilst different ligand concentrations in the syringe were tried 
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to elicit a binding curve. For the most part, ligand concentrations were 
in the range of 100-1000 µM. 
 
4.2.1 Nucleotide binding affinities 
One important role for CPR is to distinguish between nucleotides for 
effective electron transfer. Assessing the binding affinity of NADPH is 
difficult particularly since addition of NADPH to oxidised CPR will 
lead to a reduction event following hydride ion transfer from the 
nucleotide. When using ITC, this on-going process will produce 
inconsistent heat exchanges due to the presence of numerous species of 
both the enzyme and nucleotides present at any one time. This gives 
rise to poor quality binding curves. Furthermore, any binding affinity 
calculated cannot be attributed to any single species of enzyme or 
nucleotide. Ideally, therefore, in order to determine a binding affinity 
for NADPH, an inert analogue must be used. H4NADP is such an 
analogue and will bind effectively to CPR without hydride ion transfer 
and hence electron transfer taking place. This keeps both the enzyme 
and nucleotide in the same oxidation state throughout the entirety of 
the experiment. The synthesis of H4NADP is difficult, requires the use 
of specialised Palladium chemistry techniques and is beyond the scope 
of the current studies. 
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The study undertaken in this thesis focuses on understanding in greater 
depths, the role(s) of the phosphate groups in nicotinamide binding to 
CPR. This is done by comparing the interactions between NADP
+
 and 
NAD
+
.  
NADPH and NADH differ only in the lack of a second phosphate 
group on the ribose ring in NADH (Figure 4.1).  Nevertheless, clear 
differences in binding affinity between the two nucleotides have been 
widely reported. Since there is only one structural difference between 
these nucleotides, the additional phosphate group must be the major 
reason for this discrimination. Oxidised NADPH in the form of 
NADP
+
 does not fully interact with oxidised CPR due to the positively 
charged nicotinamide ring (Murataliev et al., 2000) however it is still 
able to bind weakly to the enzyme via phosphate group. Since binding 
still occurred using oxidised nucleotide, the binding affinities of 
NADP
+
 and the equivalent NAD
+ 
were compared in both A. gambiae 
and human CPR to confirm the importance of the phosphate group. 
180 
A B 
Figure 4.2. ITC Isotherms of NADP
+
 binding to A. gambiae CPR and 
isolated FAD-binding domain. Samples and ligands were prepared in 100 
mM BES; pH 7.0. Experiments were run at 25 °C. A = NADP
+ 
binding to A. 
gambiae CPR. NADP
+
 was prepared to 100 µM and injected into 10 µM A. 
gambiae CPR. B = NADP
+ 
binding to A. gambiae FAD-binding domain. 
NADP
+ 
was prepared to 100 µM and injected into 10 µM A. gambiae FAD-
binding domain. 
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The Kd of A. gambiae CPR for NADP
+ 
was 363 nM whilst for human 
CPR the Kd was determined to be 69 nM. This is an approximate 5-fold 
stronger affinity for NADP
+ 
in human CPR than is determined for A. 
gambiae CPR. The binding affinity of the A. gambiae FAD-binding 
domain alone for NADP
+ 
was also investigated and in this case, the Kd 
was found to be 292 nM. This value for the isolated FAD-binding 
domain is similar to the observed binding affinity for the full length A. 
gambiae CPR (Figure 4.2) implying that the nucleotide-binding site is 
fully localised within the FAD-binding domain. 
In considering the binding affinity of NAD
+ 
to all three enzymes, an 
exact Kd value couldn‟t be calculated under the chosen experimental 
conditions. This was due to the extremely weak affinities for NAD
+
. 
Although an exact value could not be established, the estimate is that 
the binding is at least an order of magnitude weaker than those 
observed for NADP
+
. The sheer deficiency in binding of NAD
+
 can be 
easily observed when the binding curves for NADP
+
 and NAD
+
 are 
overlaid (Figure 4.3). This confirms an absolute necessity for the 
presence of a phosphate group on the ribose ring for efficient binding 
of NADPH nucleotides to CPR. 
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A B 
Figure 4.3. ITC Isotherms of NADP
+
 binding to human CPR and A. 
gambiae CPR overlaid with NAD
+
 binding to the same samples. Samples 
and ligands were prepared in 100 mM BES; pH 7.0. Experiments were run at 
25 °C. In each case, blue isotherm = NADP
+
, red isotherm = NAD
+
 A = 
NADP
+ 
binding to human CPR overlaid with NAD
+
 binding to human CPR. 
NADP
+ 
and NAD
+
 were prepared to 100 µM and injected into 10 µM A. 
gambiae CPR.  B = NADP
+ 
binding to A. gambiae CPR overlaid with NAD
+
 
binding to A. gambiae CPR. NADP
+ 
and NAD
+
 were prepared to 100 µM 
and injected into 10 µM A. gambiae FAD-binding domain. 
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4.2.2 2‟phosphate binding affinities 
Initial recognition of NADPH by CPR is at the 2‟-phosphate moiety 
and this binding was assessed in both A. gambiae and human CPR‟s. 
The importance of the 2‟-phosphate group in nucleotide binding was 
highlighted by comparison of 2‟-AMP and 3‟-AMP nucleotides whilst 
the synergistic interaction involving a second 5‟-phosphate was shown 
by comparison between 2‟-AMP and 2‟,5‟-ADP binding. 
2‟,5‟-ADP is the phosphate derived nucleotide analogue most 
representative of the NADPH molecule since it contains both 
phosphate groups attached in the appropriate positions. It is also the 
base molecule for the resin used in the purification of CPR‟s. As 
mentioned earlier, previous studies suggested a large disparity in the 
respective 2‟, 5‟-ADP binding affinities for A. gambiae and human 
CPR. ITC data was generated for this interaction to corroborate this 
previous observation. The calculated Kd for the interaction between 2‟, 
5‟-ADP and A. gambiae CPR was 410 nM. The binding affinity for 2‟, 
5‟-ADP with human CPR was much stronger at 38 nM; this is an 
approximately 10-fold stronger affinity than what was observed with 
A. gambiae CPR. The binding affinity of the isolated A. gambiae FAD-
binding domain for 2‟, 5‟-ADP was also investigated and the Kd for 
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C 
Figure 4.4. ITC Isotherms of 2’, 5’-ADP binding to A. gambiae CPR, human CPR 
and isolated A. gambiae FAD-binding domain. Samples and ligands were prepared in 
100 mM BES; pH 7.0. Experiments were run at 25 °C. A = 2‟, 5‟-ADP binding to A. 
gambiae CPR. 2‟, 5‟-ADP was prepared to 200 µM and injected into 10 µM A. gambiae 
CPR. B = 2‟, 5‟-ADP binding to human CPR. 2‟, 5‟-ADP was prepared to 50 µM and 
injected into 10 µM human CPR. C = 2‟, 5‟-ADP binding to A. gambiae isolated FAD-
binding domain. 2‟, 5‟-ADP was prepared to 100 µM and injected into 10 µM A. gambiae 
isolated FAD-binding domain. 
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this interaction was calculated at 322 nM. This was very similar to 
what was observed for the full length A. gambiae CPR which is 
expected if the binding site is fully localised within the FAD-binding 
domain (Figure 4.4). These data do indeed corroborate what was 
suggested using inhibition experiments and provide a reasonable 
explanation for the inability to purify A. gambiae CPR using 2‟,5‟-
ADP sepharose resin. 
When 2‟-AMP was bound to A. gambiae, the generated curve showed 
clear binding of nucleotide to protein. From the binding isotherm, the 
calculated Kd for this interaction was 4 µM. Binding of 2‟-AMP to 
human CPR was also assessed using ITC. The binding isotherm looked 
a lot better than the A. gambiae CPR curve with a larger number of 
points located at the lower end of the sigmoid and the Kd was 
calculated to be 1.6 µM; this is approximately 3-fold stronger affinity 
than the affinity for seen in A. gambiae CPR (Figure 4.5). These values 
are in the µM range whilst the Kd values for 2‟,5‟-ADP binding are in 
the nM range showing that the inclusion of the 5‟-phosphate to the 
nucleotide definitively increases affinity by stabilising the interaction. 
3‟-AMP binding was analysed to confirm the importance of the 2‟-
phosphate to nucleotide interaction with CPR. Under the experimental 
conditions, no reliable Kd could be obtained showing that the binding 
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A B 
Figure 4.5. ITC Isotherms of 2’-AMP binding to A. gambiae CPR and 
human CPR. Samples and ligands were prepared in 100 mM BES; pH 7.0. 
Experiments were run at 25 °C. A = 2‟-AMP binding to human CPR. 2‟-AMP 
was prepared to 500 µM and injected into 10 µM human CPR. B = 2‟-AMP 
binding to A. gambiae CPR. 2‟-AMP was prepared to 500 µM and injected into 
10 µM A. gambiae CPR. 
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to 3‟-AMP was too weak to be determined by ITC. This is the case for 
both human and A. gambiae CPR. 
In contrast, human CPR has stronger binding affinity than A. gambiae 
CPR for both 2‟-AMP and 2‟, 5‟-ADP. Even though a figure could not 
be placed on 3‟-AMP binding affinity, what becomes clear is that 
replacing the 2‟-phosphate leads to a dramatic decrease in binding 
affinity. This illustrates the specificity of recognition of the 2‟-
phosphate moiety in NADPH binding. A clear indication of the 
weakness of 3‟-AMP binding is shown when the binding curve is 
overlaid with the 2‟, 5‟-ADP binding curves for both A. gambiae and 
human CPR (Figure 4.6). 
The Kd values observed for NADP
+ 
or 2‟, 5‟-ADP were, respectively, 
363 nM and 410 nM respectively for A. gambiae, CPR, and 69 nM and 
38 nM for human CPR. For the A. gambiae FAD-binding domain these 
values were, respectively for NADP
+
 and 2‟, 5‟-ADP, 292 nM and 322 
nM. The results emphasise the fact that NADP
+ 
does not fully interact 
with CPR and that the binding affinity is, in the most part, almost 
entirely down to 2‟-phosphate and 5‟-phosphate recognition rather than 
nicotinamide binding. 
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Figure 4.6. ITC Isotherms of 2’, 5’-ADP binding to human CPR and A. 
gambiae CPR overlaid with 3’-AMP binding to the same samples. 
Samples and ligands were prepared in 100 mM BES; pH 7.0. Experiments 
were run at 25 °C. A = 2‟, 5‟-ADP binding to A. gambiae CPR overlaid with 
3‟-AMP binding to A. gambiae CPR. 2‟,5‟-ADP was prepared to 200 µM 
and 3‟-AMP was prepared to 2 mM and injected into 10 µM A. gambiae 
CPR Blue isotherm = 2‟,5‟-ADP, black isotherm = 3‟-AMP. B = 2‟, 5‟-ADP 
binding to human CPR overlaid with 3‟-AMP binding to human CPR. 2‟,5‟-
ADP was prepared to 50 µM
 and 3‟-AMP was prepared to 1 mM and 
injected into 10 µM human CPR. Red isotherm = 2‟, 5‟-ADP, black isotherm 
= 3‟-AMP. 
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4.2.3 Analysis of thermodynamic data 
Analysis of the binding affinity alone is not enough to fully ascertain 
the characteristics of nucleotide interaction. Thermodynamic properties 
give an idea of the likelihood of binding events and assess their 
energetic favourability. Enthalpy change (ΔH) is a measure of the 
change in heat energy during the progression of a reaction. In an 
endothermic reaction, the amount of heat energy at the end of a 
reaction is higher than at the beginning; hence heat is absorbed leading 
to a positive ΔH. Conversely, in an exothermic reaction, the amount of 
heat energy at the end of a reaction is lower than the beginning. Heat is 
therefore lost during the reaction leading to a negative ΔH.  
Entropy change (ΔS) is another measurement taken into account during 
thermodynamic characterisation. The entropy of a reaction is loosely 
defined as the tendency of a reaction to become more disordered and 
can be a measure of the spontaneity of a reaction to take place. In 
general, a positive entropy, i.e. tending towards disorder, makes a 
reaction spontaneous whereas a negative entropy, i.e. tending towards 
order, require more energy input and hence is less spontaneous. 
However, in a closed system, certain spontaneous reactions can have 
negative ΔS as it is a measure of the energy gained and lost by both the 
system and its surroundings. The system can have negative entropy 
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however, when the energy lost to the surroundings is considered, the 
total entropy is positive which signifies a spontaneous process. 
 In closed thermodynamic systems which operate at constant 
temperature and pressure, an easier and more effective measure of the 
spontaneity of a reaction to take place is to consider the Gibbs free 
energy change (ΔG) of a reaction. ΔG is calculated by considering ΔH 
and ΔS as well as the temperature in the following equation: ΔG = ΔH 
– TΔS. A positive ΔG means a reaction will not take place at all, whilst 
a negative ΔG means a reaction will take place spontaneously. A 
reaction with a negative ΔG may be spontaneous but immeasurably 
slow, meaning the reaction effectively does not take place. Such 
reactions, however, may be made more likely by use of a catalyst to 
lower the activation energy barrier. ΔG is, therefore, purely a 
thermodynamic measure of feasibility and can be applied to suggest 
the likelihood of a reaction occurring. 
The thermodynamic data discussed in this section is summarised in 
Tables 4.1, 4.2 and 4.3. The measured ΔH for human CPR binding to 
2‟, 5‟-ADP was -20.36 kcal mol-1 which is quite a large exothermic 
reaction. This is much larger than what was observed for A. gambiae 
CPR binding to 2‟, 5‟-ADP where the measured ΔH was -13.13 kcal 
mol
-1
. The much larger negative ΔH observed in human CPR suggests 
more highly favourable binding than when A. gambiae CPR is bound 
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to this ligand. Although 2‟-AMP has a much lower binding affinity 
than 2‟, 5‟-ADP in both human and A. gambiae CPR, the same 
observation can be seen with respect to ΔH. The ΔH was a lot less 
negative when 2‟-AMP is the ligand in both enzymes suggesting less 
favourable binding characteristics. When NADP
+ 
was the ligand, the 
same pattern is observed when comparing human and A. gambiae 
CPR‟s. The ΔH for NADP+ binding to human CPR was -19.46 kcal 
mol
-1 
whilst in binding to A. gambiae CPR the ΔH was less negative at 
-11.97 kcal mol
-1
. The fact that in both human and A. gambiae CPRs 
the ΔH for NADP+ and 2‟, 5‟-ADP binding were very similar further 
implies that most of the energy in NADPH is drawn from the 2‟-
phosphate interaction with very little being drawn from nicotinamide 
interaction. 
The ΔG is a measure of the likelihood of the reaction to take place. 
When analysing the ΔG of each interaction, it becomes clear that there 
are differences in binding of NADPH nucleotides to human and A. 
gambiae CPR‟s. The ΔG for 2‟, 5‟-ADP binding to human CPR was 
measured at -10.39 kcal mol
-1 
whereas the same ligand binding to A. 
gambiae CPR was -8.40 kcal mol
-1. This difference, allied to the ΔH 
and Kd strongly suggest a stronger and much more favourable 
interaction between 2‟, 5‟-ADP and human CPR than with A. gambiae 
CPR. These observations were very similar when NADP
+ 
was the 
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ligand.used. The ΔG for NADP+ binding to human CPR was -10.55 
kcal mol
-1 and the ΔG for binding to A. gambiae was lower at -8.73 
kcal mol
-1
. Since most of the binding energy in NADPH binding is 
derived from 2‟-phosphate interaction, these observations in 2‟, 5‟-
ADP and NADP
+ 
binding can be transferred to what may be observed 
when native NADPH binds to CPR. 
When comparing the isolated A. gambiae FAD-binding domain to the 
full length enzyme, some interesting points can be drawn. The ΔG 
values for the isolated FAD-binding domain are -8.48 kcal mol
-1 
and -
9.07 kcal mol
-1 2‟, 5‟-ADP and NADP+ respectively. These are very 
similar to what was observed in the full length A. gambiae CPR. The 
biggest difference however was seen in the TΔS values. The entropy 
changes were much more favourable for both 2‟,5‟-ADP and NADP+ 
in the full length A. gambiae CPR than the isolated A. gambiae FAD-
binding domain; -4.73 kcal mol
-1
 and -3.24 kcal mol
-1 for 2‟,5‟-ADP 
and NADP
+
 respectively with A. gambiae CPR and -5.30 kcal mol
-1
 
and -6.54 kcal mol
-1
 for 2‟,5‟-ADP and NADP  respectively with 
isolated A. gambiae FAD-binding domain. In the three-dimensional 
structure of the rat CPR, following NADPH binding, the FMN-binding 
domain is aligned in such as way that the FMN cofactor is in fact 
spatially close to the FAD and NADPH binding sites (Wang et al., 
1997) and these data suggest that the very presence of the FMN-
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binding domain in the full length protein potentially affects the 
entropic favourability and NADPH binding. 
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Ligand n Kobs (x 10
5
 M
-1
) Kd (nM) ΔH (kcal mol
-1
) TΔS (kcal mol-1) ΔG (kcal mol-1) 
NADP
+
 1.00 ± 0.04 27.5 ± 1.29 363 ± 17 -11.97 ± 0.64 -3.24 -8.73 
2’,5’-ADP 1.01 ± 0.03 24.4 ± 1.07 410 ± 18 -13.13 ±0.35 -4.73 -8.40 
2’-AMP 1.01 ± 0.22 2.51 ± 0.11 4000 ± 175 -7.66 ± 1.98 -2.19 -5.47 
3’-AMP results not recorded 
NAD
+
 results not recorded 
Table 4.1. Measured thermodynamic parameters for A. gambiae CPR interaction with a selection of nucleotide 
ligands. Experiments were performed at 25 °C in 100 mM BES; pH 7.0. The quoted errors are standard errors derived from 
duplicate experiments. n = binding stoichiometry, Kd = 1/Kobs.  
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Ligand n Kobs (x 10
5
 M
-1
) Kd (nM) ΔH (kcal mol
-1
) TΔS (kcal mol-1) ΔG (kcal mol-1) 
NADP
+
 1.01 ± 0.12 145 ± 24.5 69 ± 12 -19.46 ± 2.92 -8.91 -10.55 
2’,5’-ADP 1.00 ± 0.02 263 ± 26.3 38 ± 3.8 -20.36 ±0.53 -9.97 -10.39 
2’-AMP 1.02 ± 0.06 6.15 ± 1.69 1600 ± 440 -11.07 ± 0.88 -3.21 -7.86 
3’-AMP results not recorded 
NAD
+
 results not recorded 
Table 4.2. Measured thermodynamic parameters for human CPR interaction with a selection of nucleotide ligands. 
Experiments were performed at 25 °C in 100 mM BES; pH 7.0. The quoted errors are standard errors derived from duplicate 
experiments.  n = binding stoichiometry, Kd = 1/Kobs.  
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Ligand n Kobs (x 10
5
 M
-1
) Kd (nM) ΔH (kcal mol
-1
) TΔS (kcal mol-1) ΔG (kcal mol-1) 
NADP
+
 0.99 ± 0.03 37.7 ± 1.49 265 ± 10 -15.61± 0.49 -6.54 -9.07 
2’,5’-ADP 0.99 ± 0.05 31.1 ± 1.80 322 ± 19 -13.78 ±0.75 -5.30 -8.48 
2’-AMP results not recorded 
3’-AMP results not recorded 
NAD
+
 results not recorded 
Table 4.3. Measured thermodynamic parameters for A. gambiae isolated FAD-binding domain interaction with a 
selection of nucleotide ligands. Experiments were performed at 25 °C in 100 mM BES; pH 7.0. The quoted errors are 
standard errors derived from duplicate experiments.. n = binding stoichiometry, Kd = 1/Kobs.  
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4.2.4 FMN binding analysis 
ITC was also utilised to assess the binding respective binding affinity 
of FMN to the isolated FMN-binding domain of both A. gambiae and 
human CPR. It was shown previously that fully purified A. gambiae 
CPR has a deficiency in FMN when compared to the human enzyme 
and the possibility that this was down to a lower flavin cofactor affinity 
in the Anopheline enzyme was investigated. The apo-FMN binding 
domain was created in each case by the removal of FMN cofactor from 
purified domain. 
Flavins were removed to generate apo-protein by modification of the 
method of Edmondson and Tollin, 1971 (Barsukov et al., 1997). For 
precipitation, protein samples were prepared to a concentration of 0.5 
mg/mL in 40 mM phosphate, 0.2 mM DTT, 0.02 mM EDTA, 20 % 
glycerol; pH 6.8. A 30 % (w/v) solution of trichloroacetic acid was 
added, in the dark at 4 °C, to the protein samples. to a final 
concentration of 3 %. The samples were centrifuged at 20, 000 x g for 
5 min at 4 °C and the pellet washed with ice-cold 3 % trichloroacetic 
acid, 1.3 mM DTT in distilled H2O. The sample was centrifuged for a 
further 5 min at 20, 000 x g at 4 °C and the pellets re-suspended in 100 
mM BES; pH 7.0 for ITC experimentation.  
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The apo-FMN-binding domains from both the human and A. gambiae 
CPR were stable at high concentrations. The binding isotherms for 
both the apo-human and apo-A. gambiae FMN-binding domains are 
shown (Figure 4.7). Both isotherms show reasonable binding and 
saturation of the apo-proteins is achieved with excess flavin. The Kd for 
FMN binding to the isolated apo-human FMN-binding domain was 
calculated to be 23 nM which is almost 4-fold stronger than for the 
isolated apo-A. gambiae FMN-binding domain which was calculated to 
be 83 nM.  
The thermodynamic characteristics also heavily favoured FMN 
binding to the human FMN-binding domain over the A. gambiae 
FMN-binding domain. The ΔH for FMN binding to the human FMN-
binding domain was -19.46 kcal mol
-1 
which is seemingly more 
favourable that the -13.18 kcal mol
-1 
which was measured for FMN 
binding to the A. gambiae FMN-binding domain. The ΔG for FMN 
binding to the human FMN-binding domain was -10.28 kcal mol
-1 
suggesting the binding of FMN flavin to human FMN-binding domain 
is more favourable than to A. gambiae FMN-binding domain which 
had a calculated ΔG of -9.60 kcal mol-1. The thermodynamic 
parameters for FMN binding is summarised in Table 4.4.
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Figure 4.7. ITC Isotherms of FMN binding to A. gambiae and human 
isolated apo-FMN-binding domains. Samples and ligands were prepared in 
100 mM BES; pH 7.0. Experiments were performed at 25 °C. A = FMN 
binding to A. gambiae apo-FMN binding domain. FMN was prepared to 300 
µM and injected into 30 µM A. gambiae apo-FMN binding domain B = FMN 
binding to human apo-FMN binding domain. FMN was prepared to 200 µM 
and injected into 30 µM human apo-FMN binding domain. 
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To fully assess how these data were represented in the full length 
enzyme, generation of the apo-full length enzyme would be ideal. This, 
however, proved fairly difficult as once flavins were stripped off, the 
apo-CPRs were unstable and prone to precipitation. This is possibly 
due to the influence of the FAD-binding domain. The apo-FAD-
binding domain from A. gambiae CPR, when expressed and purified 
separately, was very unstable, with high levels of precipitation. It is 
possible that this highly unstable apo-form may have a significant 
contribution to the instability of the full length apo-CPR. 
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apo-FMN 
domain 
n Kobs (x 10
5
 M
-1
) Kd (nM) ΔH (kcal mol
-1
) TΔS (kcal mol-1) ΔG (kcal mol-1) 
Human 1.00 ± 0.01 438 ±17.5 23 ± 0.9 -19.46 ± 0.35 -9.18 -10.28 
A. gambiae 0.98 ± 0.01 120 ± 3.19 83 ± 2.0 -13.18 ± 0.19 -3.58 -9.60 
Table 4.4. Measured thermodynamic parameters for A. gambiae and human CPR interaction with FMN. Experiments were 
performed at 25 °C in 100 mM BES; pH 7.0. n = binding stoichiometry, Kd = 1/Kobs.  
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4.3 Discussion 
ITC was used to probe the NADPH-binding site of A. gambiae CPR. A 
similar investigation has previously been performed on human CPR 
(Grunau et al., 2006). In the Grunau et al. study, a VP-ITC (MicroCal) 
calorimeter was used. In the current studies, a more recent model of the 
ITC equipment, an ITC200 (MicroCal) calorimeter was used. , In both 
these studies, the results for human CPR are comparable. The binding 
of FMN to the apo-isolated FMN binding domain of both human and 
A. gambiae CPR was also investigated and showed a marked 
difference in FMN binding affinity for both enzymes. 
The FMN-binding affinity of the apo-human FMN-binding domain 
was much stronger than was observed for the apo-A. gambiae FMN-
binding domain (Table 4.4). A. gambiae CPR shows a distinct 
deficiency of FMN in the purified enzyme, even when supposedly 
fully saturated with flavin. This lack of fully incorporated flavin is not 
common to A. gambiae as A. minimus has recently been shown to also 
be flavin deficient when compared to mammalian CPRs (Sarapusit et 
al., 2008). The observation that FMN has lower binding affinity, and 
less thermodynamically favourable binding parameters, to A. gambiae 
CPR than the human equivalent provides a strong evidence to 
corroborate this finding. 
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The three-dimensional structures of the rat (Wang et al., 1997) and 
yeast (Lamb et al., 2006) CPR and the rat nNOS FAD domain (Zhang 
et al., 2001) have collectively provided details of the cofactor binding 
sites for the oxidoreductases. FMN binds in the region 
139
TYGEGPD 
and 
175
NKTYEHFN (rat CPR numbering), with Y140 and Y178 
sandwiching the FMN isoalloxazine ring, and F181 stabilising the 
cofactor binding (Paine et al., 2001). Figure 4.8 shows a multiple 
sequence alignment of A. gambiae CPR with A. minimus CPR, rat 
CPR, S. cerevisiae CPR and rat nNOS reductase domain. As far as A. 
gambiae CPR is concerned, the residues mentioned above are all 
conserved with the exception of F181 (in rat CPR) replaced by Y184 
(in A. gambiae CPR). However, it has previously been reported that 
mutation of F181 to Y181 in human CPR had minimal effects on FMN 
binding and enzymatic activity (Paine et al., 2001); hence, replacing 
the tyrosine residue in A. gambiae CPR protein is of little consequence 
for FMN affinity. Therefore, despite the availability of good structures 
of homologous proteins, these have so far proved inadequate for 
understanding the cofactor binding characteristics of the A. gambiae 
CPR.  
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Figure 4.8. Multiple sequence alignments of the FMN binding region of A. 
gambiae CPR, A. minimus CPR, rat CPR (rCPR), S. cerevisiae CPR (yCPR) and 
the reductase domain of rat nNOS (nNOS). Residues involved in FMN binding 
(grey) and stabilisation (red) are highlighted. Sequences were aligned using 
ClustalW. 
205 
A clear and obvious difference between the human and A. gambiae 
CPR‟s is in the binding affinities of NADPH nucleotide analogues; 2‟, 
5‟-ADP, 2‟-AMP and NADP+. These corroborate previous inhibition 
studies performed on these enzymes which suggested an approximate 
10-fold decreased affinity for 2‟, 5‟-ADP in A. gambiae CPR when 
compared to human CPR. ITC data suggested this to be the case and 
the relative weak affinity to NADPH analogues extended to 2‟-AMP 
and NADP
+ 
(Tables 4.1 and 4.2).  
When the rat CPR crystal structure is compared the modelled A. 
gambiae CPR (provided by Dr. Dan Rigden, School of Biological 
Sciences, University of Liverpool) there is an apparent difference in 
the residues interacting with the 2‟,5‟-ADP group. In rat and human 
CPR, residue 606 is a glutamine whilst the corresponding residue 607 
in A. gambiae is a threonine. On further inspection, this provides a 
clear structural difference in this region. In rat CPR, the side chain of 
Q606 forms the face of a cavity and is approximately 3 Å away from 
the adenine ring of NADPH, close enough to form a hydrogen bond. In 
contrast the distance between the adenine ring and the T607 side chain 
in A. gambiae CPR is almost 6 Å; too far to form a hydrogen bond 
(Figure 4.9).  
This lack of additional stabilisation in A. gambiae CPR could possibly 
be a cause for low 2‟, 5‟-ADP binding affinity in this enzyme. The A. 
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gambiae T607Q mutant (Dr. Mark Paine, Liverpool School of Tropical 
Medicine) was generated in an attempt to alter the stabilisation of 
2‟,5‟-ADP binding in A. gambiae CPR towards that of the rat enzyme. 
This binding was analysed by ITC (Figure 4.10); however, the Kd of 
the mutant for 2‟, 5‟-ADP was near identical to that of the wild-type A. 
gambiae CPR. 
Thermodynamic parameters were also measured and difference in ΔH 
and ΔG values further point towards a potential difference in 
nucleotide binding energetics as well as affinities. In human CPR-
nucleotide binding events, a more negative ΔG combined with a more 
negative ΔH indicate these interactions occur more readily and are 
thermodynamically more favourable than A. gambiae CPR-nucleotide 
interactions. An interesting observation involves the differences in TΔS 
values of human and A. gambiae CPR. The entropies of human CPR 
binding events appear less favourable, i.e. more negative and hence 
tending more towards order, than the A. gambiae reactions. This 
apparent unfavourability however is counter balanced by much more 
favourable ΔH values making the overall energy value, ΔG, more 
favourable (Tables 4.1 and 4.2).  
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Figure 4.9. Comparison of NADPH interaction with side chains of 
Q606 in rat and T607 in A. gambiae CPR. A = Interaction of NADPH 
(red) with the Q606 side chain (blue) in rat CPR (PDB – 1AMO). B = 
Interaction of NADPH (red) with the T607 side chain (blue) in A. gambiae 
CPR model (Dr. Dan Rigden). In each case, the figures were generated 
using PyMol and the distances are shown in Å. 
A 
B 
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Figure 4.10. ITC Isotherms of 2’, 5’-ADP binding to A. gambiae CPR 
T607Q mutant. Sample and ligand were prepared in 100 mM BES; pH 7.0. 
Experiments were run at 25 °C. 2‟, 5‟-ADP was prepared to 200 µM and 
injected into 10 µM A. gambiae CPR. 
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The binding of the isolated A. gambiae FAD-binding domain was 
assessed using certain ligands. It was obvious that although the binding 
affinities and overall free energies were essentially similar to the full 
length A. gambiae CPR, the specific energetics of binding were a little 
different. The entropy changes, TΔS, were more favourable in the full 
length CPR than the FAD-binding domain (Tables 4.1 and 4.3). This 
suggests the presence of the FMN-binding domain can influence 
NADPH binding.  
In the three-dimensional structure of the rat CPR, following NADPH 
binding, the FMN domain is aligned in such as way that the FMN 
cofactor is in fact spatially close to the FAD and NADPH binding sites 
This observation concurs with all the known structures of CPRs whose 
„bowl‟ shapes bring the FMN and FAD domain in close proximity 
(Figure 1.10, section 1.6.6); in fact the FMN is 3.5Å from the FAD at 
the closest point (Wang et al., 1997). The model of the A. gambiae 
CPR and this structure demonstrates a similar trait with regards to 
FMN and FAD position within the NADPH-bound enzyme (Figure 
4.11). In this case, the FMN and FAD-cofactors were 3.8Å at the C8M 
atoms and 4.3Å at the C7M atoms of the respective xylene rings.  
Upon NADPH binding, the flexibility of CPR allows the FMN-domain 
to be brought closer to the FAD and NADPH binding sites. This 
210 
A 
B 
Figure 4.11. Proximity of FMN and FAD cofactors in NADPH-bound A. 
gambiae CPR modelled structure. A = The proximity of the C8M atoms on 
the xylene rings. B = The proximity of the C7M atoms on the xylene rings. 
Green = FMN; Red = FAD; Blue = NADPH. Distances are expressed in 
angstroms. The model was built by Dr. Dan Rigden (University of Liverpool, 
School of Biological Sciences) and the figure generated using PyMol.  
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conformational shift could account for the thermodynamic differences 
observed between the full length CPR and the isolated FAD-binding 
domain. In addition to the full length CPR, the binding of both 2‟, 5‟-
ADP and NADP
+
 to the FAD-binding domain was investigated. For 
both the CPR and the FAD-binding domain, the ΔG value for each 
ligand was quite similar (Tables 4.1 and 4.3). Despite this near 
identical overall energy, there are more clear discrepancies in the ΔH 
and TΔS values in each case. There is consistently a more favourable 
ΔH value observed in ligand binding to the FAD-binding domain, 
however, this is counteracted by a much more favourable TΔS value in 
binding to CPR.  
In exothermic reactions, the ΔH is a measurement of the energy 
released to the surroundings, thus in binding to the FAD-binding 
domain, more energy is released. This is potentially due to the fact that 
in the full length CPR, which includes the FMN binding domain, the 
act of nucleotide binding necessitates a conformational change to bring 
the FMN cofactor in close proximity to the FAD and NADPH. It is 
possible; therefore, that some of the binding energy is expended in 
shifting the FMN-binding domain in full length CPR. This is not an 
issue in the case of the isolated-binding domain and could explain the 
more favourable ΔH values observed in this case. In the FAD-binding 
domain, this increased favourability with respect to ΔH is counter-
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balanced by a less favourable entropic measurement. The increased 
number of potential conformational substates in the full length CPR, 
because of the presence of the FMN-binding domain, means that a 
more favourable entropic value is not entirely surprising. Upon 
nucleotide binding, the presence of the FMN-binding domain has a 
dual effect; to decrease the ΔH favourability whilst increasing the TΔS 
favourability. These opposite and almost equal effects are responsible 
for the similarities in ΔG. The results here appear to corroborate the 
suggestion that the N-terminal FMN-binding domain affects global 
energetic properties in full length CPR (Grunau et al., 2006). 
These findings strongly suggest that there are differences in the 
binding strength and energetics of both nucleotide analogues and FMN 
cofactor between A. gambiae and human CPRs. Possible structural 
differences in and around the NADPH binding site may be the cause 
although as previously mentioned, the events within the FMN-binding 
domain could also potentially impart an effect. Such differences in the 
NADPH binding site are an encouraging find when the goal of novel 
insecticide synthesis in taken into consideration. In order however, to 
fully expose and utilise such findings may require more comprehensive 
structural determination. 
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Chapter 5 
 
 
5. CATALYTIC AND KINETIC ANALYSIS OF 
CYTOCHROME P450 REDUCTASE 
 
5.1 Introduction 
Elucidation of enzymic activity is a critical aspect in the 
characterisation of CPR. Since the reductases, expressed without the 
membrane anchor are unable to interact with a P450, it is not possible 
to investigate the enzymatic activity of the reductase in the presence of 
the P450. Instead, the CPR enzymatic activity is studied using non-
physiological electron acceptors such as cytochrome c and potassium 
ferricyanide with the use of these molecules now being a routine and 
accepted approach. These molecules have proved themselves to be 
useful diagnostic tools in determining activity and kinetics in these 
enzymes. 
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The specific activity of an enzyme is measured by the amount of 
product formation per milligram of enzyme over a given period of 
time. It is the measure of the activity of a protein at a specific substrate 
concentration under a defined set of conditions and hence should be 
fairly constant for pure enzyme. Measurement of the specific activity 
can sometimes be useful in determining the purity of a protein sample 
during the purification process. Cytochrome c binds at the FMN-
binding domain and is a measure of the diflavin reductase activity of 
CPR. Potassium ferricyanide however, binds at FAD-binding domain 
and is a measure of the C-terminal domain activity, accepting electrons 
directly from the FAD flavin. 
Using the cytochrome c reduction assay, steady state-kinetics can be 
measured to determine the kinetic parameters Km and Vmax. V is a 
measure of the number of reaction catalysed per second per mol of 
enzyme. The rate of a reaction increases asymptotically with increasing 
substrate concentration towards the maximal rate, Vmax. With this in 
mind, it is difficult to define an actual substrate concentration at which 
the enzyme is fully saturated. Therefore the value of Km is readily used 
as an appropriate characterisation of the enzyme as this is the substrate 
concentration at half the maximal rate; Vmax/2, and is more easily 
defined. 
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The specific activity of A. gambiae CPR for cytochrome c and 
potassium ferricyanide has been determined. Steady-state kinetics with 
respect to cytochrome c and NADPH were also determined for A. 
gambiae CPR. Human CPR was used throughout as a comparative aid 
in an attempt to highlight any possible differences in activity and 
kinetic properties between these two enzymes. 
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5.2 Methodologies and results 
To measure enzyme activity, the rate of change of absorbance of horse 
heart cytochrome c (Sigma) at 550 nm was measured at 22 °C using a 
Cary 300 Bio U.V visible spectrophotometer. 1 mL 50 µM cytochrome 
c (dissolved in either 300 mM potassium phosphate; pH 7.7 or 100 
mM Tris-HCl; pH 7.7 containing 1M KCl) was incubated with 14.3 
pmol purified CPR. To initiate the reaction, NADPH was added to a 
final concentration of 50 µM and the change in absorbance measured 
over a 2 min period. For activity measurements, the extinction 
coefficient of cytochrome c, 21.41 mM cm
-1
 was used and each rate 
measured in triplicate. 
CPR is involved in a multi substrate enzyme reaction, with the two 
substrates being cytochrome c and NADPH. However by keeping one 
substrate at a constant concentration, the kinetic parameters of the 
other can be ascertained by experimenting over a large range of 
concentrations. With this in mind, the kinetic parameters Km and Vmax 
were calculated for A. gambiae and human CPRs with respect to both 
cytochrome c and NADPH. Once again, buffer influence, in particular 
that of phosphate, was investigated by performing steady-state kinetics 
in both phosphate and Tris-HCl based buffers. 
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To measure ferricyanide reduction, the change in absorbance at 420 
nm was measured at 22 °C using a Cary 300 Bio U.V visible 
spectrophotometer. 1 mL of 1 mM potassium ferricyanide (Sigma) in 
50 mM potassium phosphate, pH 7.7 was incubated with purified 
enzyme (14.3 pmol CPR or 20 pmol AgFAD). The reaction was 
initiated with NADPH at a final concentration of 50 µM. The change 
in absorbance was measured over a period of 2 min and the activity 
measured as µmol ferricyanide reduced per minute per mg enzyme 
(µmol/min/mg) using the extinction coefficient of reduced potassium 
ferricyanide of 1.02 mM
-1
cm
-1
.
  
An attempt was made to reconstitute a functional enzyme using the 
isolated FMN and FAD-binding domains. 1 mg/mL A. gambiae FMN-
binding domain and 2.5 mg/mL A. gambiae FAD-binding domain were 
mixed together in a total volume of 3 mL and left at room temperature 
with gentle shaking overnight. Samples of the mixture were taken, 
diluted to 1 mg/mL and used in cytochrome c reduction assays in order 
to assess activity. A positive result would confirm that the isolated 
domains could indeed be combined to form a functioning reconstituted 
enzyme, hence, corroborating the idea that CPR came to be by a 
genetic fusion event of two separate enzymes, each capable of folding 
independently (Porter and Kasper, 1986). 
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5.2.1 Specific activities of cytochrome c and potassium ferricyanide 
reduction 
The specific activities of A. gambiae and human CPR‟s were measured 
with respect to cytochrome c reduction. Specific activity was 
calculated using the measured slope of absorbance change at 550 nm 
and the extinction coefficient for reduced cytochrome c of 21.41 mM
-1 
cm
-1
. For measurement of the specific activity of potassium 
ferricyanide reduction, the negative change in absorbance at 420 nm 
was measured and the extinction coefficient of reduced potassium 
ferricyanide; 1.02 mM
-1 
cm
-1
. An example of a typical slope of a 
potassium ferricyanide reduction is shown (Figure 5.2). 
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Figure 5.1. A typical cytochrome c reduction curve. The change in 
absorbance at 550 nm is measured over a period of time, in this case 60 s. In 
this example, 50 µM cytochrome c was made up in 100 mM Tris-HCl, pH 7.7 
containing 100 mM KCl. 14.3 pmol human CPR was added and the reaction 
started by addition of NADPH to a final concentration of 50 µM. The 
absorbance was measured at 22 °C using a Cary 300 Bio U.V visible 
spectrophotometer. A control experiment which contained no enzyme was 
performed to confirm that there was no background absorbance change in 
enzyme deficient reactions. 
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Figure 5.2. A typical potassium ferricyanide reduction curve. The change 
in absorbance at 420 nm is measured over a period of time, in this case 120 s. 
In this example, 1 mM potassium ferricyanide was made up in 50 mM 
phosphate, pH 7.7. 20 pmol A. gambiae FAD-binding domain was added and 
the reaction started by addition of NADPH to a final concentration of 50 µM. 
The absorbance was measured at 22 °C using a Cary 300 Bio U.V visible 
spectrophotometer. A control experiment which contained no enzyme was 
performed to confirm that there was no background absorbance change in 
enzyme deficient reactions. 
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5.2.1.1 Cytochrome c reduction 
The specific activity, with respect to cytochrome c reduction, when 
measured in Tris-HCl based buffer was 14.08 µmol min
-1
mg
-1
 for A. 
gambiae CPR and 11.28 µmol min
-1
mg
-1
 for human CPR. These values 
are similar, with A. gambiae CPR appearing to have an ever so slightly 
higher activity for cytochrome c reduction.  
Traditionally, cytochrome c assays are performed in 300 mM 
phosphate buffer. However, the known inhibitory effect of free 
phosphate on NADPH binding could potentially diminish activity in 
this buffer. Phosphate has been shown to lower the binding affinity of 
nicotinamide nucleotides to CPR (Grunau et al., 2006). Tris-HCl 
buffer does not cause the problem of free phosphate affecting 
coenzyme binding, however, 100 mM Tris-HCl is not an ideal buffer 
from a physiological perspective. Phosphate is a much more favourable 
buffer base which highlights an interesting dilemma regarding the 
choice of buffer for specific activity measurement. To address this 
issue, the same assay was also performed in 300 mM phosphate buffer 
to determine the buffer best suited to cytochrome c reduction by CPR: 
the less physiologically relevant Tris-HCl or the more favourable, yet 
potentially prone to inhibitory effects, phosphate buffer. The specific 
activity of cytochrome c reduction in phosphate buffer by A. gambiae 
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CPR was calculated to be 23.85 µmol min
-1
mg
-1 
whilst the specific 
activity for human CPR was 18.27 µmol min
-1
mg
-1
.  
The observation is similar in phosphate buffer in that A. gambiae has 
slightly higher specific activity than human CPR. There is a difference 
however in specific activities in the two buffers. There is between a 1.5 
– 2 fold increase in activity in both A. gambiae and human CPR when 
the assay was performed in phosphate buffer. This shows that despite 
the potential inhibitory effects, phosphate is a much more favourable 
buffer for cytochrome c reduction. Despite some inhibitory effects of 
the phosphate buffer, its physiological relevance tends to make this a 
preferred buffer rather than the Tris-HCl buffer. 
It has been shown that A. gambiae CPR is FMN, and to a lesser extent 
FAD, deficient relative to the human enzyme. Work on A. minimus 
CPR, which is also binds both flavins weakly, concluded that the 
addition of exogenous FAD during cytochrome c and potassium 
ferricyanide reduction improved specific activity by up to 2-fold. To 
determine if this was the case in A .gambiae CPR, the specific activity 
of cytochrome c was measured following the addition of a 10-fold 
excess of FMN to the protein sample. The specific activity of A. 
gambiae CPR with exogenous FMN was almost identical to that which 
was calculated without additional flavin. The same was seen when 
exogenous FAD was added to the reaction suggesting that A. gambiae 
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CPR is fully saturated with flavin. By way of comparison, the specific 
activity of cytochrome c reduction by human CPR was also 
investigated following exogenous flavin addition. Again, as for the A. 
gambiae CPR, there was no improvement of the specific activity with a 
10-fold excess of FMN and FAD. 
The specific activities of measured CPRs have been shown to lie 
within the range of 30 -60 µmol min
-1 
mg
-1 
(Shen et al., 1989; 
Murataliev et al., 1999)
 
At specific activities of, respectively, 23.85 
and 18.27 µmol min
-1 
mg
-1
 in phosphate buffer for both A. gambiae 
and human CPR, these specific activities seemed a little low. One 
potential reason for this could be the temperature at which the 
reactions were performed. Cytochrome c reduction assays are 
traditionally performed between 25 and 30 °C, however, due to the 
lack of a thermostat on the spectrophotometer used; these data were 
collected at room temperature which was readily maintained at 22 °C. 
The lower temperature used for these assays could account for the low 
specific activities and in order to investigate this further, an alternative 
spectrophotometer; one with a functioning thermostat, was trialled. 
The same samples had their specific activities measured at 25 °C and 
the increased temperature had an effect on specific activity. There was 
an approximate 2-fold increase in specific activity when measured at 
25 °C; with 42.21 and 35.07 µmol min
-1 -
mg
1
 calculated for A. gambiae 
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and human CPR respectively For the human protein, this value agrees 
with published values (Smith et al., 1994). The specific activities of A. 
gambiae and human CPR‟s under all conditions are summarised in 
Table 5.1. 
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Specific activity (µmol/mg/min) 
 Tris Buffer Phosphate Buffer 
A. gambiae CPR 
22 °C 
25 °C 
14.08 ± 0.52 
- 
23.85 ± 1.10 
42.21 ± 3.96 
Human CPR 
22 °C 
25 °C 
11.28 ± 0.37 
- 
18.27 ± 0.96 
35.07 ± 1.42 
Regenerated  CPR - 0.78 ± 0.12 
Table 5.1. Cytochrome c reduction data of A. gambiae and human CPR 
under a variety of conditions. The buffers used were either 100 mM Tris-
HCl; pH 7.7 containing 100 mM KCl or 300 mM phosphate buffer; pH 7.7. 
In each case, 50 µM cytochrome c was reduced using 14.3 pmol CPR. The 
reactions were initiated by addition of NADPH to a final concentration of 
50 µM. The absorbance was measured at either 22 °C or 25 °C using a Cary 
300 Bio U.V visible spectrophotometer. Using the extinction coefficient of 
21.41 mM
-1 
cm
-1 
for reduced cytochrome c, the slope of change in 
absorbance was converted to specific activity. The quoted errors are 
standard errors derived from triplicate reactions. 
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5.2.1.2 Potassium ferricyanide reduction 
The specific activity for potassium ferricyanide reduction of A. 
gambiae CPR was 16.28 µmol min
-1 
mg
-1
whilst the specific activity of 
human CPR which was calculated to be 12.41 µmol min
-1 
mg
-1
. 
Although these values are similar, the specific activity of the A. 
gambiae CPR is slightly higher than that of the human CPR, indicating 
a more active FAD-binding domain in Anopheline CPR compared to 
the human equivalent. Once again; these measurements were taken at 
22 °C and it is possible that raising the temperature up to 25-30 °C 
could increase these specific activities further by maximising the 
reaction conditions.  
Potassium ferricyanide reduction is a measure of the activity of the 
FAD-binding domain as it accepts electrons directly from the FAD 
cofactor. Since the binding of the coenzyme, NADPH, and the 
substrate, potassium ferricyanide, are both contained within the single 
FAD-binding domain, the activity of the isolated FAD-binding domain 
can also be assessed using this assay. The specific activity of the 
isolated A. gambiae FAD-binding domain was 28.31 µmol min
-1 
mg
-1
; 
approximately 1.5 - 2-fold higher than the calculated specific activity 
of the full length A. gambiae CPR (Table 5.2). The increased activity 
of the isolated FAD-binding domain relative to the full length enzyme 
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could prove to be significant when considering the overall activity of 
A. gambiae CPR. 
 
5.2.1.3 Regeneration of CPR using the isolated flavin-binding domains 
The isolated FMN and FAD-binding domains are homologous to 
flavodoxin and FNR respectively and are thought to attribute their 
ancestry to these domains (Porter and Kasper, 1986). This is most 
likely the reason why the isolated binding domains are able to be 
expressed and fold independently of each other. It is therefore feasible 
that the FMN and FAD-binding domains can be combined to 
regenerate an active CPR enzyme. The specific activity for cytochrome 
c reduction of A. gambiae CPR was 23.85 µmol min
-1 
mg
-1
 in 
phosphate buffer however the specific activity of the regenerated 
enzyme dropped to 0.78 µmol min
-1 
mg
-1
: only 3.3 % of the activity of 
the full length enzyme (Table 5.3). The lack of activity of the 
reconstituted CPR is illustrated by comparing the observed slopes of 
this regenerated enzyme to the intact reductase (Figure 5.3) 
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Specific activity (µmol/mg/min) 
Human CPR 12.41 ± 0.71 
A. gambiae CPR 16.28 ± 1.36 
A. gambiae FAD-binding domain 28.31 ± 1.12 
Table 5.2. Potassium ferricyanide reduction of A. gambiae CPR, human 
CPR and A. gambiae isolated FAD-binding domain. The buffer used was 
50 mM phosphate buffer; pH 7.7. In each case, 1mM potassium ferricyanide 
was reduced using 14.3 pmol CPR or 20 pmol FAD binding domain. The 
reactions were initiated by addition of NADPH to a final concentration of 50 
µM. The absorbance was measured at either 22 °C using a Cary 300 Bio 
U.V visible spectrophotometer. Using the extinction coefficient of 1.02 mM
-
1 
cm
-1 
for reduced potassium ferricyanide, the slope of change in absorbance 
was converted to specific activity. The quoted errors are standard errors 
derived from triplicate reactions. 
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Figure 5.3. The relative cytochrome c reduction capabilities of A. 
gambiae CPR and the regenerated FAD/FMN-binding domain 
reductase. The reactions took place in 300 mM phosphate; pH 7.7 at 22 °C. 
In each case the reaction was initiated by addition of NADPH to a final 
concentration of 50 µM. A = 14.3 pmol A. gambiae CPR B = Equimolar 
concentrations of isolated FMN and FAD-binding domains to a final 
concentration of 1.43 µM. The absorbance was measured using a Cary 300 
Bio U.V visible spectrophotometer. 
A 
B 
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This confirms that although a functioning reductase can be regenerated 
from the two flavin binding domains, its activity is poor. This is due to 
the lack of the inter-domain linker region. This unstructured domain 
shows a high degree of flexibility and is responsible for bringing the 
FMN and FAD flavins in close proximity to each other, and for 
orientating the domains in order for efficient electron transfer to occur. 
In the regenerated enzyme, although both flavins are present, the lack 
of the linker regions makes inter-flavin electron transfer vastly more 
difficult, hence the poor specific activity relative to the fully intact 
enzyme. 
 
5.2.2 CPR steady-state kinetics 
Reduction by CPR involves interaction with two substrates; NADPH 
and the terminal acceptor. Multi-substrate enzyme reactions often 
follow complex rate equations to assess the binding of the various 
substrates making data analysis difficult. This can be simplified if the 
concentration of one substrate is kept constant whilst the other is 
varied over a wide range of concentrations. Under these conditions, the 
enzyme behaves like a single-substrate enzyme and if v vs [S] is 
plotted, the Km and Vmax of the varied substrate can be calculated. The 
cytochrome c reduction assay was used in order to ascertain kinetic 
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parameters Km and Vmax with respect to NADPH and cytochrome c 
itself. Due to the proposed random bi-bi kinetic mechanism observed 
in CPR, the use of the term Km is somewhat misleading. In this scheme 
the Km values for both NADPH and cytochrome c will likely be 
interchangeable and be altered as the concentration of each substrate 
changes. Since the Km values for each substrate were measured at a 
single fixed concentration of the other, all Km values reported are not 
true Km and should be taken to mean apparent Km.   
For determination of cytochrome c kinetics, a series of cytochrome c 
concentrations were made (0, 1, 2, 4, 5, 10, 15, 20, 25, 50, 75, 100 
µM). 10 µL 0.1 mg/mL purified enzyme was incubated with 1 mL of 
each cytochrome c concentration. Again, the reaction was initiated by 
addition of NADPH to a final concentration of 50 µM and the change 
in absorbance measured over 2 min. For kinetic analyses, each reaction 
was performed in duplicate. For determination of NADPH kinetics, 10 
µL 14.3 pmol purified enzyme was incubated with 1 mL 50 µM 
cytochrome c. The reactions were initiated by the addition range of 
NADPH concentrations (0, 1, 2, 4, 5, 10, 15, 20, 25, 50, 75, 100, 
150.µM final concentrations) and the change in absorbance measured 
over 2 min. Again, for NADPH kinetic analyses, the reactions were 
performed in duplicate  
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Having observed a difference in specific activity between Tris-HCl and 
phosphate buffers, kinetic parameters were determined for the 
reactions performed in both buffers to check that this difference 
transfers to kinetic parameters as well as specific activity. Reaction 
temperature has been shown to have an effect on specific activity 
however experiments performed at 22 °C still show a consistent 
reasonable rate of reaction. Because of this, all kinetic experiments 
were run at 22 °C. It was also shown that the addition of exogenous 
flavins prior to the reaction showed had little effect thus they were not 
added before the commencement of kinetic experiments. 
 
5.2.2.1 Phosphate buffer kinetics 
Following the series of experiments using a range of cytochrome c 
concentrations, the Km and Vmax values were calculated. In phosphate 
buffer, the buffer more suited to enzyme activity, the Km of A. gambiae 
CPR for cytochrome c was 24.21 µM. This value was similar, albeit 
slightly higher than the human CPR value which was 18.01 µM. There 
is a similar observation when the Km values for NADPH are 
considered. In A. gambiae CPR, the Km for NADPH was calculated to 
be 26.03 µM whilst in human CPR the Km dropped to 15.04 µM (Table 
5.3). Both A. gambiae and human CPR fit to the Michaelis-Menten  
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A 
B 
Figure 5.4. Steady state kinetic data of A. gambiae and human CPR in phosphate 
based buffer. A = Kinetics with respect to cytochrome c. A range of cytochrome c 
concentrations, 0-100 µM, were tested. The concentration of cytochrome c was 
plotted against the rate of reaction when the concentration of NADPH was kept at a 
constant 50 µM. B = Kinetics with respect to NADPH. A range of NADPH 
concentrations, 0-150 µM, were tested. The concentration of NADPH was plotted 
against the rate of reaction when the concentration of cytochrome c was kept at a 
constant 50 µM. The reactions took place in 300 mM phosphate; pH 7.7 at 22 °C. Red 
line = Human CPR; Blue line = A. gambiae CPR. 
234 
Apparent Km (µM) 
Enzyme Cytochrome c NADPH 
 
A. gambiae CPR 
 
24.21 ± 4.05 26.03 ± 4.40 
Human CPR 
 
18.01 ± 3.15 15.04 ± 3.03 
Table 5.3. Apparent Km values of A. gambiae and human CPR with 
respect to cytochrome c and NADPH in phosphate buffer. The apparent 
Km values were calculated using SigmaPlot v.11 using dats from Figure 5.4. 
The quoted errors are standard errors derived from duplicate reactions. 
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kinetic model (Figure 5.4). These data indicate that the mode of 
substrate binding is similar in both A. gambiae and human CPR 
although the human CPR shows stronger interaction with each 
substrate than A. gambiae CPR.  
The Vmax of human and A. gambiae CPR was calculated with respect to 
each of the substrates. Vmax is the maximal rate of reaction and is 
expressed as the amount of substrate reduced per minute per amount of 
CPR (nmol/min/nmol). The Vmax of A. gambiae CPR with respect to 
cytochrome c was 1562 nmol/min/nmol which was similar to that 
calculated for human CPR of 1488 nmol/min/nmol. The Vmax of the 
same enzymes with respect to NADPH were 1466 nmol/min/nmol and 
1568 nmol/min/nmol for A. gambiae and human CPR respectively 
(Table 5.4). These values are again similar however the human CPR 
shows a slightly higher Vmax with respect to NADPH than A. gambiae 
CPR. 
Due to the deficiency in FMN and FAD observed in A. gambiae CPR 
when compared to human CPR, a truer indication of enzyme activity 
would be to express Vmax as the amount of substrate reduced per minute 
per the amount of flavin cofactor (nmol/min/nmol flavin). This allows 
the lack of bound flavin to be taken into account when considering the 
rate of reaction. When the flavin content is taken into account, there is 
a slight change in the pattern of activity. The Vmax values with respect 
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to cytochrome c in A. gambiae CPR were 1951 and 2171 
nmol/min/nmol FAD and FMN respectively compared to 1623 and 
1686 nmol/min/nmol FAD and FMN respectively in human CPR. 
The Vmax values which had been very similar when expressed with 
respect to enzyme concentration become increased in A. gambiae when 
flavin content is considered. The Vmax with respect to NADPH show a 
reversal when expressed as a function of flavin concentration. The 
values are 1832 and 2038 nmol/min/nmol FAD and FMN respectively 
in A. gambiae CPR which and 1711 and 1776 nmol/min/nmol FAD 
and FMN respectively in human CPR (Table 5.5). These values are 
higher in A. gambiae CPR when the reverse was true when Vmax was 
expressed relative to enzyme concentration. 
These data highlight how the rate of reaction value can be misleading 
depending on how the units are expressed. CPR activity is dependent 
on reaction conditions and substrate concentrations but it is also 
heavily influenced by the FMN and FAD concentrations. Thus for 
direct comparison of rates, due to the obvious flavin deficiency in A. 
gambiae CPR, expressing Vmax as a function of flavin concentration is 
a more appropriate measure of the rate.  
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Vmax (nmol/min/nmol reductase) 
 
Enzyme Cytochrome c 
 
NADPH 
 
A. gambiae CPR 
 
1562 ± 90 1466 ± 87 
Human CPR 
 
1488 ± 88 1568 ± 75 
Vmax (nmol/min/nmol flavin) 
 
`Enzyme Cytochrome c NADPH 
FAD FMN FAD FMN 
A. gambiae CPR 
 
1951 ± 112 2171 ± 125 1832 ± 109 2038 ± 121 
Human CPR 
 
1623 ± 96 1686 ± 99 1711 ± 82 1776 ± 85 
Table 5.4. Vmax values of A. gambiae and human CPR with respect to 
cytochrome c and NADPH in phosphate-based buffer. The Vmax values were 
calculated using SigmaPlot v.11 using data from Figure 5.4. The quoted errors are 
standard errors derived from duplicate reactions. 
Table 5.5. Vmax values of A. gambiae and human CPR with respect to 
cytochrome c and NADPH in phosphate based buffer expressed as a function 
of flavin concentration. The Vmax values are the same as in table 5.4 however 
expressed as a function of flavin concentration rather than reductase concentration. 
The quoted errors are standard errors derived from duplicate reactions. 
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5.2.2.2 Tris-HCl buffer kinetics 
The steady-state kinetic experiments were repeated in Tris-HCl buffer 
in order to assess any potential influence of the buffer on Km and Vmax. 
With respect to cytochrome c, the Km of A. gambiae CPR is 12.68 µM 
which is similar to the 8.70 µM measured for human CPR. There is 
more of a difference seen in the Km values with respect to NADPH. For 
A. gambiae CPR, a value of 9.24 µM was measured which is 
significantly higher than the human CPR value of 5.70 µM (Table 5.6). 
Again, both A. gambiae and human CPR data fit to the Michaelis-
Menten model and both enzymes adhere to a similar mode of substrate 
binding (Figure 5.5). 
The clearest observation is in the comparison of Tris-HCl and 
phosphate buffer Km values. There is an approximate 3-fold decrease in 
the Km values of both enzymes with respect to NADPH in Tris-HCl. 
This is not unexpected, especially when the known inhibitory effect of 
free phosphate is taken into consideration. There is also a decrease in 
the Km values with respect to cytochrome c in Tris-HCl albeit less of a 
decrease than what was observed with respect to NADPH. The Vmax of 
A. gambiae with respect to cytochrome c was 1000 nmol/min/nmol 
compared to that of human CPR which was 1125 nmol/min/nmol.
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Figure 5.5. Steady state kinetic data of A. gambiae and human CPR in Tris-HCl 
based buffer. A = Kinetics with respect to cytochrome c. A range of cytochrome c 
concentrations, 0-100 µM, were tested. The concentration of cytochrome c was 
plotted against the rate of reaction when the concentration of NADPH was kept at a 
constant 50 µM. B = Kinetics with respect to NADPH. A range of NADPH 
concentrations, 0-150 µM, were tested. The concentration of NADPH was plotted 
against the rate of reaction when the concentration of cytochrome c was kept at a 
constant 50 µM. The reactions took place in 100 mM Tris-HCl; pH 7.7 containing 
100 mM KCl at 22 °C. Red line = Human CPR; Blue line = A. gambiae CPR. 
A 
B 
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Apparent Km (µM) 
Enzyme Cytochrome c NADPH 
 
A. gambiae CPR 
 
12.68 ± 2.49 9.24 ± 1.17 
Human CPR 
 
8.70 ± 1.54 5.70 ± 0.67 
Table 5.6. Apparent Km values of A. gambiae and human CPR with 
respect to cytochrome c and NADPH in Tris-HCl based-buffer. The 
apparent Km values were calculated using SigmaPlot 11 using data from 
Figure 5.5. The quoted errors are standard errors derived from duplicate 
reactions. 
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Vmax (nmol/min/nmol reductase) 
 
Enzyme Cytochrome c 
 
NADPH 
 
A. gambiae CPR 
 
1000 ± 84 858 ± 46 
Human CPR 
 
1125 ± 53 1156 ± 23 
Vmax (nmol/min/nmol flavin) 
 
Enzyme Cytochrome c NADPH 
FAD FMN FAD FMN 
A. gambiae CPR 
 
1250 ± 105 1391 ± 117 1072 ± 58 1193 ± 64 
Human CPR 
 
1227 ± 57 1274 ± 60 1261 ± 25 1309 ± 26 
Table 5.7. Vmax values of A. gambiae and human CPR with respect to 
cytochrome c and NADPH in Tris-HCl-based buffer. The Vmax values were 
calculated using SigmaPlot v.11 using data from Figure 5.5. The quoted errors are 
standard errors derived from duplicate reactions. 
Table 5.8. Vmax values of A. gambiae and human CPR with respect to 
cytochrome c and NADPH in Tris-HCL based buffer expressed as a function 
of flavin concentration. The Vmax values are the same as in table 5.7 however 
expressed as a function of flavin concentration rather than reductase concentration. 
The quoted errors are standard errors derived from duplicate reactions. 
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These are very similar not only to each other, but also to the Vmax 
values with respect to NADPH. For A. gambiae, this was 858 
nmol/min/nmol and for human CPR, 1156 nmol/min/nmol (Table 5.7). 
As described previously, a more appropriate unit for Vmax takes into 
account the flavin concentration. When this was applied, for A. 
gambiae CPR, the Vmax with respect to cytochrome c were 1250 and 
1391 nmol/min/nmol FAD and FMN respectively compared to 1072 
and 1193 nmol/min/nmol FAD and FMN respectively with respect to 
NADPH. In general, these are similar to what was observed for human 
CPR. With respect to cytochrome c, the Vmax were 1227 and 1274 
nmol/min/nmol FAD and FMN respectively whilst with respect to 
NADPH, the human CPR Vmax were 1261 and 1309 nmol/min/nmol 
FAD and FMN respectively (Table 5.8).  
These data are very similar to what was observed when the reactions 
were performed in phosphate buffer. One difference is that the Vmax 
with respect to NADPH in A. gambiae CPR is lower than human CPR 
in Tris-HCl buffer whilst it is higher than human CPR in phosphate; 
any differences in Vmax observed between A. gambiae and human CPR 
are negligible suggesting that, in general, the rates of reaction in these 
enzymes are very similar. The largest difference when the Vmax data are 
compared is that the values measured in phosphate buffer are 1.5 – 2-
fold higher than those from the Tris-HCl buffer. All in all, the type of 
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buffer used in cytochrome c reaction does have an influence on the 
kinetic properties of A. gambiae and human CPR‟s without affecting 
the overall mode of substrate binding of these enzymes. 
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5.3 Discussion 
The specific activities and steady-state kinetic parameters of both A. 
gambiae and human CPR‟s were measured. The data for the two 
enzymes were directly compared to each other. However, for an 
additional level of comparison to investigate the effects of two buffers, 
Tris-HCl vs phosphate was also undertaken. The inhibitory effect of 
free phosphate on NADPH interaction with CPR is well known 
(Murataliev et al., 1999) and the possibility of this inhibition affecting 
both activity and kinetic parameters was the rationale for the additional 
study in phosphate-free buffer. 
The specific activities were measured with cytochrome c; to assess the 
diflavin reductase activities of these enzymes whilst potassium 
ferricyanide was used to measure to efficiency of the FAD-binding 
domain. In general, the activities of A. gambiae and human CPR with 
respect to both electron acceptors were very similar with A. gambiae 
CPR being slightly more active in both cases. The largest differences 
were seen when the two buffer types were compared for cytochrome c 
reduction. Both enzymes were approximately 1.5 – 2-fold more active 
in phosphate buffer compared to Tris-HCl. Why this should be the case 
is not entirely clear. Since phosphate is a more physiological buffer, it 
follows that the data from experiments performed in this buffer is more 
relevant.    
245 
The increased specific activity observed in phosphate buffer is 
corroborated by the Vmax values. These are also increased with respect 
to both cytochrome c and NADPH for both the A. gambiae and human 
enzymes confirming that phosphate is the preferable buffer for 
investigating CPR activity. The Km values measured in these two 
buffers support the theory surrounding the inhibitory effect of free 
phosphate with regards to NADPH binding. For both enzymes, there 
was an approximate 3-fold increase in Km in phosphate buffer 
conditions. This clearly suggests an inhibitory effect of phosphate 
derived buffer on CPR affinity for NADPH. 
The potassium ferricyanide reduction assay allowed the isolated FAD-
binding domain of A. gambiae CPR to be studied alongside the full 
length domain. These data show that the isolated domain was much 
more active, approximately 1.5 – 2-fold, than the full length protein. It 
is possible that the FMN-binding domain in the full length enzyme has 
an „inhibitory‟ effect on potassium ferricyanide reduction by the FAD-
binding domain. This could be through an overall conformation or 
spatial constraints.  
A. minimus CPR, another mosquito reductase, was shown to have a 
deficiency in FMN and FAD cofactors (Sarapusit et al., 2008) and the 
addition of exogenous flavins prior to cytochrome c reduction 
increases the specific activity of this enzyme. The binding of the 
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cofactors FMN and FAD to A. gambiae CPR is relatively weak and 
recombinant A. gambiae CPR is deficient in both cofactors. Unlike A. 
minimus CPR, the addition of exogenous FMN and FAD just prior to 
the enzyme reaction had little to no effect on the specific activity of 
this enzyme. This suggests that despite the low level of the diflavin 
cofactors, particularly FMN, the enzyme appears to be fully active.  
A further study involved the regeneration of an active reductase from 
the constituent FMN and FAD-binding domains. These were 
recombined to form an active reductase. However the actual activity 
was only 3 - 4 % of that of the intact enzyme. This is due to the lack of 
the inter-domain hinge region. It is absolutely clear that this region is 
entirely responsible for bringing the flavin cofactors into a proximity 
which encourages efficient electron transfer.  
The specific activity and kinetic data do not themselves fully explain 
the action of CPR, be it in A. gambiae or human. The main aspect to be 
gained from this is that the buffer conditions are crucial and the free-
phosphate inhibitory effect has been confirmed. There are aspects of 
the data which can be easily explained such as the specific activity and 
Km values in phosphate and phosphate-free buffers. Some aspects 
however; such as the similarities in specific activities and Vmax values 
of A. gambiae and human CPR and how this relates to the anomalous 
observed FMN-binding, are a lot more difficult to explain using these 
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data alone.  It is therefore important to realise that in order to fully 
understand and interpret kinetic data, a greater level of in-depth 
structural information is an essential requirement.  
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Chapter 6 
 
 
6. GENERAL DISCUSSION 
 
The main aim of this work was the expression of recombinant A. 
gambiae cytochrome P450 reductase with a view to biophysical 
characterisation by NMR. A considerable amount of CPR research has 
focussed on the mechanisms of kinetics and electron transfer 
(Murataliev et al., 2004) whilst aside from a few notable exceptions 
(Wang et al., 1997; Lamb et al., 2006), the structural nuances are less 
well understood. Malaria is a significant disease with A. gambiae being 
the principal vector in the Sub-Saharan African region.  
Before this work was undertaken, very little was known about A. 
gambiae CPR except the intriguing finding that CPR knocked-out 
strains were permethrin susceptible (Lycett et al., 2006). Preliminary 
work also highlighted that the use of a standard 2‟, 5‟-ADP sepharose 
during recombinant A. gambiae CPR purification was consistently 
unsuccessful due to poor interaction with the resin and was 
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corroborated by inhibition studies (unpublished data). Over recent 
years, the efficacy of modern day insecticides has been on the wane 
due to growing populations of resistant mosquito strains. Moreover, 
monooxygenase-mediated in common and often involving the up-
regulation of cytochromes P450 (Vulule et al., 1994), and in this 
mechanism, CPR interaction with cytochromes P450 is pivotal. The 
impact of A. gambiae CPR in relation to permethrin susceptibility 
allied to the proposed weak interaction with 2‟, 5‟-ADP has made A. 
gambiae CPR a tempting and exciting target for a potential novel class 
of insecticides for malarial control (Lycett et al., 2006). 
Much is known about a number of mammalian CPRs, namely rat and 
human in addition to the insect CPRs, house fly and A. minimus. 
Before this work, A. gambiae CPR had not been studied in any detail, 
thus, through enzyme characterisation, its behaviour could be analysed 
both in isolation as well as relative to that of the more established 
CPRs. Throughout the course of this thesis, the human CPR has been 
used primarily as a control enzyme for direct comparison to A. 
gambiae data. Human CPR has been reasonably well studied and 
shows incredible sequence homology to rat CPR, which provided the 
first CPR structure (Wang et al., 1997) with 96 % similarity (Figure 
1.10). The main rationale in including human CPR in this study 
impinges on A. gambiae CPR as a potential insecticide target. For this 
250 
to be the case, any novel compounds need to specifically target A. 
gambiae CPR, thus, any possible action against or effects on the 
human monooxygenase system need to be fully realised and assessed. 
For any characterisation, be it biochemical or biophysical, to be carried 
out, the recombinant protein must be efficiently expressed in a folded, 
active form meaning an effective expression system needs to be 
established. Throughout this work, BL-21 Codon Plus RP competent 
E. coli were utilised for recombinant protein expression and the system 
optimised for the production of reasonably high yields. 1D proton 
NMR experiments were performed to determine whether the enzyme 
was fully folded and for A. gambiae samples, this was the case. 
Activity assays using non-physiological electron acceptors cytochrome 
c and potassium ferricyanide, which assess electron transfer 
capabilities from the FMN-binding and FAD-binding domain 
respectively, were used to confirm that this correctly folded enzyme 
was indeed active (chapter 5).  
CPR consists of two principal domains, the FMN and FAD-binding 
domains, connected by an unstructured linker region (Figure 1.10). The 
homology of these FMN and FAD-binding domains to the bacterial 
enzymes flavodoxin and FNR respectively (Porter and Kasper, 1986) 
strongly suggests that the individual components could be studied as 
separate and independent entities. This was achieved and the isolated 
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flavin binding domains were assessed for cofactor binding, enzyme 
activity and biophysical characterisation.  
Possibly the most significant role of the isolated domains was in the 
determination of redox potentials (section 3.2.5). In this case, the 
isolated flavins are analysed to corroborate the data generated for the 
intact enzyme and ease the convolution of redox potential data. 
Although in this thesis, only the FMN-binding domain had its data 
fully deconvoluted, experiments involving the FAD-binding domain 
and intact CPR were carried out. A combination of sample behaviour 
and time constraints prevented full data analysis from being carried 
out. Despite the only calculated redox potentials being of the FMN-
binding domain, when compared to the human equivalent (Munro et 
al., 2001) they are still of interest. The oxidised/semiquinone transition 
in human FMN-binding domain was -43 mV which is much more 
positive than the -92 mV seen in A. gambiae FMN-binding domain 
(Table 3.2). This suggests that in the oxidised form, human FMN 
accepts electrons more readily than the Anopheline equivalent which is 
possibly due to a weaker binding of FMN to its binding site. 
Differences in the binding affinity of FMN to its binding site between 
human and A. gambiae CPR was an interesting, yet not completely 
unexpected, discovery. Mosquito CPR, derived from A. minimus, has 
been shown to be deficient in both FMN and FAD cofactors (Sarapusit 
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et al., 2008) and a similar trait could be seen in A. gambiae CPR. In 
fact, when the flavin content of A. gambiae CPR was analysed, there 
was only a 0.72:1 FMN: protein ratio which represents a 20 % 
deficiency in FMN relative to human CPR (Table 3.1). The specific 
activity, calculated as a function of cytochrome c reduction, of A. 
gambiae CPR was not improved following the addition of exogenous 
FMN of FAD to the reaction mixture. This implies that FMN deficient 
A. gambiae CPR is still fully active suggesting this enzyme contains a 
naturally low level of bound flavin cofactors, particularly FMN. 
The data regarding the activity of A. gambiae CPR relative to the 
concentration of bound flavin is somewhat anomalous as it would be 
expected that in an enzyme deficient in FMN and FAD, the addition of 
exogenous flavin would increase enzyme activity – as was shown with 
A. minimus (Sarapusit et al., 2008). As this is not the case for A. 
gambiae CPR, it is likely that there are subtle structural influences that 
affect flavin binding and enzyme activity which have yet to be 
resolved meaning the observations presented in this thesis remain 
unexplained. 
Further evidence for a difference in FMN interaction between A. 
gambiae and human CPRs was highlighted using Isothermal Titration 
Calorimetry (ITC) (section 4.2.4). Using the ITC200 system (MicroCal), 
FMN was sequentially titrated into the apo-form of the FMN-binding 
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domain of both A. gambiae and human CPR. The resultant binding 
isotherms suggested an approximate 4-fold decreased affinity for FMN 
in A. gambiae FMN-binding domain compared to the human domain 
(Table 4.4). Ideally this would have been corroborated using FAD 
bound, FMN apo-CPR samples to determine whether this behaviour 
was replicated in the full length CPR. The FAD-binding site would 
have to be fully saturated in order to prevent FMN binding to the FAD-
binding domain and clouding any data. Unfortunately, the instability of 
the apo-form of both A. gambiae and human CPR prevented such 
experiments being carried out. The same was also observed for the 
FAD-binding domains indicating that this domain is the driving force 
behind apo-CPR instability. 
Throughout this work, ITC was primarily used to probe the NADPH 
binding site in order to establish possible differences in coenzyme 
nucleotide binding properties between the A. gambiae and human 
CPRs (chapter 4). The finding that 2‟,5‟-ADP binds up to 10-fold less 
strongly to A. gambiae CPR than to the human CPR was intriguing and 
suggested a difference in coenzyme binding which could potentially 
impinge on basal activity of the mosquito reductase. The weaker 
affinity of A. gambiae CPR for 2‟, 5‟-ADP was confirmed by ITC 
(section 4.2.2) and analysis of further nucleotide analogues was 
probed.  
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The 2‟-phosphate moiety of NADPH was shown to be essential for 
interaction of the coenzyme to CPR. NADP
+ 
bound much more 
strongly to both A. gambiae and human CPRs than NAD
+
 which was 
simply down to the presence of an additional phosphate group at the 2‟ 
position in NADP
+. This 2‟-phosphate group is also responsible for the 
majority of the binding energy in NADPH judging by the similarities 
between NADP
+ and 2‟, 5‟-ADP binding affinities and 
thermodynamics. The fact that these values, observed in both A. 
gambiae and human CPRs, were so similar suggested that the 
incorporation of the nicotinamide moiety, present in NADP
+
, had little 
impact on the binding characteristics of the ligands. This finding 
corroborates previous findings (Grunau et al., 2006) and confirms that 
A. gambiae CPR adheres to known conventions regarding the bipartite 
nature of NADPH binding in these enzymes (Deng et al., 1999). 
Comparison of 2‟, 5‟-ADP and 2‟-AMP binding data also shows that 
although the significant interaction is at the 2‟-phosphate, addition of 
the 5‟-phosphate group improves the binding affinity by at least an 
order of magnitude. This is likely due to secondary interactions and has 
previously been observed in human CPR (Grunau et al., 2006). 
The increased binding affinity of this range of nucleotide analogues for 
human CPR was confirmed by the thermodynamic parameters (section 
4.2.3). A very interesting observation was that in A. gambiae CPR, the 
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isolated FAD-binding domain bound these ligands quite differently 
than the intact CPR (Tables 4.2 and 4.3). Although the overall binding 
energies (ΔG) were apparently the same, the values for ΔH and TΔS 
suggest key differences in binding. It is possible that the presence of 
the FMN-binding domain in the intact enzyme could be at least partly 
responsible for these differences in thermodynamic characteristics. The 
very fact that upon NADPH binding, FMN is brought close to the 
FAD-binding domain to allow swift, efficient electron transfer is 
potentially energetically detrimental in the intact enzyme. In the FAD-
binding domain binding, where no FMN-binding domain is present, 
there is a more favourable observed ΔH value than the intact enzyme. 
It is quite possible that some of the binding energy is expended to 
necessitate the conformational shift of the FMN-binding domain in the 
intact enzyme.  
Despite both deficiency in flavin cofactors and apparent weaker 
NADPH interaction, the activity of cytochrome c and potassium 
ferricyanide reduction of A. gambiae CPR is not too dissimilar to 
human CPR (section 5.2.1). In fact, the A. gambiae CPR was more 
active for reduction of these electron acceptors in laboratory 
conditions. Although there was little observed difference in enzyme 
activity between A. gambiae and human CPR, the calculated kinetic 
parameters Km and Vmax indicated a possible contrast in how these 
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activities are achieved. The lower Km values measured with respect to 
both NADPH and cytochrome c in human CPR suggested a stronger 
affinity for both these substrates in the human enzyme (Table 5.3). 
When the ITC nucleotide binding study (chapter 4) is considered, in 
the case of NADPH, this is not surprising but this apparent improved 
affinity for cytochrome c in human CPR is potentially more 
interesting. It has been suggested that the cytochrome c and 
cytochrome P450 binding sites in CPR are either very close or indeed 
overlap (Tamburini and Schemkman, 1986). Therefore, a possible 
weaker affinity for cytochrome c in A. gambiae CPR may also possibly 
relate to a weaker affinity for some cytochrome P450s.  
The isolated A. gambiae FAD-binding domain was assessed for its rate 
of potassium ferricyanide reduction (section 5.2.1.2). Interestingly, the 
isolated domain was approximately 2-fold more active than the intact 
enzyme. This suggests some sort of inhibitory effect imparted by the 
FMN-binding domain with respect to potassium ferricyanide reduction. 
Potassium ferricyanide receives electrons directly from the FAD 
cofactor. It is, therefore, possible that there is conformational or spatial 
crowding in presence of the FMN-binding domain and potassium 
ferricyanide interaction is optimised in the isolated FAD-binding 
domain. 
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When all of the specific activity and kinetic data is considered, it is 
very difficult to rationalise as the data themselves do not appear to 
fully explain A. gambiae CPR action relative to the human enzyme. 
The fact that the specific activities of A. gambiae and human CPR are 
practically the same seems contradictory when other data is taken into 
account. Since A. gambiae CPR is deficient in bound flavin cofactors 
and has an apparent weaker affinity for NADPH it is unclear as to why 
the activities are so similar. It is eminently possible that because the 
two CPRs used in this study are from very different sources; insect and 
mammalian, the CPRs have evolved to act differently due to contrasts 
in the encountered environments of the two organisms. It is possible 
that interaction with cytochrome P450 is not the major role of 
mosquito and instead, interactions with other acceptors such as heme 
oxygenase (Schacter et al., 1972),  
Mutations in human CPR have been shown to have a dramatic effect 
on the activity of heme oxygenase (Pandey et al., 2010). This 
observation could also prove to be particularly relevant within blood-
sucking insects such as mosquitoes and the relationship between CPR 
and heme oxygenase in these organisms is of growing importance. The 
possible shift in focus could have lead to slightly altered structural 
properties in A. gambiae CPR, to optimise interaction with these 
alternative acceptors, which in turn could explain the flavin 
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incorporation and NADPH analogue binding data. Whatever the 
explanation may be, what is abundantly clear is that to fully explain 
any of the data presented in this thesis, more comprehensive structural 
determination of A. gambiae CPR is required. 
To date, the knowledge regarding CPR structure has been determined 
from X-ray crystallography (Wang et al., 1997; Lamb et al., 2006) 
however NMR should not be disregarded as a valuable tool. Although 
CPR is a very large protein in terms of NMR viability, it has been 
demonstrated that protein deuteration is effective at improving spectral 
quality (Figure 3.20). The multi-domain nature of CPR also means 
NMR has a role to play in biophysical analysis. Taken as separate 
entities, the isolated FMN and FAD-binding domains are a more 
manageable size, in particular the FMN-binding domain, and can be 
structurally assessed to provide valuable information regarding CPR 
even if the structure of the intact protein is unattainable. In this thesis, 
the FMN and FAD-binding domains, along with the intact CPR, have 
been analysed by NMR and significant progress has been made with 
each. The FMN-binding domain has proved the most successful 
sample to study, primarily due to its small size and relative stability, 
with sufficient triple resonance spectra being gathered for backbone 
assignments. The FAD-binding domain and intact CPR have proved 
more problematic but both have been deuterated with varying degrees 
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of success. Although much more work is required, particularly on the 
higher molecular weight samples, the work to date has been invaluable 
and provided solid foundations for this more comprehensive study to 
be carried out. 
The structural difference between rat and mosquito CPRs highlighted 
by the A. gambiae CPR model provided a plausible explanation for the 
low affinity of A. gambiae CPR for 2‟,5‟-ADP however the data failed 
to corroborate the theory. In the absence of a protein structure, 
mutagenesis is likely to be the most useful tool in the elucidation of 
further information regarding A. gambiae CPR. Despite the T607Q 
mutant not advancing current knowledge, by mutating further residues 
known to be involved in either flavin cofactor or NADPH interaction, a 
vast amount of data could potentially be gathered, even without a fully 
determined structure. 
The work carried out in this thesis has been the first of its kind by 
focussing on the biochemical and biophysical characterisation of A. 
gambiae CPR. The data gathered has served to highlight differences 
between the mosquito CPR and the more established human 
equivalent. The growing number of insecticide resistant strains of 
mosquitoes has magnified the threat of malarial spread and accelerated 
the need for the elucidation of novel effective compounds (Ranson et 
al., 2002). Insecticide detoxification is in part down to the 
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monooxygenase family of enzymes (Feyereisen, 1999) of which CPR 
is a prominent member. This work, therefore, has given a valuable 
insight into the A. gambiae CPR enzyme and could serve a crucial role 
in full structural determination making the production of desired novel 
compounds imminently possible in years to come. 
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Appendix A. MaldiTOF mass spectrometry identification of A. gambiae NADPH cytochrome P450 reductase. 
Two peptides from a trypsin digested sample of full length A. gambiae CPR were identified. Pages 276-277, the 
fragmentation spectra of the two peptides. Page 278, the BLAST search results for the two peptides and associated 
hit. 
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205gagaactcgttcatcaagaagctacagtcctcgggccgccggctcgtagtgttttacggttcc
caaacaggcacggcagaggaatttgccggtcgcctggcgaaggaaggaatccgctaccaaatga
agggcatggtcgccgacccagaggagtgcaatatggaagagctgctgatgctgaaggacatcgac
aaatcgttggccgtgttttgcttagcgacgtacggcgagggcgacccgacggacaactgcatggag
ttctacgactggattcaaaacaacgatctagatatgaccggtttgaattacgcggtgtttggccttggca
acaaaacgtacgagcactacaacaaggtcggcatctacgtggacaagcgtctcgaggagctcggc
gcgaacagagtgtttgagctcggtctgggtgacgatgatgccaacatcgaggactacttcatcacgt
ggaaggaaaagttttggcccacggtttgcgactacttcggcatcgagagcacgggcgaggatgtg
ctgatgcggcagtaccgcctgctggagcagccggacgtgagcgcggaccgcatctacaccggc
gag795 
 
731tgatgcggcagtaccgcctgctggagcagccggacgtgagcgcggaccgcatctacaccg
gcgaggtggcccggctccattcgctccagacgcagcggccaccgttcgacgcgaagaacccgttc
ctcgccccgatcaaggtgaaccgggagctgcacaaggcgggcggccggtcctgcatgcacgtcg
agttcgacatcgagggctcgaagatgcggtacgaggcgggcgaccatctcgcgatgtacccggtg
aacgatcgcgatctggtcgagcggctcggccggctgtgcaatgccgagctcgatacggtcttctcg
ctcatcaacaccgacacggacagcagcaagaagcatccgttcccgtgccccaccacctaccggac
cgcgctcacccactatctggagataacggcgctgccgcgcacccacatcctgaaggagctggccg
agtactgcggcgaggagaaggacaaggagttcctgcgcttcatctcgtcgaccgcgcccgacggc
aaggcgaagtaccaggagtgggtgcaggacagctgccgcaacatcgtgcacgtgctcgaggaca
tcccgtcctgccatccgccgatcgatcacgtgtgcgagctgctgccccggctgcagccccgctacc
actcgatctcctcctcgtccaagctgcacccgacgacggtgcacgtgaccgcggtgctggtgaagt
acgagacgaagacgggccggctgaacaagggcgtcgcgacgaccttcctcgcggagaagcacc
cgaacgatggggagccggcaccgcgcgtaccaatcttcatccgcaagagccagttccggttgccg
cccaagccggaaacgcccgtgatcatggtggggcccggcaccgggctggcaccgttccggggct
tcatccaggagcgggaccactgcaagcaggagggcaaggagattggccagacgacgctgtacttt
ggctgccgcaagcgctccgaggactacatctacgaggatgaactggaagactactccaagcgcgg
catcatcaaccttcgcgttgcgttctcgcgcgaccaggagaagaaggtgtacgtgacgcacctgctc
gagcaggactcggacctcatatggagcgtgatcggcgaaaacaagggacacttttacatctgcggt
gatgcgaaaaatatggccaccgatgtgcgaaacattctgctgaaggtcatccgctcgaagggtggg
ctcagcgaaaccgaggcccagcagtacatcaaaaagatggaagcccaaaaacgatactcggcgg
acgtgtggagctaa2040 
 
 
B 
A 
Appendix B. Primer sequences of FMN and FAD-binding domains of A. gambiae 
CPR. A = FMN-binding domain primers: Red = Forward primer; Brown = Reverse 
primer #1; Green = Reverse primer #2, Purple = Reverse primer #3 B = FAD-binding 
domain primers: Red = Reverse primer; Purple = Forward primer #1; Brown = 
Forward primer #2. Forward primers include an Nco1 restriction site whilst reverse 
primers include a Kpn1 restriction site for ligation of cloned domain into pETM11 
vector.  
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FMN29-Sep-200914:34:31
mass
18000 19000 20000 21000 22000 23000 24000 25000
%
0
100
20090928 MT FMN Lock  161 (5.637) Cn (Cen,5, 80.00, Ht); Sm (SG, 3x3.00); M1 [Ev-222530,It21] (Gs,0.750,400:3000,1.00,L33,R33); Sm (SG, 3x3.00); Sb (19,1
5.60e420754.680
55976
20626.662
23863
20470.449
183819834.160
60118716.113
426
18082.797
312
20917.961
25743
21095.295
3772
22861.908
203622148.701
616
23379.148
611 24969.266
340
24289.145
305
FAD29-Sep-200914:58:32
mass
44000 45000 46000 47000 48000 49000 50000 51000 52000 53000 54000
%
0
100
20090928 MT FAD Lock  160 (5.602) Cn (Cen,5, 80.00, Ht); Sm (SG, 3x3.00); M1 [Ev-52907,It27] (Gs,0.750,1000:2009,1.00,L33,R33); Sm (SG, 3x3.00); Sb (19,1
3.96e348628.863
3960
48592.387
462
44577.984
132
47618.730
12744966.992
121
46676.328
114
48663.227
1032
48692.488
299
48808.320
170
49876.414
152 53187.070
140
51488.332
97
53883.969
70
Appendix C. Intact mass spectrometry of A. gambiae FMN-binding and FAD-
binding domains. A = FMN-binding domain B = FAD-binding domain. Electrospray 
mass spectrometry performed at Manchester Interdisciplinary Biocentre. 
 
 
 
A 
B 
